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Abstract 
Background 
Dementia with Lewy bodies (DLB) is the second commonest type of neurodegenerative 
dementia, but accurate antemortem diagnosis remains challenging, especially at the 
earliest (prodromal) disease stages and in the presence of mixed (Alzheimer) pathology.  
To investigate this we undertook two studies, an investigation of  
123
I-FP-CIT imaging 
as a possible biomarker of prodromal DLB (at the mild cognitive impairment (MCI) 
stage), and a study of the effect of amyloid deposition measured by 
18
F-Florbetapir PET 
on clinical phenotype in established DLB.  
 
Methods 
Prodromal DLB Study: 53 subjects with MCI and symptoms suggestive of Lewy body 
disease underwent comprehensive clinical and cognitive assessment and 
123
I-FP-CIT 
SPECT imaging.  
Amyloid Imaging Study: 22 DLB, 10 Alzheimer’s disease (AD) and 15 control subjects 
underwent comprehensive clinical and cognitive assessment, MRI and 
18
F-Florbetapir 
PET amyloid imaging. 
 
Results 
Prodromal DLB Study: An abnormal 
123
I-FP-CIT scan was associated with increased 
rates of parkinsonism and RBD, but was not associated with a specific pattern of 
cognitive impairment. The pattern of 
123
I-FP-CIT binding loss was symmetrical. Males 
were more likely to have an abnormal scan than females.  
Amyloid Imaging Study: AD subjects displayed greater amyloid binding than DLB in 
frontal, temporal, cingulate and striatal regions. There were no significant differences 
between DLB and controls, but binding in DLB was intermediate between AD and 
controls in all regions. Frontal:Occipital binding ratio differentiated AD from DLB and 
controls. There were no consistent effects of amyloid on the phenotype of DLB 
subjects.  
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Conclusions 
123
I-FP-CIT SPECT appears to be a marker of Lewy body disease in the prodromal 
stage. Longitudinal analysis is needed to determine its sensitivity and specificity.  
Amyloid deposition is present in a proportion of DLB subjects, but is not associated 
with a clear difference in clinical phenotype. Longitudinal follow-up will determine 
whether it is associated with a difference in disease progression. 
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1 Chapter 1   Introduction  
 
Dementia is a decline in cognitive function that interferes with a person’s ability to 
undertake their usual activities, which is not explained by delirium or another 
psychiatric disorder (McKhann et al., 2011).  It is one of the most important public-
health issues confronting our society. Around 36 million people worldwide were living 
with dementia in 2010 and this will rise to over 110 million people by 2050 (Prince et 
al., 2013). Approximately 670,000 people in the UK have dementia, or 6.5% of the 
population over 65 years of age (Matthews et al., 2013). The prevalence rises with age, 
from around 1-2% in those aged 65-69 years to 10% in those aged 80-84 years 
(Matthews et al., 2013). This high prevalence is associated with significant distress for 
patients and carers, along with substantial financial costs to society (Wimo et al., 2013). 
In light of this it is unsurprising that finding a treatment for dementia is seen as a 
priority for national governments (G8, 2013).  
There are many different dementia subtypes, but Alzheimer’s disease, vascular 
dementia, dementia with Lewy bodies, Parkinson’s disease dementia and 
frontotemporal dementia together account for the vast majority of cases (Stevens et al., 
2002). Dementia with Lewy bodies (DLB) is the second most common type of 
neurodegenerative dementia after Alzheimer’s disease (AD), accounting for over 4% of 
diagnosed cases (Vann Jones and O'Brien, 2014). It is characterised by the presence of 
visual hallucinations, parkinsonism, cognitive fluctuations, REM sleep behaviour 
disorder, sensitivity to antipsychotic medications and reduced striatal dopamine 
transporter levels on SPECT or PET imaging (McKeith et al., 2005).  
Recent unsuccessful trials of anti-amyloid therapies in AD have led some to suggest that 
commencing treatment after dementia has developed may be too late, as irreversible 
widespread neuronal damage has already occurred (Aisen et al., 2013). As a result, 
increasing attention has been given to the identification of dementia subtypes in their 
pre-dementia or prodromal phase. Identifying prodromal dementia enables researchers 
to examine the early pathophysiological processes involved in each dementia subtype 
and to develop and test treatments aimed at stopping or slowing these specific 
processes. Biomarkers that measure the presence of a specific brain pathology (e.g. 
amyloid PET imaging), or that are indicative of a particular dementia subtype (e.g. 
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striatal dopamine transporter reduction in DLB) may be important tools to identify the 
pathological subtype of dementia more accurately and much earlier in the disease 
process. This factor was the key driver behind the studies which comprise this thesis, 
which will investigate amyloid PET imaging in established DLB and striatal dopamine 
transporter imaging in prodromal DLB. 
 
1.1 Dementia with Lewy Bodies 
1.1.1 Epidemiology 
Dementia with Lewy bodies (DLB) is the second most common type of 
neurodegenerative dementia after Alzheimer’s disease (AD). A recent meta-analysis 
found that DLB accounts for 4.2% of dementia cases in community samples and 7.5% 
of cases in secondary care, with an incidence of 0.87 per 1000 person-years (Vann Jones 
and O'Brien, 2014). The increased prevalence seen in secondary care may be due to 
increased rates of neuropsychiatric symptoms and greater caregiver stress in DLB 
compared with AD (Walker et al., 2012). The actual prevalence and incidence of DLB 
may be significantly higher, due to under-diagnosis (Boot, 2013). One study that 
compared clinical diagnosis with pathological findings  reported that only 52/162 cases 
of diffuse cortical LB disease (in the absence of significant neurofibrillary tangle (NFT) 
pathology) were classed as ‘pure DLB’ clinically (Nelson et al., 2010). In the overall 
sample 14.3% of dementia cases had ‘diffuse neocortical type LB disease’, with more 
than half of these also having significant NFT pathology. 
 
1.1.2 Clinical features and diagnostic guidelines 
DLB is a progressive cognitive disorder of sufficient severity to interfere with normal 
social or occupational function accompanied by other characteristic symptoms which 
will be discussed below (McKeith et al., 2005).  
 
1.1.2.1 Cognitive Impairment 
The pattern of neuropsychological deficits seen in DLB is different from AD, with less 
marked memory impairment and more severe impairments of visuospatial, attentional 
and frontal-executive function (Metzler-Baddeley, 2007).  
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DLB is also associated with pronounced and clinically relevant fluctuations in arousal, 
cognition and function. Indeed, cognitive fluctuation is a core feature in the diagnostic 
criteria for DLB. Carers of those with DLB are more likely to report the person to have 
significant differences in function during the day, to be drowsy or to sleep during the 
day, to stare into space for long periods and to have periods where their flow of ideas 
seems disorganised (Ferman et al., 2004; Lee et al., 2014). These fluctuations in 
alertness and concentration can be demonstrated in computerised tests of reaction times 
(Ballard et al., 2001). Severe fluctuations can manifest as transient, unexplained 
episodes of loss of consciousness (McKeith et al., 2005). Fluctuations may be most 
specific to DLB in the milder stages (MMSE >18) of cognitive impairment (Lee et al., 
2014). 
 
1.1.2.2 Neuropsychiatric Symptoms 
DLB is associated with a greater degree of neuropsychiatric symptoms than AD, and 
associated carer distress (Walker et al., 2012). Visual hallucinations are common in the 
early stages of DLB, unlike AD (Ferman et al., 2013a). These tend to be vivid and most 
commonly feature people or animals (Aarsland et al., 2001a). Other visual symptoms 
seen in dementia, such as misperception and misidentification of family members tend 
to appear earlier in DLB than AD (Ferman et al., 2013a). DLB is also associated with 
higher rates of auditory hallucinations, delusions and depression (Ballard et al., 1999; 
Aarsland et al., 2001a). 
 
Rapid eye movement (REM) sleep behaviour disorder (RBD) is a parasomnia 
characterised by the enactment of dreams (e.g. punching, kicking, shouting out) that 
often results in injury (Schenck and Mahowald, 2002). It is strongly associated with the 
synucleinopathies (DLB, Parkinson’s disease (PD), PD dementia (PDD) and multiple 
system atrophy (MSA)) (Iranzo et al., 2013), and can be a very early symptom of DLB 
(Boeve et al., 2003). RBD is one of the strongest predictors of a diagnosis of DLB at 
post mortem (Ferman et al., 2011).  
 
1.1.2.3 Physical symptoms 
DLB is associated with severe sensitivity to antipsychotic medications, with reactions 
including confusion, sedation, rigidity, immobility, features of neuroleptic malignant 
syndrome (fever, rigidity and raised serum creatinine kinase) and increased mortality 
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(McKeith et al., 1992). Sensitivity can occur both with typical and atypical neuroleptics 
(Ballard et al., 1998). 
 
Extrapyramidal symptoms are common in DLB (Del Ser et al., 2000; Aarsland et al., 
2001b). Compared with Parkinson’s disease, people with DLB are more likely to have 
predominant symptoms of postural instability and gait difficulty, rather than the tremor 
dominant phenotype (Burn et al., 2006). However, Ballard et al. investigated the signs 
most useful in identifying parkinsonism in DLB and found that rest tremor, action 
tremor, bradykinesia, decreased facial expression and rigidity were most characteristic 
of DLB (Ballard et al., 1997).   
 
Autonomic features such as orthostatic hypotension, constipation and urinary 
incontinence are also common in DLB, and may be associated with increased mortality 
(Stubendorff et al., 2012).  
 
1.1.3 Diagnostic Criteria 
The diagnostic criteria for DLB were agreed by international consensus in 1996 
(McKeith et al., 1996) and revised in 2005 (McKeith et al., 2005). The current (2005) 
criteria are summarised in Table 1.1. A conclusive (definite) diagnosis of DLB can only 
be made at post-mortem, but a diagnosis of ‘probable’ or ‘possible’ DLB can be made 
based on clinical presentation. Three symptoms are defined as ‘core features’: recurrent 
visual hallucinations, spontaneous motor parkinsonism and fluctuations in cognition. 
Three ‘suggestive features’ are also identified: rapid eye movement sleep behaviour 
disorder (RBD), reduced dopamine transporter uptake in the basal ganglia on PET or 
SPECT imaging and severe neuroleptic sensitivity. The presence of two core features, 
or one core feature and one or more suggestive features in a person with dementia is 
sufficient for a diagnosis of probable DLB. Possible DLB is diagnosed if one core 
feature is present without other suggestive features, or if one or more suggestive 
features are present in the absence of core features.  
 
DLB is clinically and pathologically similar to PDD. DLB and PDD are differentiated 
on the basis of the ‘1-year rule’ (McKeith et al., 2005), meaning that DLB is diagnosed 
if dementia develops prior to, or within one year of parkinsonism. PDD should be 
diagnosed if dementia develops more than one year after parkinsonism. 
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Table 1.1. Diagnostic criteria for DLB (from McKeith et al., 2005) 
1. Central feature 
Dementia defined as progressive cognitive decline of sufficient magnitude to interfere 
with normal social or occupational function. Impairments of attention, executive and 
visuospatial function may be particularly prominent. 
 
2. Core features  
Fluctuating cognition with pronounced variations in attention and alertness 
Recurrent visual hallucinations that are typically well formed and detailed 
Spontaneous features of parkinsonism 
 
3. Suggestive features 
REM sleep behaviour disorder (RBD) 
Severe neuroleptic sensitivity 
Low dopamine transporter uptake in basal ganglia on SPECT or PET imaging 
 
For a diagnosis of probable or possible DLB, dementia must be present. 
Probable DLB: at least one core feature and one other feature (core or suggestive) 
Possible DLB: one core feature and no suggestive features; or one or more suggestive 
features 
 
4. Supportive features (commonly present but not proven to have diagnostic accuracy) 
Repeated falls and syncope 
Transient, unexplained loss of consciousness 
Severe autonomic dysfunction, e.g., orthostatic hypotension, urinary incontinence 
Hallucinations in other modalities 
Systematized delusions 
Depression 
Relative preservation of medial temporal lobe structures on CT/MRI scan 
Generalized low uptake on SPECT/PET perfusion scan with reduced occipital activity 
Abnormal (low uptake) MIBG myocardial scintigraphy 
Prominent slow wave activity on EEG with temporal lobe transient sharp waves 
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1.1.4 Prognosis 
Rates of cognitive decline are comparable between clinically diagnosed DLB and AD, 
but mortality may be greater in DLB (Williams et al., 2006; Garcia-Ptacek et al., 2014). 
A Swedish Dementia Registry study found that DLB was associated with high levels of 
comorbidity including depression and stroke (Fereshtehnejad et al., 2014). In cohorts 
that have come to post-mortem, those with combined LB and AD pathology are seen to 
have had faster rates of decline than those with ‘pure’ AD or DLB (Olichney et al., 
1998; Kraybill et al., 2005; Nedelska et al., 2015a). 
 
1.1.5 Genetics 
Mutations in genes associated with AD (amyloid precursor protein [APP], presenilin 1 
[PSEN1] and 2 [PSEN2], apolipoprotein [APOE]) and PD (α-synuclein [SNCA] and 
scavenger receptor B [SCARB2]) have been shown to be associated with Lewy body 
deposition and dementia (Meeus et al., 2012; Bras et al., 2014). In the general 
population, the APOE ε4 allele is the most important genetic risk factor for AD. Rates 
of the APOE ε4 allele in DLB are higher than in normal controls and similar to those in 
AD (Kobayashi et al., 2011; Tsuang et al., 2013). These findings support the hypothesis 
that AD, DLB and PD lie on a spectrum, with DLB showing pathologic and phenotypic 
traits of both conditions (Meeus et al., 2012). The SNCA and SCARB2 mutations found 
in DLB and PD are different, which may account for some of the phenotypic differences 
between these two diseases (Bras et al., 2014). 
 
1.1.6 Neuropathology 
Lewy bodies (LBs) and Lewy neurites (LNs) are the pathological hallmarks of DLB 
(Figure 1.1). These are abnormal filamentous protein inclusions containing α-synuclein 
(αSyn) found in the neuronal cytoplasm (LBs) and dystrophic neurites (LNs).  
 
LBs and LNs are widely distributed throughout the peripheral and central nervous 
systems in DLB (Beach et al., 2009). The DLB consensus criteria define 3 patterns of 
deposition: brainstem, limbic, and diffuse neocortical (McKeith et al., 2005). Cases are 
assigned a likelihood that the observed LB pathology explains the DLB clinical 
syndrome based on the extent of LB pathology (diffuse neocortical – most likely; 
brainstem – least likely) and the amount of AD pathology present (Table 1.2). AD 
pathology (Aβ plaques and NFTs) is often seen in DLB, this will be discussed in more 
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detail in chapter 3. The temporal progression of LB pathology will be discussed in 
chapter 2. 
 
 
 
 
1.1.7 Clinicopathologic Correlations 
The severity of cognitive impairment seen in DLB does not correlate with the severity 
of LB pathology (Beach et al., 2009). This may be because smaller presynaptic 
accumulations of αSyn are responsible for the phenotype of DLB, rather than LBs and 
 
Figure 1.1. Lewy body and Lewy neurite pathology. Photomicrograph of 
Lewy bodies (arrows) and Lewy neurites (arrow heads) in the substantia nigra 
stained with α-synuclein antibody (made available by Suraj Rajan under 
creative Commons License http://commons.wikimedia.org/wiki/ 
File:Substantia_nigra_with_Lewy_body_pathology.svg).  
Table 1.2. Assessment of the likelihood that pathologic findings are associated with 
a DLB clinical syndrome (from McKeith et al., 2005 ) 
Lewy body pathology 
NIA-Reagan rating of AD pathology 
Low Intermediate High 
Brainstem predominant Low Low Low 
Limbic High Intermediate Low 
Diffuse neocortical High High Intermediate 
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LNs (Schulz-Schaeffer, 2010) or because the amount of LB pathology decreases in the 
later stages of DLB following cell death and reabsorption (Parkkinen et al., 2008). 
Visual hallucinations have been associated with LB pathology in limbic (Ferman et al., 
2013a) and temporal (Harding et al., 2002) areas. 
 
1.1.8 Striatal Dopaminergic Imaging in DLB 
1.1.8.1 Pathological basis of striatal dopaminergic imaging 
DLB is associated with Lewy body pathology and cell death in the substantia nigra, 
with the resultant loss of nigrostriatal dopaminergic axons (Beach et al., 2009). The 
integrity of these nigrostriatal axons can be assessed by measuring the density of 
presynaptic dopamine transporters in the striatum using SPECT or PET imaging. A 
variety of ligands are available; the most commonly used is n-fluoropropyl-2β-
carbomethoxy-3β-(4-iodophenyl)nortropane (FP-CIT). 123I-FP-CIT SPECT binding has 
been shown to correlate with nigral dopaminergic neuronal density post-mortem 
(Colloby et al., 2012). Some drugs can affect FP-CIT binding, for example 
amphetamines, modafinil, bupropion and benzatropine (Booij and Kemp, 2008) but 
cholinesterase inhibitors do not affect the clinical utility of the scan (Taylor et al., 
2007).  
 
123
I-FP-CIT  scans can be graded on a four point scale that was initially developed for 
the assessment of scan abnormalities in those with Parkinson’s disease: 0 = normal; 1 = 
reduced putamen uptake in one hemisphere; 2 = symmetrical reduction in putamen 
uptake; 3 = bilateral reduction in putamen and caudate (Fig. 4.7).  This scale reflects the 
pattern of disease progression in PD, with early 
123
I-FP-CIT binding reductions in the 
putamen, often unilaterally. However, in DLB a different pattern of reduction is 
observed with less asymmetry between the two hemispheres and reduced binding 
throughout the striatum, rather than just the putamen (Walker et al., 2004; Marquie et 
al., 2014). 
 
1.1.8.2 Clinical Utility of 123I-FP-CIT SPECT 
123
I-FP-CIT SPECT imaging can accurately identify striatal dopaminergic deficiency in 
Parkinson’s disease and DLB (O'Brien et al., 2014b). A meta-analysis of four large 
studies found that 
123
I-FP-CIT SPECT imaging has a sensitivity of 86.5% and a 
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specificity of 93.6% for the diagnosis of DLB (Papathanasiou et al., 2012). Only one of 
these studies compared imaging results with pathological diagnosis, finding sensitivity 
of 88% and specificity of 83% for visually rated scans, with specificity increasing to 
100% when a semiquantitative measure was used (Walker et al., 2007). People with 
possible DLB and a positive 
123
I-FP-CIT scan are more likely to convert to clinically 
diagnosed probable DLB than those with negative scans (O'Brien et al., 2009). 
123
I-FP-
CIT imaging increases clinicians’ diagnostic certainty in dementia, particularly in the 
case of a positive scan (Walker et al., 2015b) 
 
123
I-FP-CIT  scans can be positive in the absence of significant parkinsonism (McKeith 
et al., 2007) as up to 60% of nigrostriatal neurones can be lost prior to the development 
of motor symptoms (Cummings et al., 2011). A proportion of DLB cases have negative 
123
I-FP-CIT scans,  which may be due to a relative absence of pathology in the 
substantia nigra (Colloby et al., 2012), with the synuclein disease burden being 
predominantly in other parts of the brain or nervous system (Zaccai et al., 2008). A 
significant proportion of frontotemporal dementia (FTD) cases have positive scans, 
most likely due to pathological changes in the substantia nigra and striatum (Morgan et 
al., 2012). 
123
I-FP-CIT imaging cannot differentiate between DLB, PD, PDD or other 
parkinsonian syndromes such as MSA, progressive supranuclear palsy or corticobasal 
degeneration (Cummings et al., 2011). 
 
1.1.8.3 Clinical Correlations 
There is conflicting data on the relationship between 
123
I-FP-CIT  binding and clinical 
phenotype in DLB. Decreased FP-CIT binding in the right putamen was correlated with 
increased NPI apathy score in a mixed AD (n=14) and DLB (n=8) group, though this 
could be attributed to apathy and decreased 
123
I-FP-CIT binding both being associated 
with DLB (David et al., 2008). Roselli et al. found a negative correlation with striatal 
uptake and NPI hallucinations score (n=18) (Roselli et al., 2009). They found 
significant correlation between caudate binding and NPI apathy, depression and 
delusion scores. Putamen binding was negatively correlated with UPDRS score. A more 
recent and larger study (n=51) using 
123
I-PE2I found no relationship between dopamine 
transporter binding and MMSE score, Hoehn and Yahr score  of PD severity, or the 
presence of hallucinations and fluctuations (Ziebell et al., 2013). However, a study 
involving serial scans 1 year apart found that decline in FP-CIT binding in the posterior 
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putamen was associated with decline in cognition; there was no correlation with change 
in UPDRS score (Colloby et al., 2005). 
 
1.1.9 Other Biomarkers 
1.1.9.1 Structural and Functional Imaging 
DLB is associated with brain atrophy on structural imaging, particularly in subcortical 
structures. The medial temporal lobe is relatively spared compared with AD (Watson et 
al., 2009). 
 
Imaging of cerebral perfusion and glucose metabolism can be achieved using SPECT 
and PET imaging. DLB is associated with hypoperfusion and hypometabolism, most 
marked in the posterior parietal and occipital regions, with relative sparing of the 
posterior cingulate and medial temporal areas, which are particularly affected in AD  
(Sinha et al., 2012). 
18
F-FDG PET is more effective than perfusion SPECT at 
differentiating dementia from controls (Area under the curve (AUC) 0.93 v 0.72), and 
differentiating DLB from AD (AUC 0.80 v 0.58) (O'Brien et al., 2014a). 
DLB with cognitive fluctuations is associated with lower functional connectivity in left 
frontoparietal, sensorimotor and temporal networks on functional MRI, without the 
disruption to the default mode network that is commonly seen in AD (Peraza et al., 
2014).  
 
1.1.9.2 Cardiac Imaging 
123
I-MIBG cardiac scintigraphy uses a noradrenaline analogue to detect the loss of 
presynaptic sympathetic nerve terminals in the heart. The autonomic nervous system is 
an early site of LB pathology and MIBG has been shown to differentiate between DLB 
and AD. A systematic review of 8 studies with a total of 152 DLB patients found a 
pooled sensitivity of 98% and specificity of 94% for the differentiation of DLB and 
other dementias (Treglia and Cason, 2012). However, a more recent multicentre study 
with 61 cases of probable DLB found a lower sensitivity of 69% and a specificity of 
89% (Yoshita et al., 2015). The reason for this difference is not clear, though Yoshita 
and colleagues commented that the sensitivity was higher in the mild dementia group, 
potentially reflecting greater accuracy of clinical diagnosis of DLB at this stage. In more 
advanced disease AD cases may be more likely to mimic DLB with the presence of 
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symptoms such as visual hallucinations or parkinsonism, resulting in contamination of 
the DLB group. 
 
Cardiac MIBG uptake can be abnormal in congestive cardiac failure, ischaemic heart 
disease and diabetic autonomic neuropathy (Chirumamilla and Travin, 2011). The 
results above were derived from cohorts that exclude those with heart failure and 
diabetes, both of which are common in the elderly, potentially limiting the 
generalisability of these results to a normal clinical population. A small study including 
patients with diabetes and heart failure found a sensitivity of 100% and specificity of 
75% but there were only 4 non-LB dementia and 16 LB dementia cases in this sample 
(Slaets et al., 2015). Although the sensitivity and specificity of MIBG appear 
comparable to FP-CIT SPECT, there is a need for large-scale studies in normal clinical 
populations along with post-mortem follow-up to determine its diagnostic accuracy. 
 
1.1.9.3 Amyloid Imaging 
Amyloid imaging in DLB is reviewed in Chapter 3. 
 
1.1.9.4 Fluid biomarkers 
There are no established fluid biomarkers for DLB. Conflicting reports of cerebrospinal 
fluid (CSF) αSyn level abnormalities in DLB have been published (Kasuga et al., 2012). 
This heterogeneity of results may reflect methodological differences in the measurement 
of αSyn, or cerebrospinal fluid contamination with red blood cells, which are relatively 
rich in αSyn (Kasuga et al., 2012). CSF Aβ42 is decreased in both AD and DLB, 
consistent with the finding of amyloid deposition in some cases of DLB in PET imaging 
studies (Sinha et al., 2012). On the other hand, tau levels are higher in AD than DLB, 
consistent with a relative lack of tau pathology in DLB (Ferreira et al., 2014).  
Several other potential biomarkers have been investigated including serum fatty acid 
binding protein levels and CSF calcium, magnesium and cocaine and amphetamine 
regulated transcript levels, but these require further investigation (Schade and 
Mollenhauer, 2014). 
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1.1.9.5 EEG 
Increased EEG slow wave activity and increased frequency variability are seen in DLB 
compared with AD in posterior cortical areas (Bonanni et al., 2008). Increased 
frequency variability correlates with clinical measures of fluctuations (Walker et al., 
2000a). 
 
1.1.10 Management 
There are no treatments available that slow or reverse the pathologic progression of 
DLB. Symptomatic pharmacological treatments are available for some of the cognitive 
and non-cognitive symptoms of the disorder. 
 
1.1.10.1 Cognitive symptoms 
Reductions in cholinergic activity are greater in DLB than AD, and occur earlier in the 
disease course (Tiraboschi et al., 2002). These reductions may be the product of Lewy 
body pathology and neuronal loss in the nucleus basalis of Meynert (Lippa et al., 1999). 
Relationships have been found between reduced cholinergic activity and cognitive 
dysfunction (Tiraboschi et al., 2002) and visual hallucinations (Francis and Perry, 
2007). Acetylcholinesterase inhibitors are the mainstay of drug treatment in DLB, both 
for cognitive and non-cognitive symptoms. Three double-blind, randomised controlled 
trials of acetylcholinesterase inhibitors in DLB have been reported. Rivastigmine was 
found to reduce neuropsychiatric symptoms (apathy, anxiety, delusions, hallucinations 
and aberrant motor behaviour), as well as improving scores in computerised tests of 
attention and memory (McKeith et al., 2000). Donepezil was found to improve 
cognitive function measured by the MMSE (Mori et al., 2012; Ikeda et al., 2015). This 
cognitive improvement was sustained over 52 weeks in an open-label continuation 
study (Mori et al., 2015). There is conflicting evidence on whether donepezil reduces 
neuropsychiatric symptoms (Mori et al., 2012; Ikeda et al., 2015).  
 
The NMDA-receptor blocker memantine has also been investigated for its use in DLB. 
Two randomised, placebo-controlled trials in mixed DLB/PDD groups produced 
somewhat conflicting results. The first study found an improvement in global status in 
the combined DLB/PDD group, but no difference in the DLB subgroup, and no 
difference in neuropsychiatric symptoms measured by the Neuropsychiatric Inventory 
(NPI) (Aarsland et al., 2009). In the combined PDD/DLB group they did find an 
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improvement in computerised tests of memory and choice reaction time (Wesnes et al., 
2014). The second, larger trial found an improvement in global status and a relative 
improvement in neuropsychiatric symptoms (delusions, hallucinations, night-time 
behaviour and appetite/eating disorders) in the DLB group treated with memantine 
(Emre et al., 2010). This study did not find any improvement in choice reaction time. 
Neither study found any significant improvement in activities of daily living scales. 
 
1.1.10.2 Non-cognitive symptoms 
The principal treatment for parkinsonism in DLB is levodopa, though the treatment may 
be less effective in DLB than PD (Molloy et al., 2005; Lucetti et al., 2010). Other 
therapies used in Parkinson’s disease (e.g. dopamine agonists, anticholinergics, 
selegiline and amantadine) are unsafe due to side effects such as confusion, somnolence 
and hallucinations (Molloy et al., 2005). Levodopa may also be associated with similar 
side-effects, but is tolerated in the majority of patients (Molloy et al., 2005). 
 
Antipsychotics are generally not recommended for psychotic symptoms in DLB as their 
efficacy is unproven (Aarsland et al., 2012), and they are associated with severe adverse 
effects (McKeith et al., 1992; Ballard et al., 1998). Where treatment with an 
antipsychotic is felt necessary quetiapine and clozapine may be least likely to cause 
adverse-effects, whereas antipsychotics with strong D2-blocking actions are best 
avoided (e.g. typical antipsychotics, olanzapine, riperidone) (Boot et al., 2013a). 
 
The treatment of RBD in DLB is based on general guidelines for the management of 
RBD. The American Academy of Sleep Medicine recommends the use of clonazepam 
or melatonin (Aurora et al., 2010). Clonazepam is associated with greater side-effects, 
such as sedation, but also has a stronger evidence base. 
 
1.1.11 Summary 
DLB is a common form of dementia characterised by the presence of symptoms such as 
visual hallucinations, parkinsonism, cognitive fluctuations, RBD and sensitivity to 
neuroleptic medications. The pattern of cognitive impairment in DLB differs from AD, 
with less marked amnestic impairment and more marked visuospatial, attentional and 
frontal-executive impairments. αSyn-containing LBs and LNs are the pathological 
hallmarks of DLB. DLB is associated with less cortical atrophy than AD and cortical 
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hypoperfusion and hypometabolism tend to be more marked in occipital regions. 
Nigrostriatal dopaminergic and cardiac sympathetic denervation can be detected using 
SPECT imaging and are used in the diagnosis of DLB. The management of DLB is 
based on symptomatic treatment of cognitive impairment, parkinsonism, RBD and 
neuropsychiatric symptoms.  
 
1.2 Alzheimer’s Disease 
1.2.1 Epidemiology 
Alzheimer’s disease (AD) is the most common type of dementia, accounting for around 
70% of all cases (Reitz et al., 2011). Based on overall dementia prevalence figures from 
the Cognitive Function and Ageing Study, this would equate to around 470,000 people 
in the UK in 2011 (Matthews et al., 2013). 
 
1.2.2 Clinical features and diagnostic guidelines 
AD is characterised by a dementia of insidious onset and gradual progression, usually 
with prominent amnestic symptoms (McKhann et al., 2011). In some cases the most 
prominent deficits are in language, visuospatial or executive function, but by definition 
the deficit is not focal, and involves at least two domains of cognition. Neuropsychiatric 
symptoms are common in AD. The most common features include apathy, irritability 
and agitation (Craig et al., 2005). Hallucinations are less common and tend to occur 
later in the course of the illness (Ferman et al., 2013a). 
 
A definitive diagnosis of AD can only be made at post-mortem. Clinical criteria for 
‘probable AD’ are displayed in Table 1.3. The diagnosis of probable AD is to some 
extent a diagnosis of exclusion, and cannot be made in the presence of evidence of other 
disorders such as vascular dementia, DLB or frontotemporal dementia. The updated 
National Institute on Ageing/Alzheimer’s Association (NIAAA) criteria include the use 
of biomarkers for the diagnosis of ‘probable AD dementia with evidence of the AD 
pathophysiological process’ (McKhann et al., 2011). These are markers of amyloid 
pathology (low CSF Aβ42 or positive amyloid PET imaging) and biomarkers of neuronal 
degeneration or injury (elevated CSF tau, hypometabolism in the temporo-parietal 
cortex on 
18
F-FDG PET and disproportionate atrophy in the medial, basal and lateral 
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temporal lobe and medial parietal cortex). In recent years considerable attention has 
been given to the concept of prodromal AD, this will be discussed in Chapter 2. 
 
1.2.3 Genetics 
Early onset AD can cluster in families, showing an autosomal dominant pattern of 
inheritance. Three genes involved in amyloid production (APP, PSEN1 and PSEN2) 
have been identified that have high penetrance for early onset AD (Bettens et al., 2013). 
However, the majority of cases of AD are sporadic, with onset later in life. Many 
genetic and non-genetic risk factors (e.g. cerebrovascular disease, head injury and type 
2 diabetes) have been identified (Reitz and Mayeux, 2014). The most clearly established 
genetic risk factor is the APOE gene. The APOE ε4 allele is associated with an 
increased risk of developing AD, whereas the APOE ε2 allele confers decreased risk. 
One copy of APOE ε4 increases the risk of developing AD by a factor of 3 and two 
copies increase the risk by a factor of 12 (Verghese et al., 2011). The mechanism of this 
effect is unknown and may be via amyloid-β (Aβ) metabolism or through another 
pathway such as tau phosphorylation, cell signalling or lipid metabolism (Verghese et 
al., 2011). Recent large genome-wide association studies have identified other genes 
that may be associated with AD, including genes involved in the immune system, APP 
pathways, tau pathways, and lipid metabolism (Reitz and Mayeux, 2014). 
 
1.2.4 Neuropathology 
The two most characteristic neuropathological findings, considered essential for the 
diagnosis of AD, are neurofibrillary tangles (NFTs) and Aβ plaques (Hyman et al., 
2012). NFTs are intracellular accumulations of the microtubule-associated protein tau 
and are the pathology most strongly correlated with cognitive deficit in AD (Nelson et 
al., 2012). The Aβ peptide, like tau, is a normal cellular constituent. Aβ can form 
extracellular deposits containing various other proteins, lipids and cells. These can be 
classified as diffuse, focal or stellate (Duyckaerts et al., 2009). Aβ accumulation can 
also occur in vessel walls, termed cerebral amyloid angiopathy. Neuritic plaques are a 
type of focal plaque containing an Aβ core surrounded by dystrophic neurites. Post-
mortem studies have found that this type of plaque is most closely associated with 
neuronal injury and cognitive deficit (Nelson et al., 2012).  
The revised NIAAA Guidelines for the neuropathologic assessment of AD (Hyman et 
al., 2012) recommend a 3 dimensional ‘ABC’ approach – NFTs, amyloid plaque and 
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neuritic plaque pathology are each rated from 0-3 based on established criteria. These 
measures are then combined to give an overall measure of likelihood of AD (Table 1.4). 
 
 
The criteria are supported by findings from a neuropathologic cohort. 91% of those with 
high scores on semiquantitative measures for NFTs and neuritic plaques had moderate 
or severe dementia (Hyman et al., 2012). That said, some cases with significant AD 
pathology did not display signs of dementia before death. The importance of amyloid in 
the pathogenesis of AD remains controversial. The amyloid hypothesis posits that Aβ is 
the initiating factor of a cascade of events that leads to tau tangle formation, cell death 
and the clinical syndrome of AD (Karran et al., 2011). This is supported by evidence 
that Aβ is found in the brains of people clinically diagnosed with AD both at post-
mortem and more recently during life using PET amyloid imaging (Jack et al., 2013). In 
addition, genes associated with early-onset Alzheimer’s disease such as APP, PSEN1 
and PSEN2 are known to be involved in the production of amyloid from APP, and the 
APOE ε4 gene may be involved in amyloid clearance (Karran et al., 2011). Set against 
this are the findings that amyloid load does not correlate well with disease progression, 
many people with plaques do not experience dementia and AD-like cognitive decline 
Table 1.3. Criteria for the diagnosis of probable AD (from the NIAAA criteria 
(McKhann et al., 2011)) 
1. Meets Criteria for dementia  
- Evidence of cognitive decline in at least two domains 
- Significant interference in ability to function at work or usual daily activities 
 
2. In addition the dementia has the following characteristics 
- Insidious onset 
- Clear cut history of worsening cognition 
- The initial and most prominent cognitive deficits are in the areas of memory, language, 
visuospatial or executive function 
 
The diagnosis of probable AD should not be given when there is evidence of substantial 
cerebrovascular disease, core features of Lewy body disease, prominent features of 
frontotemporal dementia or primary progressive aphasia or another neurological or 
medical disease that may have a substantial effect on cognition. 
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and brain atrophy can occur in the absence of significant Aβ (Fjell and Walhovd, 2012). 
Perhaps most importantly, recent trials of anti-amyloid therapies have been 
unsuccessful, despite some agents demonstrating efficacy at Aβ removal from the brain 
(Sarazin et al., 2013). Large-scale neuroimaging studies currently underway may help to 
clarify the importance of amyloid in AD. 
 
 
Table 1.4. Evaluation of AD pathological change according to NIAAA guidelines 
(Hyman et al., 2012). 
Amyloid 
Plaque Phase 
Neuritic Plaque 
Score 
Neurofibrillary Tangle Stage 
0-II III/IV V/VI 
0 0 Not Not Not 
1/2 0/1 Low Low Low 
2/3 Low Intermediate Intermediate 
3 0-3 Low Intermediate Intermediate 
4/5 0/1 Low Intermediate Intermediate 
2/3 Low Intermediate High 
The degree of amyloid plaque (Thal et al., 2002), neuritic plaque (Mirra et al., 1991) 
and neurofibrillary tangle (Braak and Braak, 1991) pathology is rated on three 
semiquantitative scales. The likelihood that this pathology is sufficient explanation for 
dementia is then classed as ‘low’, ‘intermediate’ or ‘high’. 
 
 
1.2.5 Imaging and other biomarkers 
1.2.5.1 Structural Imaging 
The early stages of AD are associated with hippocampal and entorhinal cortex atrophy 
on structural MRI, this is followed by more widespread medial temporal atrophy and 
involvement of the parietal and frontal lobes as well as subcortical structures such as the 
thalamus (Zakzanis et al., 2003). This atrophy is correlated with cognitive decline 
(Braskie and Thompson, 2014). 
 
1.2.5.2 Functional Imaging 
In AD impaired perfusion and glucose metabolism are observed in temporo-parietal 
areas, particularly the angular gyrus, the cuneus and the posterior cingulate cortex 
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(Herholz, 2011). Metabolism in the basal ganglia, motor cortex and visual cortex is well 
preserved. 
 
1.2.5.3 Amyloid PET Imaging 
Amyloid imaging using the 
11
C ligand Pittsburgh Compound B (PiB) has been in use 
for a decade (Klunk et al., 2004). More recently, 
18
F ligands such as Florbetapir, 
Flutametamol and Florbetaben have been developed,  allowing amyloid imaging to 
become more widely used due to the longer half-life of 
18
F (110 minutes) compared 
with 
11
C (20 minutes) (Herholz and Ebmeier, 2011). These ligands bind to fibrillar 
amyloid and correlate well with Aβ plaque pathology assessed at autopsy, though some 
medial temporal lobe areas known to undergo early Aβ deposition, such as 
parahippocampal gyrus and occipitotemporal gyrus do not show high ligand binding 
(Jack et al., 2013). 
The prevalence of amyloid deposition in cognitively healthy people increases with age 
(Jack et al., 2014). At the age of 70 around 23% of cognitively normal subjects, 49% of 
MCI subjects and 88% of people with AD have positive amyloid PET scans (Jansen et 
al., 2015; Ossenkoppele et al., 2015). MCI subjects and normal controls with significant 
amyloid pathology demonstrate more rapid brain atrophy and are more likely to convert 
to dementia than those with negative scans (Rowe et al., 2013; Doraiswamy et al., 
2014; Huijbers et al., 2015; Vemuri et al., 2015). There have been inconsistent reports 
of correlation between amyloid ligand binding and cognitive impairment in AD, though 
the association may be stronger in MCI (Braskie and Thompson, 2013).  
 
1.2.5.4 Fluid biomarkers 
Compared with healthy controls, decreased Aβ42, increased total tau and increased 
phospho-tau each have a sensitivity in the region of 80% and specificity between 80 and 
90% for AD (Ferreira et al., 2014). Sensitivity and specificity can be increased by 
combining Aβ42 and total tau markers. These markers are much less accurate in 
differentiating between AD and other dementias (Ferreira et al., 2014). The clinical 
utility of CSF biomarkers is limited by huge variability in results between different 
sites, possibly due to variations in procedures for the collection, processing and analysis 
of samples. Even within sites results can vary based on assay batches used 
(Vanderstichele et al., 2012). There are no validated blood biomarkers for AD at present 
(Rosen et al., 2013). 
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1.2.6 Management 
The acetylcholinesterase inhibitors donepezil, galantamine and rivastigmine, along with 
the NMDA antagonist memantine are the mainstay of symptomatic treatment of 
cognitive impairment in AD (Tan et al., 2014). Non-drug treatment of the highly 
prevalent behavioural and psychological symptoms of AD should be used before 
medication except in severe behavioural disturbance. Drugs are considered a last option 
due to the prevalence of severe side effects, particularly with antipsychotic medications 
(Schneider et al., 2005; Ihl et al., 2011). Non-pharmacological interventions such as 
care-giver education and support may delay institutionalisation (Olazaran et al., 2010) 
and cognitive training and ADL training may improve specific areas of function 
(Olazaran et al., 2010). No disease modifying agent for AD has yet been established. 
 
1.2.7 Summary 
AD is characterised by the insidious onset and gradual progression of cognitive 
impairment, usually with prominent amnestic features. Aβ plaques and NFTs are found 
post-mortem in AD, but the pathophysiological significance of Aβ in the development 
of AD remains controversial. AD is associated with cortical atrophy on structural 
imaging, particularly in the medial temporal lobes; cerebral hypometabolism and 
hypoperfusion on SPECT or PET imaging and amyloid deposition on PET imaging. 
CSF Aβ, tau and phospho-tau can be used to differentiate AD from controls, but are less 
useful in differentiating between AD and other dementias. Cholinesterase inhibitors and 
memantine are used to improve cognitive function in AD, though no disease modifying 
agents are yet available.  
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2 Chapter 2   Prodromal Dementia with Lewy bodies 
2.1 Introduction 
The clinical condition of dementia, by definition a global cognitive decline with 
functional impairment, is now recognised as a diagnosis that can only be applied too 
late in the disease process to be useful for current and future therapeutic approaches 
which centre on disease modification. As a result, in recent years increasing research 
attention has been given to mild cognitive impairment (MCI) and the diagnosis of 
prodromal dementia. Petersen et al. (1999) described MCI as an entity with clinical 
characteristics intermediate between dementia and healthy controls, and high rates of 
conversion to dementia (most commonly Alzheimer’s disease, because of the amnestic 
weighting of the MCI definition). Later, the diagnosis was refined to subcategorise MCI 
into amnestic and non-amnestic MCI (aMCI and naMCI respectively), depending on 
whether memory was significantly affected or not (Petersen et al., 2001; Winblad et al., 
2004). aMCI was hypothesised to precede AD or vascular dementia, whereas naMCI 
was felt more likely to precede dementia with Lewy bodies (DLB), vascular dementia or 
frontotemporal dementia (Petersen, 2004). That said, these are descriptive terms, and do 
not imply any specific pathological cause for the cognitive impairment. 
 
Following the disappointing results in recent trials of anti-amyloid therapies, some have 
hypothesised that such treatments may only be successful in the earliest stages of the 
disease (Aisen et al., 2013). This, coupled with the expectation that different types of 
dementia will require different treatments has led to the development of diagnostic 
criteria for prodromal dementia i.e. criteria that do specify the pathological cause of 
mild cognitive impairment. AD, the most common type of dementia, has received 
significant attention in this regard. Criteria for the diagnosis of MCI due to AD (Albert 
et al., 2011) and prodromal AD (Dubois et al., 2010) have been put forward. These 
diagnostic criteria are similar to previous descriptions of aMCI but also include 
validated disease biomarkers indicative of brain amyloid deposition and/or neuronal 
injury.  
The existence of a prodromal phase of DLB is to be expected, given the insidiously 
progressive nature of the disorder, as with AD. There are validated consensus criteria 
for the clinical diagnosis of DLB (McKeith et al., 2005). These display high positive 
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predictive value for the post-mortem neuropathological classification of intermediate- or 
high-likelihood DLB (Fujishiro et al., 2008). Prodromal DLB may display some of the 
features characteristic of established DLB (Table 2.1) (McKeith et al., 2005; Troster, 
2008). The identification of a DLB prodrome would enable investigation of the early 
pathophysiology of DLB and the development of treatments to interrupt these 
pathophysiological processes. Prodromal DLB may require different management from 
other dementia prodromes. For example, DLB may potentially be more responsive to 
Table 2.1. Diagnostic features of DLB (from McKeith et al., 2005) 
 
Pattern of cognitive deficits – impairments of attention, executive and visuospatial 
function 
 
Core features – spontaneous parkinsonism, complex visual hallucinations, fluctuating 
cognition 
 
Suggestive features – REM sleep behaviour disorder (RBD), neuroleptic sensitivity, 
reduced dopamine transporter density in the striatum 
 
Supportive features – repeated falls/syncope, transient unexplained loss of 
consciousness, autonomic dysfunction, depression, hallucinations, delusions  
 
Imaging findings and other biomarkers – preservation of medial temporal lobe 
structures on structural imaging, reduced occipital perfusion, abnormal MIBG 
myocardial scintigraphy, EEG abnormalities 
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cholinesterase inhibition in its prodromal phase, given the early and widespread 
cholinergic losses seen in DLB compared with AD (Tiraboschi et al., 2002). 
This chapter reviews the evidence available on the prodromal presentation of DLB, 
examining if mild cognitive impairment or other symptoms and biomarker 
abnormalities can be observed prior to the development of dementia. Before this, the 
neuropathology of DLB will be reviewed, as it may provide insights into the likely 
presentation of prodromal DLB. 
 
2.2 The neuropathology of DLB 
Knowledge of the temporal development of LB pathology may guide our hypotheses on 
the prodromal presentation of DLB. Much of the work on the pathology of Lewy body 
disease comes from research in Parkinson’s disease.  Just over a decade ago, Braak and 
colleagues proposed a staging system for Lewy pathology in Parkinson’s disease (Braak 
et al., 2003). In a sample of brains from PD patients and asymptomatic individuals with 
LB disease they found that all could be classified into one of six stages of disease 
development. At the earliest stage (stage 1), LB pathology was confined to the dorsal 
motor nucleus of cranial nerves IX/X and the intermediate reticular zone of the medulla. 
Over the subsequent stages LB pathology ascended sequentially through the pons, 
midbrain and subcortical structures to finally affect the neocortex itself in stages 5 and 
6. A key feature of Braak staging was that the sequential ascent of LB pathology from 
the brainstem to the neocortex was common to all cases – i.e. the cortex was not 
involved in every case, but where the cortex was affected, so were lower structures such 
as the limbic system and brainstem. Others  have observed that LB pathology does not 
necessarily follow this pattern of distribution, particularly when cases are sampled from  
the general population, in which LB pathology can be found in higher centres such as 
the neocortex, despite sparing of lower regions (Parkkinen et al., 2005; Zaccai et al., 
2008; Beach et al., 2009; Frigerio et al., 2011). Nevertheless, it is clear that some 
structures are particularly susceptible to LB pathology and may potentially act as 
‘sentinels’ for the development of LB disease: the olfactory bulb (Beach et al., 2009); 
the dorsal motor nucleus of the vagal nerve and other brainstem structures (Braak et al., 
2003) and the peripheral autonomic nervous system (Minguez-Castellanos et al., 2007; 
Palma and Kaufmann, 2014), including the enteric nervous system (Braak et al., 2006). 
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As such, symptoms or biomarkers reflecting dysfunction in these areas may be some of 
the earliest indicators of DLB. 
 
2.3 Epidemiological studies of rates of conversion from MCI to DLB 
Four studies have prospectively followed-up patients with MCI for the development of 
DLB. However, these studies studied diverse populations with varying duration of 
follow-up. Unsurprisingly they found very different results.  
Two studies based in tertiary referral centres found that 20-30% of MCI cases 
converting to dementia had probable DLB (Bombois et al., 2008; Ferman et al., 2013b). 
A memory-clinic cohort found 5.6% of MCI cases that later developed dementia had 
DLB (Palmqvist et al., 2012). Conversely, a population-based cohort, the majority of 
whom were cognitively healthy at baseline, found no cases that converted to probable 
DLB, but 11% of dementia cases had possible DLB (Fischer et al., 2007). 
Despite the heterogeneity of these results, it is clear that at least some cases of DLB 
have an identifiable MCI stage. Interestingly, one study found that naMCI had a much 
higher annual conversion rate to DLB than aMCI (20% v. 1.5%) (Ferman et al., 2013b). 
(Ferman et al., 2013b). 
In a post-mortem study of 134 patients who died with a diagnosis of MCI, 8 (6%) had 
cortical Lewy bodies (LBs); 5 of these 8 in the absence of vascular or AD pathology. A 
further 10% had nigral or limbic LBs (Schneider et al., 2009). Saito and Murayama 
(2007) found  that, of 33 MCI cases showing degenerative pathology post-mortem, 6 
(18%) had LB pathology, with half of these showing only DLB type changes. Another 
small study of an aMCI group found that 1/15 cases had transitional LB pathology post-
mortem, along with some AD pathology (Petersen et al., 2006). 
 
2.4 Clinical studies of the symptoms of prodromal DLB 
Three prospective studies have compared the prevalence of core and suggestive features 
in MCI cases that later developed DLB (LB-MCI) to those that later developed AD 
(AD-MCI) 
A longitudinal study of MCI (both amnestic and non-amnestic) found that those 
converting to DLB had higher rates of RBD, cognitive fluctuations and daytime 
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sleepiness than those that converted to AD (Ferman et al., 2013b). 53% of DLB-MCI 
had one or more core features of LB disease at least one year before the estimated onset 
of cognitive symptoms, compared to 2% of AD-MCI. Two other longitudinal studies 
confirmed the increased prevalence of core features of LB disease and RBD in LB-MCI 
compared with AD-MCI (Cagnin et al., 2015; Yoon et al., 2015). The reported 
prevalence of each symptom varied between cohorts (Table 2.2), each of which used 
different methods to identify diagnostic features. It would seem that RBD is the most 
common diagnostic feature, but all symptoms appear to be relatively common. 
Though two studies found significantly higher scores in the UPDRS in LB-MCI than 
AD-MCI, the severity of parkinsonism was very mild (mean UPDRS = 4.9 (Ferman et 
al., 2013b) and 4.4 (Yoon et al., 2015)). 
 
 
Three further studies (Auning et al., 2011; Chiba et al., 2012; Fujishiro et al., 2013b) 
have asked patients with DLB and/or their carers to retrospectively report on the early 
symptoms of DLB (Table 2.3). 
Auning et al. (2011) interviewed carers of patients newly diagnosed with mild DLB 
about the presenting symptoms of DLB (MMSE>20; n=61). Visual hallucinations 
(44%), gait problems (28%), tremor/stiffness (25%) and a tendency to fall (13%) were 
significantly more common in DLB compared with an AD control group, whereas 
memory problems were significantly less common. Fluctuating cognition was not 
offered as an option for presenting symptom. Carers did have the opportunity to report 
symptoms not on the preselected list, but any other reported symptoms were infrequent 
(<10%). 
Table 2.2. Prevalence of DLB diagnostic features in LB-MCI in longitudinal studies 
 Ferman et al. 2013 Yoon et al. 2015 Cagnin et al. 2015 
Visual Hallucinations (%) - 39* 30* 
Parkinsonism (%) - 78* 63* 
Fluctuations (%) 41* 22* 53* 
RBD (%) 80* 67* 57* 
* = significantly more common than AD-MCI comparison group 
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Chiba et al. (2012) asked patients and carers to fill in a survey of pre-defined symptoms 
without any additional instruction. They looked at the temporal onset of symptoms 
relative to memory loss. This was to allow comparison of DLB (n=34) and AD (n=32), 
both of which are associated with progressive memory impairment. 
The most common symptoms present in the same year as the onset of memory loss were 
sleep rhythm change (62%), crying/shouting in sleep (62%), anosmia/hyposmia (41%), 
constipation (47%) and limb movements in sleep (35%; Table 2.3). 
Of those symptoms that were more common in DLB than AD, the earliest to develop 
were constipation (mean = 9.4 years before memory impairment); crying/shouting 
during sleep (4.9 years); limb movements during sleep (3.9 years); anosmia/hyposmia 
(2.9 years) and nightmares (2.5 years). 
The three symptoms taken to be most representative of DLB (due to high prevalence in 
DLB and relatively low prevalence in AD/controls) were crying/shouting during sleep, 
constipation and anosmia/hyposmia. One or more of these symptoms differentiated 
DLB from AD with a sensitivity of 0.71 and a specificity of 0.81. Increasing the 
threshold to two or more symptoms resulted in a decrease of sensitivity to 0.38 but an 
increase in specificity to 0.97. The questionnaire did not enquire about parkinsonism, 
hallucinations or fluctuations. 
The same group later assessed the presence and time of onset of core features and eight 
symptoms of Lewy body disease in 90 patients with probable DLB (Fujishiro et al., 
2013b). There was no comparison group. As with the previous study, the presence of 
each symptom at the onset of memory loss was recorded. This study found comparable 
rates of constipation, anosmia/hyposmia, RBD, depression and orthostatic dizziness to 
their previous study (Table 2.3). Lower rates of urinary incontinence were found (8%), 
and syncope was relatively rare (7%).  
This study confirmed that constipation, anosmia and RBD often precede the onset of 
memory loss by several years. Visual hallucinations and extrapyramidal symptoms each 
were present in around one third of individuals at the onset of memory loss, though on 
average these symptoms developed 1.5 years after memory loss. 
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Table 2.3. Prevalence of key symptoms in retrospective clinical studies of prodromal 
DLB 
 
Auning et al. 2011 
(% of DLB patients 
with symptom as a 
presenting symptom; 
n=61) 
Chiba et al. 2012 
(% of DLB patients 
with each symptom 
in year of onset of 
memory loss; n=34) 
Fujishiro et al. 2013 
(% of DLB patients 
with each symptom 
in year of onset of 
memory loss; n=90) 
 
Cognitive Problems 
Memory 57 100 100 
Problem- solving 33   
Language 16   
 
Neuropsychiatric Symptoms 
Visual Hallucinations 44*  31 
Depression 34 24 19 
Anxiety  26*  
Lack of motivation  26  
 
Locomotor Symptoms 
Tremor/stiffness 25*   
Gait problems 27*   
Falls 13*   
Extrapyramidal signs   31 
 
Autonomic symptoms 
Constipation  47* 57 
Orthostatic dizziness  24* 18 
Urinary incontinence  27 8 
Increased salivation  21*  
 
Sleep symptoms 
Sleep rhythm change  62*  
Crying/shouting in 
sleep 
 62*  
Limb movements  35*  
Nightmares  27*  
RBD   46 
 
Other 
Anosmia/hyposmia  41* 38 
* = significantly more common than AD (no comparison group in Fujishiro et al.) 
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2.5 Post-mortem studies of prodromal symptoms of DLB 
Some post-mortem studies of established DLB have retrospectively assessed the 
chronological development of symptoms. Ferman et al. (2011) examined 98 patients 
with intermediate-high likelihood of DLB on post-mortem examination who had been 
part of a longitudinal study.  On average, RBD preceded dementia by 6 years (with wide 
variation (SD=12 years), possibly reflecting some cases with very early onset RBD). 
Conversely visual hallucinations and parkinsonism followed the estimated dementia 
onset by an average of 2.6 and 1.8 years respectively. Another Mayo Clinic post-
mortem study examined 52 patients diagnosed during life with probable or possible 
DLB (Fujishiro et al., 2008). The authors remarked that “RBD antedated the diagnosis 
of DLB in almost all cases in which RBD was noted”, whereas the presence of notable 
visual hallucinations followed the development of dementia by an average of 2.8 years. 
 
Both of the above studies recruited subjects when they had already been diagnosed with 
dementia and prospectively collected information through regular clinical and 
neuropsychiatric assessments. Two further studies specifically recruited non-demented 
subjects for prospective follow-up. These studies reported a different pattern of 
symptom development in prodromal DLB. 
 
Jicha et al. (2010) enrolled cognitively normal patients for regular clinical follow-up 
and brain donation following death. Nine patients with neocortical DLB post-mortem 
and no significant AD or vascular pathology had an identified MCI phase during their 
illness. This group was compared with 12 patients with a post-mortem diagnosis of AD. 
None of the AD-MCI group displayed parkinsonism, cognitive fluctuations or 
psychiatric symptoms (hallucinations/delusions/paranoia) during the MCI phase. 8/9 
MCI-DLB demonstrated at least one of these features concurrent with the MCI 
diagnosis (parkinsonism n=5; fluctuations n=3; psychiatric symptom n=4).  
DLB-MCI was associated with significant memory impairment, but the group 
performed better on immediate recall than AD-MCI. They were worse on phonemic 
fluency and tended toward being worse at trail-making, but were better at the Boston 
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Naming Test. It must be noted that, due to the strict inclusion criteria, these findings 
only represent the MCI phase of patients with later neocortical LB deposition (i.e. a 
subset of all those who have DLB, some of whom will not have cortical involvement) 
and without significant vascular or AD pathology. 
 
In a similar study, Molano et al. (2010) identified 8 patients from their research 
databases that had been prospectively followed up after a diagnosis of MCI, and later 
were found have LB disease post-mortem (limbic- or neocortical-predominant). In the 
year of MCI diagnosis, or preceding this, 5 displayed parkinsonism and 3 had visual 
hallucinations, whereas none displayed fluctuations. RBD was present in 7 cases at the 
diagnosis of MCI, preceding it by up to 47 years.  
7 cases developed dementia before death. Of these 5 had parkinsonism, 5 had 
hallucinations and 2 had fluctuations before the development of dementia. 
The patients had a variety of MCI subtypes. Attention/executive function (n=6) and 
visuospatial function (n=6) were the cognitive domains most commonly affected.  
 
2.6 Cognitive profile of prodromal DLB 
Whereas amnestic impairments are by definition usually an early feature of AD, 
attention, executive and visuospatial impairments are more characteristic of DLB 
(Metzler-Baddeley, 2007). These differences are present in the prodromal stage, with 
non-amnestic MCI cases being 10 times more likely to convert to clinically diagnosed 
DLB than AD in one sample, and amnestic MCI 10 times more likely to convert to AD 
than DLB (Ferman et al., 2013b). Single domain amnestic MCI was particularly 
unlikely to progress DLB, with 88% of those converting to DLB having impairment in 
attention and/or visuospatial function at baseline assessment. That said clinically 
significant memory impairment was present in over 30% of LB-MCI cases. 
Two other longitudinal studies have investigated the pattern of cognitive deficits in MCI 
cases that later developed DLB (LB-MCI) compared with those that later developed AD 
(AD-MCI). LB-MCI displayed worse attention/executive function (trailmaking A, digit 
span, Stroop colour test), better memory (delayed recall, recognition) and worse 
visuospatial function (Rey complex figure test, number of angles in pentagon-drawing 
test) than AD-MCI (Cagnin et al., 2015; Yoon et al., 2015). 
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2.7 Biomarkers in Prodromal DLB 
2.7.1 Striatal Dopamine Terminal Imaging  
Striatal dopaminergic imaging is a sensitive and specific biomarker for the diagnosis of 
DLB (Papathanasiou et al., 2012) and is a suggestive feature in the 2005 diagnostic 
criteria (McKeith et al., 2005). There has been little investigation into its use in the 
prodromal stage of DLB. One study performed PET dopamine terminal imaging on 
subjects with MCI with follow-up for the development of DLB (Albin et al., 2013). Of 
27 MCI subjects, two had markedly reduced striatal 
11
C-dihydrotetrobenazine binding. 
Both developed dementia at follow-up; one was classified as DLB, the other as 
frontotemporal dementia. However, 3/25 MCI subjects with normal 
11
C-
dihydrotetrabenazine scans also developed DLB.  
 
2.7.2 Clinical Biomarkers 
There is no available evidence on fluid biomarkers in prodromal DLB.  
LB-MCI cases have significantly worse olfactory function than AD-MCI or stable MCI 
cases in the Cross-Cultural Smell Identification Test (area under the curve 0.84 for 
DLB-MCI v. AD-MCI and 0.91 for DLB-MCI v. stable MCI) (Yoon et al., 2015). 
 
2.7.3 Magnetic Resonance Imaging 
In a pathological study discussed above (Molano et al., 2010), 3 cases had serial MRI. 
Compared with previously published data, hippocampal volumes at the time of MCI and 
rates of hippocampal atrophy were within the range of cognitively normal subjects.  
A cross-sectional study of patients clinically diagnosed as prodromal DLB or prodromal 
AD found that prodromal AD displayed cortical thinning in the parietal lobes and left 
hippocampal gyri compared with prodromal DLB, whereas prodromal DLB displayed 
thinning in a small area of the right insula and pars opicularis (false discovery rate 
corrected) (Blanc et al., 2015). There were no differences between prodromal DLB and 
healthy controls after correction for false discovery rate. 
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In a group of 170 patients with MCI, baseline subcortical hyperintensities on MRI were 
associated with an increased risk of developing mixed or vascular dementia, but not 
DLB or other dementia subtypes (Bombois et al., 2008).  
A longitudinal MR spectroscopy study measured the ratios of N-acetylaspartate (NAA), 
Choline and myoinositol to creatine (Cr) in three cortical voxels (frontal, posterior 
cingulate and occipital) in MCI patients that later converted to DLB (n=10), AD (n-27) 
or remained stable (n=27) (Zhang et al., 2015). AD-MCI subjects had lower NAA/Cr in 
the precuneus voxel than DLB-MCI suggesting greater neuronal integrity in prodromal 
DLB compared with prodromal AD. There were no differences between the groups in 
any other measurements. 
Another study performed MR spectroscopy, diffusion weighted imaging (DWI) and 
perfusion imaging on 119 patients with MCI (Fayed et al., 2008). After follow-up 
subjects could be classified as AD (including mixed dementia, n=49); Lewy body 
dementia (LBD) (n=5; criteria not stated); MCI due to vascular disease (n=15); MCI 
due to depression (n=22); or MCI due to AD (n=28). There were no differences between 
LBD and the other groups in baseline spectroscopy or perfusion findings. On DWI in 
the right hippocampus, the LBD group higher baseline Apparent Diffusion Coefficient 
(ADC) values compared with the 3 MCI groups, indicating greater white matter 
disruption. The difference between LBD and AD approached significance (p=0.08). 
Values in the AD/mixed dementia group did not differ from the MCI groups. Baseline 
characteristics were not provided, so the findings could be due to differences between 
groups at baseline (e.g. age or severity of cognitive impairment). 
 
2.7.4 PET Imaging 
Clerici et al. (2009) performed 
18
F-FDG PET on 16 patients with single domain aMCI 
and 14 patients with naMCI with executive dysfunction. These were compared with 
controls that were undergoing PET scans for cancer restaging. Of those who completed 
follow-up, 1/14 aMCI and 5/12 naMCI developed DLB. In a voxel-based analysis, the 
naMCI who developed DLB had heterogeneous patterns of hypometabolism compared 
to controls. The inferior and mesial frontal; anterior and posterior cingulate; superior 
temporal and inferior parietal areas were most frequently involved. Frontal 
hypometabolism may have been expected, given that executive dysfunction was one of 
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the inclusion criteria for the naMCI group. This may not be representative of all 
prodromal DLB. 
Pardo et al. (2010) followed 19 army veterans with MCI for 3 years following baseline 
FDG-PET scans. Two developed DLB; both had an ‘AD-like’ pattern of 
hypometabolism (hypometabolism in medial parietal and lateral parietal regions) on 
visual inspection. Neither displayed occipital hypometabolism. Conversely, in another 
FDG-PET cohort of 45 subjects with MCI, two subjects displayed a ‘DLB-like’ pattern 
with occipital hypometabolism, and both later developed DLB (Cerami et al., 2015). 
Cases have been reported of occipital hypometabolism on 
18
F-FDG PET imaging 
(Fujishiro et al., 2013a) or cardiac sympathetic denervation measured by 
123
I-MIBG 
SPECT (Fujishiro et al., 2012) in non-demented individuals that later went on to 
develop DLB.  
 
2.7.5 EEG 
Resting state, eyes-closed EEG analysis was performed in 47 memory clinic cases of 
MCI, 20 of whom later developed DLB (Bonanni et al., 2015). All of the DLB-MCI 
cases had baseline EEG abnormalities, whereas 93% of AD-MCI cases had a normal 
EEG. Dominant frequency variability was significantly greater in DLB-MCI group than 
the AD-MCI or stable MCI groups. The proportion of DLB cases was high because 
21/47 cases were specifically selected because they had a core or suggestive feature of 
DLB in the MCI phase. 
 
2.8 REM Sleep Behaviour Disorder 
RBD is associated with high rates of conversion to dementia. Longitudinal studies have 
estimated that over half of patients with RBD go on to develop a neurodegenerative 
disorder which is nearly always a synucleinopathy (e.g. Parkinson’s disease (PD), 
Parkinson’s disease dementia, DLB, multi-system atrophy) if followed-up for more than 
a decade, rising to up to 93% if followed-up over longer periods (Postuma et al., 2009; 
Iranzo et al., 2013; Schenck et al., 2013). In these studies, 14-39% of those who 
developed a neurodegenerative disorder were diagnosed with DLB. 
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Studies specifically looking at RBD in DLB have confirmed that RBD tends to precede 
cognitive symptoms by several years (Boeve et al., 1998; Boeve et al., 2003). In some 
cases the gap is over 25 years (Claassen et al., 2010). Core symptoms may develop 
earlier in DLB patients with RBD than those without RBD (Dugger et al., 2012). 
 
2.8.1 Imaging in RBD to predict the development of DLB 
Dang-Vu et al. (2012) performed 
99m
Tc-ECD SPECT perfusion scanning on 20 patients 
with RBD who did not have dementia (though 13 had MCI), and compared these to 10 
healthy controls. After an average follow-up of 3 years, 5 RBD subjects developed DLB 
(criteria not stated) and 5 PD. All those who developed DLB had an initial diagnosis of 
MCI. The PD/DLB group had increased baseline hippocampal regional cerebral blood-
flow (rCBF) compared to the RBD group that did not develop neurodegenerative 
disease. The 5 DLB patients had increased hippocampal rCBF compared with controls. 
There were no significant differences between the PD and DLB groups. The PD/DLB 
group was on average 4.8 years older than the RBD subjects that did not develop 
disease. 
 
Iranzo et al. (2010) performed striatal dopamine terminal binding of 
123
I-FP-CIT and 
transcranial echosonography of the substantia nigra in 43 patients with RBD. Eight 
patients later developed neurodegenerative disease (5 PD, 2 DLB and 1 multi-system 
atrophy), all of whom had at least one abnormal imaging finding. 30% of those with an 
abnormal finding developed a neurodegenerative disease at 2.5 years, compared with 
0% of those with 2 normal scans. Both DLB cases displayed substantia nigra 
hyperechogenicity and one had reduced striatal 
123
I-FP-CIT uptake at baseline. 
 
2.8.2 Other biomarkers in RBD to predict the development of DLB 
Postuma and colleagues commenced a longitudinal study of RBD in 2004. After several 
years they have been able to identify baseline symptoms and signs that were associated 
with the development of neurodegenerative disease. In their latest report, 32 of 91 RBD 
subjects in their cohort had developed neurodegenerative disease (11 probable DLB, 4 
possible DLB, 17 parkinsonism) (Postuma et al., 2013). 
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The RBD group that developed neurodegenerative disease reported greater baseline 
levels of urinary dysfunction, erectile dysfunction and constipation than controls 
(Postuma et al., 2013). They did not report more symptoms of orthostatic hypotension, 
but did have a greater postural drop in blood pressure. These abnormalities were present 
four or more years before the development of neurodegenerative disease. The results of 
the RBD without neurodegenerative disease group were intermediate between the 
controls and the disease group, possibly reflecting that some of this group were in the 
process of developing a neurodegenerative disease. Baseline postural hypotension and 
urinary dysfunction were significantly more common in the disease than the non-disease 
RBD group. ECG measures of autonomic dysfunction did not predict the development 
of neurodegenerative disease in RBD (Postuma et al., 2010). 
Motor abnormalities assessed by the UPDRS, the alternate-tap test, the Purdue 
Pegboard and the timed up-and-go were all found to be abnormal in DLB three or more 
years before the diagnosis of dementia (Postuma et al., 2012). These tests appeared to 
be abnormal for longer periods before the development of DLB than PD. A multicentre 
study including this cohort found that patient-reported stooped posture (odds ratio (OR) 
1.88) and tremor (OR 2.03) were more common in patients that went on to develop 
neurodegenerative disease (Postuma et al., 2015b). Cardiovascular autonomic 
symptoms were also significantly more common (OR 1.28). 
 
Patients that developed DLB or PD dementia had abnormal baseline colour vision and 
olfactory function, assessed using the Farnsworth-Munsell-100-Hue and University of 
Pennsylvania Smell Identification tests respectively (Postuma et al., 2011). These 
abnormalities were present at the first assessment, up to 5 years before the development 
of dementia. Those with both abnormal olfaction and colour vision had an estimated 
disease-free survival (i.e. no DLB, PD dementia or PD) of 18%, compared with 82% of 
those with normal function on both tests. A separate study found that olfactory 
impairment assessed with  ‘Sniffin’ Sticks’ differentiated between those with RBD that 
later developed Lewy body disease and those that did not, with an area under the curve 
of  0.82 (Mahlknecht et al., 2015). 
In general, each of the abnormalities discussed above had high specificity but low 
sensitivity in identifying those with RBD that would go on to develop 
neurodegenerative disease. They were present some years before the diagnosis of 
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disease and tended to progress slowly. Postuma et al. (2015a) have suggested a 
combination of markers to predict risk of conversion from RBD to neurodegenerative 
disease. These could be used to identify patients at high risk of progression to DLB or 
PD. When olfaction, colour vision and motor tests were used, those with abnormalities 
in two of these areas had a 3-year conversion rate of 60%. 
 
2.9 Discussion 
2.9.1 Clinical presentation of prodromal DLB 
The above evidence suggests that DLB can be preceded by an MCI phase before the 
development of dementia. Two studies that followed up participants with MCI for the 
development of DLB (Fischer et al., 2007; Palmqvist et al., 2012) reported figures 
similar to reported rates of DLB in clinically diagnosed dementia samples (Vann Jones 
and O'Brien, 2014); though rates varied greatly between studies, most likely due to 
recruitment from different clinical populations. 
Although the data available are limited, the pattern of symptoms in prodromal DLB 
appears to differ from that of prodromal AD. Particular symptoms that are more 
frequent in prodromal DLB include RBD, autonomic dysfunction (including 
constipation and orthostatic dizziness), hyposmia, visual hallucinations and motor 
symptoms. Even without including core symptoms, prodromal DLB may be 
discriminated from prodromal AD with reasonable sensitivity and specificity (Chiba et 
al., 2012). The earliest symptoms of DLB are constipation, RBD and hyposmia. RBD 
has been demonstrated to precede DLB by decades in some cases. Table 2.4 shows 
approximate temporal relationships between symptoms in prodromal DLB from the 
evidence currently available. The order of symptom development is similar to that 
reported in PD (Gaenslen et al., 2011). 
 
Prodromal DLB can present with either amnestic or nonamnestic cognitive impairment 
(Fischer et al., 2007; Clerici et al., 2009; Molano et al., 2010), though naMCI is much 
more likely to progress to DLB than aMCI (Ferman et al., 2013b). This is supported by 
findings in a recent study comparing neuropsychological measures at initial presentation 
(including MCI and mild dementia cases) (Yoshizawa et al., 2013). Those with ‘pure’ 
DLB pathology at post mortem had greater visuospatial impairment and less memory 
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impairment at initial assessment compared to ‘pure’ AD or mixed DLB+AD pathology 
groups. 
 
There is conflicting evidence on when the core features of DLB develop. Two 
longitudinal post-mortem cohorts that recruited subjects with dementia found that core 
features developed after the onset of dementia (Fujishiro et al., 2008; Ferman et al., 
2011). Conversely, two longitudinal post-mortem studies that recruited before the onset 
of dementia (Jicha et al., 2010; Molano et al., 2010), three longitudinal clinical studies 
(Ferman et al., 2013b; Cagnin et al., 2015; Yoon et al., 2015) and two retrospective 
interview studies (Auning et al., 2011; Fujishiro et al., 2013b) found that core 
symptoms commonly develop before the onset of dementia.  
These studies differed greatly in design and selection criteria, which may account for 
the differences in findings. Duration of dementia before death was notably different 
between some of the studies (≤4 years in Molano et al. (2010) v. 8-10 years on average 
in the two cohorts that recruited dementia patients (Fujishiro et al., 2008; Ferman et al., 
2011)). This suggests that the studies may have recruited cohorts that were not clinically 
similar, or that diagnostic thresholds were different between the studies. 
From this evidence, it appears that most cases of prodromal DLB will display clinical 
and neuropsychological characteristics similar to established DLB. The exact proportion 
of cases that conform to this phenotype remains to be established. In those cases that do 
not, other biomarkers may be needed to identify prodromal DLB.  
 
2.9.2 Biomarkers of prodromal DLB  
There has been little investigation into the use of imaging and other biomarkers to 
identify prodromal DLB. Indeed no studies were found that investigated CSF or blood 
biomarkers in prodromal DLB. Autonomic symptoms are common in prodromal DLB 
(Chiba et al., 2012), therefore objective biomarkers of autonomic function such as 
postural hypotension could potentially be useful in the diagnosis of prodromal DLB.  
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Table 2.4. Temporal order of symptom development in prodromal DLB 
 Very Early 
(developing before cognitive 
symptoms) 
Early 
(developing during MCI) 
Late 
(developing around the time of 
conversion to dementia or later) 
Symptoms RBD 
Constipation 
Hyposmia  
Depression 
Urinary dysfunction 
Erectile dysfunction 
 
Memory impairment 
Parkinsonian symptoms 
Visual hallucinations 
Anxiety 
Cognitive fluctuations 
 
Signs/neuropsychological 
findings/biomarkers 
Orthostatic hypotension/dizziness 
Impaired olfactory function 
Minor motor abnormalities 
Impaired colour vision 
 
Attention/executive dysfunction 
Visuospatial dysfunction 
Striatal dopaminergic denervation 
Substantia nigra hyperechogenicity 
Increased hippocampal rCBF 
Occipital hypometabolism 
Items in italics reflect evidence from cohorts with RBD at baseline that may not be applicable to prodromal DLB as a whole 
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Dopamine terminal imaging, the most established biomarker for DLB, can be abnormal 
in mild DLB in the absence of clinical features of parkinsonism, suggesting that it may 
have a role in identifying prodromal DLB (Auning et al., 2011; Siepel et al., 2013). The 
only paper to investigate this (Albin et al., 2013) found that 1 of 2 MCI subjects with 
baseline striatal dopaminergic denervation later developed DLB. Three other subjects 
that developed DLB had normal dopamine terminal scans in the MCI phase. The same 
authors had previously reported a case of rapid striatal dopaminergic denervation 
around the time of onset of DLB (Albin and Koeppe, 2006).  
The typical DLB pattern of occipital hypometabolism on FDG-PET is present in some 
cases of prodromal DLB, but others display a more ‘AD-like’ pattern (Clerici et al., 
2009; Pardo et al., 2010; Cerami et al., 2015). As in established DLB, cortical atrophy 
is less prominent in prodromal DLB compared with prodromal AD (Blanc et al., 2015). 
With regards to other imaging modalities, raised hippocampal diffusivity on DWI 
compared with controls was found in one study, but this was not significantly greater 
than the prodromal AD group (Fayed et al., 2008).  
In summary, it appears that striatal dopaminergic denervation and occipital 
hypometabolism are present in some, but not all patients with prodromal DLB. Further 
research is needed to evaluate the usefulness of these imaging modalities, and others 
known to be abnormal in established DLB. Cardiac 
123
I-MIBG scintigraphy is sensitive 
and specific in differentiating mild DLB from mild AD (MMSE≥22) and may be a good 
biomarker in the prodromal stage given that the peripheral autonomic system is 
involved in the early stages of LB disease (Minguez-Castellanos et al., 2007; Yoshita et 
al., 2015).  
 
2.9.3 RBD as a prodrome of DLB 
RBD patients represent a particular cohort at risk for developing DLB. Poor olfaction 
and colour vision; autonomic and motor dysfunction; reduced striatal dopaminergic 
innervation on SPECT; substantia nigra hyperechogenicity and increased hippocampal 
perfusion may all help to predict those with RBD that will go on to develop DLB or PD 
(Iranzo et al., 2010; Postuma et al., 2010; Postuma et al., 2011; Dang-Vu et al., 2012; 
Postuma et al., 2012; Postuma et al., 2013; Mahlknecht et al., 2015). None of these 
markers differentiate between those who will develop DLB from those who will 
develop PD. The evidence for these biomarkers is generally based on small DLB 
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samples and few of the findings have been replicated. Findings in RBD groups may not 
be generalizable to the wider prodromal DLB population. 
 
2.9.4 Limitations 
With the exception of three retrospective symptom questionnaire studies (Auning et al., 
2011; Chiba et al., 2012; Fujishiro et al., 2013b), most of the evidence above relates to 
small groups of DLB patients and these three studies did not systematically evaluate all 
symptom domains. Few findings have been replicated. 
In general, the evidence is from clinical studies, without post-mortem verification of 
diagnosis. In some cases, this may have led to false positive or false negative results due 
to the misclassification of study subjects and such misclassification would in turn affect 
the apparent performance of biomarkers. Due to the heterogeneity of the data available, 
it is not possible at this stage to combine the data or objectively compare the reliability 
of conflicting findings. This prevents us from objectively testing whether or not DLB 
has a distinct prodrome using this data. Longitudinal studies will be required, first to 
develop criteria for the prodrome of DLB, and then to test their validity.  
 
2.10 Conclusions 
The evidence available, though limited, suggests that DLB has an identifiable 
prodromal phase. It may be possible to differentiate prodromal DLB from prodromal 
AD based on the presence of core and suggestive features of DLB, autonomic 
dysfunction and other biomarkers. 
123
I-FP-CIT and 
131
I-MIBG SPECT findings are abnormal in established DLB. It 
remains to be ascertained at what point in the evolution of the disease these findings 
become abnormal, and if these scans will be clinically useful in the identification of 
prodromal DLB.  
Longitudinal studies are certainly needed to further characterise the clinical presentation 
of prodromal DLB and investigate the utility of biomarkers (including CSF biomarkers) 
in its identification. Interesting findings in RBD suggesting that olfactory, visual, 
autonomic and motor dysfunction; hippocampal hyperperfusion and substantia nigra 
hyperechogenicity may predict the development of DLB should be investigated in a 
‘normal’ MCI group, not recruited in a specialist sleep disorders centre.  
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Characterisation of the DLB prodrome is vital to enable the identification of DLB 
patients in the prodromal stage. This will facilitate research into the pathophysiology of 
prodromal DLB and the development of treatments aimed at halting or reversing these 
pathophysiological processes.
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3 Chapter 3   Amyloid imaging in Lewy body disorders 
3.1 Introduction 
The pathological hallmarks of LB disorders are Lewy bodies and Lewy neurites, but 
many cases also display AD pathology (amyloid-β (Aβ) plaques and neurofibrillary 
tangles (NFTs)) post-mortem (Kovari et al., 2009). The importance of AD pathology in 
LB disorders and its relationship to cognitive impairment is unclear. Post-mortem 
studies of confirmed DLB cases have reported that concurrent AD pathology measured 
by increased NFTs was associated with a lower likelihood of visual hallucinations and a 
lower chance of a DLB diagnosis during life (Merdes et al., 2003; Weisman et al., 
2007; Walker et al., 2015a). Similarly greater neuritic Aβ plaque pathology has been 
associated with fewer core features of DLB (Tiraboschi et al., 2015). A combination of 
AD and LB pathology in dementia is associated with a lower occurrence of 
parkinsonism and hallucinations compared with LB pathology alone (Del Ser et al., 
2001), and faster rates of cognitive decline (Kraybill et al., 2005) and brain atrophy 
(Nedelska et al., 2015a). Greater cortical Aβ pathology has been associated with 
increased cognitive impairment (Nelson et al., 2009) and a shorter time from onset of 
parkinsonian symptoms to cognitive impairment (Ballard et al., 2006; Selikhova et al., 
2009; Fujishiro et al., 2010) in LB disorders.  
DLB has been associated with a greater Aβ burden than Parkinson’s disease dementia 
(PDD) and PD (Jellinger et al., 2003; Aarsland et al., 2004; Fujishiro et al., 2010; 
Walker et al., 2015a). It has been suggested that the co-occurrence of AD and LB 
pathology represents more than coincidence, and that there may be synergism, with Aβ 
increasing the propensity of α-synuclein to accumulate and aggregate (Pletnikova et al., 
2005). 
Post-mortem studies are by their nature cross sectional and tend to report end-stage 
disease. Thus patients with initial ‘pure Lewy body pathology’ may be found post-
mortem to have significant AD pathology, although this may not have been related to 
their initial presentation. PET amyloid imaging, initially with 
11
C-PiB (Pittsburgh 
compound B) and now with 
18
F-labelled compounds, was developed to measure brain 
Aβ burden in vivo (Rowe and Villemagne, 2011). Post-mortem studies have 
demonstrated that amyloid imaging with these ligands correlates well with Aβ 
deposition in the form of neuritic and diffuse plaques, and amyloid angiopathy 
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(Ikonomovic et al., 2008; Clark et al., 2011; Sojkova et al., 2011). Aβ deposition in 
vivo is consistently elevated in AD, and also in some healthy control subjects (Quigley 
et al., 2011; Rosenberg et al., 2013). This chapter will review all studies to date that 
have investigated amyloid imaging in LB disorders to examine the contribution of Aβ 
pathology to these disorders. 
Terminology in this research field has been a subject of some debate (McKeith, 2009). 
In this chapter ‘LB dementias’ refers to both DLB and PDD. ‘LB disorders’ refers to all 
LB pathologies (in this chapter generally PD (+/- MCI), PDD and DLB). 
 
3.2 Dementia with Lewy bodies 
3.2.1 DLB vs controls 
A summary of all PET amyloid imaging studies involving patients with Lewy body 
disease is provided in Table 3.1 at the end of this chapter. When compared with healthy 
controls, four studies have found DLB to be associated with significantly greater 
cortical 
11
C-PiB binding on PET imaging (Edison et al., 2008; Gomperts et al., 2008; 
Gomperts et al., 2012; Kantarci et al., 2012b). A 32% greater uptake was found in one 
study (Edison et al., 2008), although 6 controls with raised 
11
C-PiB binding had been 
excluded from analysis, as the aim of the study was to examine patterns of raised Aβ 
deposition in LB disorders. 
Three studies failed to find a significant difference between DLB and controls in global 
or regional Aβ ligand binding (Foster et al., 2010; Villemagne et al., 2011; Siderowf et 
al., 2014). However, in each study DLB displayed greater binding (mean cortical 
binding potential: 0.18 v. 0.08 (Foster et al., 2010); neocortex standardised uptake value 
ratio: 1.38 v. 1.26 (Villemagne et al., 2011); 1.32 v 1.02 (Siderowf et al., 2014)). It 
should be noted that these studies contained relatively small DLB samples (n=6, n=7 
and n=11 respectively) compared to those that found significant differences (n=8-21 
(Edison et al., 2008; Gomperts et al., 2008; Gomperts et al., 2012; Kantarci et al., 
2012b)). 
Particular areas of increased Aβ ligand binding in DLB include frontal, parietal and 
cingulate areas, along with the striatum  (Rowe et al., 2007; Gomperts et al., 2008; 
Claassen et al., 2011; Gomperts et al., 2012; Kantarci et al., 2012b), with relative 
42 
 
sparing of the medial temporal lobe (Rowe et al., 2007; Gomperts et al., 2008; Kantarci 
et al., 2012b). 
 
3.2.2 DLB vs AD 
Five studies have compared amyloid brain imaging in DLB and AD. The largest study 
(n=42) found global 
11
C-PiB retention ratio to be significantly lower in DLB (Kantarci 
et al., 2012b).  Two other studies have also found lower cortical Aβ ligand binding in 
DLB compared with AD (Rowe et al., 2007; Villemagne et al., 2011) (distribution 
volume ratio: 1.7 v. 2.0 (Rowe et al., 2007); standardised uptake value ratio: 1.38 v. 
1.93 (Villemagne et al., 2011)).  
One study found AD to have significantly greater amyloid deposition than DLB only in 
the parietal and anterior cingulate regions (Siderowf et al., 2014). Another study found 
no difference between DLB and AD, with very similar results in both groups in all 
cortical areas (Gomperts et al., 2008). In this study, the DLB group was on average 9 
years older than the AD group, with significantly greater cognitive impairment, 
although results held after adjusting for age (but not cognition) in multivariate analysis. 
 
3.2.3 DLB vs other LB disorders 
Gomperts et al. (2012) compared DLB with the other Lewy body disorders: PDD, PD 
with mild cognitive impairment (PD-MCI) and PD. The study compared precuneus 
11
C-
PIB retention, as retention was particularly high in this region and correlated very 
highly with global retention (r=0.939). Mean precuneus 
11
C-PiB distribution volume 
ratio was significantly higher in DLB than the other Lewy body disorders (DLB=1.49, 
PDD=1.28, PD-MCI=1.16, PD=1.16). This echoed their earlier findings of higher 
global cortical 
11
C-PiB retention in DLB (Gomperts et al., 2008). Edison et al. (2008) 
also reported higher 
11
C-PiB binding in DLB compared with PDD and PD, but did not 
report direct statistical testing between the groups. Another study comparing 3 DLB 
patients and 3 with multiple systems atrophy (MSA) found higher cortical 
11
C-PiB 
binding in the DLB group (Claassen et al., 2011). 
Three studies found no difference in Aβ ligand binding between DLB and PD (cortical 
standardised uptake value ratio: DLB=1.38, PD=1.14 (Villemagne et al., 2011); 
DLB=1.32, PD=1.12 (Siderowf et al., 2014)); or PD, PD with MCI and PDD (mean 
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cortical binding potential: DLB=0.18, PDD=0.11, PD-MCI=0.08, PD=0.04 (Foster et 
al., 2010)). In these studies, although not significant, Aβ ligand binding in the groups 
bore the same relationship to each other seen in studies that did find a significant 
difference (DLB>PDD>PD). 
When present, the pattern of Aβ ligand binding in Lewy body disorders is broadly 
similar to that seen in AD (Rowe et al., 2007; Gomperts et al., 2008; Maetzler et al., 
2008; Maetzler et al., 2009; Kantarci et al., 2012b; Petrou et al., 2012; Shimada et al., 
2013), although one study found occipital cortex binding relative to overall binding to 
be lower in AD (Gomperts et al., 2008). A principle component analysis by Campbell et 
al. found that the pattern of deposition of amyloid in LB disease (PD-MCI, PDD and 
DLB) was more similar to that seen in controls than to the pattern seen in AD 
(Campbell et al., 2013). 
 
Amyloid imaging scans can be classified as amyloid positive or amyloid negative based 
on a quantitative threshold of amyloid ligand binding or visual rating of the scan, using 
thresholds derived from studies in AD. The differences between Lewy body diseases 
become more stark using this method.  In a recent meta-analysis the prevalence of 
amyloid positive scans was 68% in DLB, compared with 34% in PDD and 5% in PD-
MCI (Petrou et al., 2015). A separate analysis which only included studies in which 
participant-level demographic data was available found the prevalence in DLB to be 
51%, compared with 88% in AD and 24% in controls (Ossenkoppele et al., 2015). 
Meta-analyses in dementia (Ossenkoppele et al., 2015), MCI and healthy older people 
(Jansen et al., 2015) identify increasing age and the presence of the APOE ε4 genotype 
as the primary risk factors for amyloid positivity on PET imaging.  
 
3.3 Parkinson’s disease dementia 
3.3.1 PDD vs controls/AD 
All seven studies comparing Aβ ligand binding in PDD and controls have found no 
significant difference between the two groups (Edison et al., 2008; Gomperts et al., 
2008; Maetzler et al., 2008; Foster et al., 2010; Jokinen et al., 2010; Gomperts et al., 
2012; Edison et al., 2013). In general PDD results were very similar to controls, with a 
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tendency toward a small number of outliers in the PDD group with high levels of 
cortical Aβ (Edison et al., 2008; Maetzler et al., 2009; Foster et al., 2010; Gomperts et 
al., 2012).  
Maetzler et al. (Maetzler et al., 2008) compared PDD and AD after removing 2 PDD 
patients with markedly raised 
11
C-PiB binding that they felt indicated a different disease 
entity to ‘pure’ PDD.  The remaining PDD subjects demonstrated remarkably similar 
cortical Aβ binding to the control group and lower cortical and striatal binding than the 
AD group .The two high 
11
C-PiB binding subjects had an ‘AD-like’ pattern of 
deposition. The only other study to compare PDD and AD found no outlying PDD 
subjects, with Aβ ligand binding significantly lower in PDD than AD (Gomperts et al., 
2008). 
 
3.3.2 PDD vs PD 
Several studies have noted no significant difference in Aβ binding between PDD and 
PD (Edison et al., 2008; Gomperts et al., 2008; Foster et al., 2010; Jokinen et al., 2010; 
Gomperts et al., 2012; Edison et al., 2013) or PD with MCI (Gomperts et al., 2012; 
Gomperts et al., 2013) However, PDD consistently has a greater proportion of Aβ 
positive subjects when groups are divided in a binary fashion as positive or negative 
(Petrou et al., 2015). 
Relevant to this, Petrou et al. (Petrou et al., 2012) identified 40 patients with PD at risk 
for dementia (with MCI/older age /long duration of PD/prominent gait or balance 
impairments). On further testing 5/40 subjects were diagnosed as having mild dementia. 
When the subjects underwent amyloid imaging 4/5 subjects with dementia had elevated 
11
C-PiB binding on visual inspection, compared with 2/30 patients with PD-MCI and 
0/5 with PD and some other risk factor for dementia. This finding of increased rates of 
Aβ positive subjects in PDD groups compared with PD or controls, without any 
difference in mean cortical Aβ ligand binding, may be accounted for by a subgroup of 
outlying PDD subjects with high Aβ binding (Edison et al., 2008; Maetzler et al., 2009; 
Foster et al., 2010; Gomperts et al., 2012), or a different pattern of deposition in PDD 
that results in focal increases in binding without a significantly increased overall Aβ 
load (Gomperts et al., 2008). 
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3.4 Parkinson’s Disease 
Eight studies have compared amyloid imaging findings in PD and controls. One small 
study compared a group of PD patients with controls from a previous study and found 
the PD group had significantly lower 
11
C-PiB binding in the frontal (
11
C-PiB 
uptake/cerebellum: 1.10 v 1.30), parietal (1.15 v 1.35) and posterior cingulate (1.04 v 
1.43) cortices (Johansson et al., 2008).  The PD subjects were well known to the 
investigators, with no evidence of cognitive impairment on routine assessment. It may 
be that they represented a subgroup of particularly cognitively healthy individuals. 
Other studies have found no difference between PD and controls (Edison et al., 2008; 
Gomperts et al., 2008; Foster et al., 2010; Jokinen et al., 2010; Villemagne et al., 2011; 
Gomperts et al., 2012; Siderowf et al., 2014), although mean cortical Aβ ligand binding 
was marginally lower in PD in some (Foster et al., 2010; Villemagne et al., 2011; 
Gomperts et al., 2012) (mean cortical binding potential: 0.04 v 0.08 (Foster et al., 
2010), standardised uptake value ratio: 1.14 v 1.26 (Villemagne et al., 2011)). One 
study found 
11
C-PiB binding to be higher in PD than controls (cortex:cerebellum ratio: 
1.19 v 1.11, p<0.05) (Edison et al., 2013). 
Three studies comparing PD with AD have all found lower brain Aβ ligand binding in 
PD (Gomperts et al., 2008; Johansson et al., 2008; Villemagne et al., 2011). 
 
3.5 Relationship between Aβ and clinical picture 
3.5.1 Cognitive impairment and dementia severity 
Two studies have found a significant correlation between MMSE score and Aβ ligand 
binding when analysing data across multiple disease groups (DLB, PDD, PD: r=-0.5, 
p=0.01, n=26 (Gomperts et al., 2008); DLB, PD, AD, MCI, FTD, VaD, controls:        
r=-0.49, p<0.0001, n=109 (Villemagne et al., 2011)). However, over both studies, only 
the MCI group in Villemagne et al. (2011) displayed the same correlation within the 
group (r=-0.76, p<0.0001, n=20). 
Other studies have considered PDD/DLB as a single group for analysis. In such a group 
the Aβ positive subjects were found to have a significantly lower MMSE than the Aβ 
negative group, but this group was also older (Maetzler et al., 2009). Conversely, Foster 
et al. (Foster et al., 2010) were not able to identify differences between Aβ positive and 
negative PDD/DLB groups in MMSE, NPI or cognitive fluctuations. However, pooling 
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the Aβ positive and Aβ negative PDD/DLB subjects (n=21) they found mean cortical 
and caudate Aβ binding correlated modestly with MMSE (cortical: r=-0.47, p=0.04; 
caudate: r=-0.44 p=0.05) and Clinical Dementia Rating Scale (CDR) global (cortical: 
r=0.55, p=0.01; caudate: r=0.51, p=0.02). No such correlation existed in PD or control 
groups. In PD with MCI, MMSE correlated strongly with caudate Aβ (r=-0.82, p=0.007, 
n=9) but not mean cortical Aβ (p=0.52).  
 
In a population mostly consisting of PD-MCI, Aβ ligand binding was found to correlate 
with global cognitive scores (r=-0.55, p=0.0006, n=40) and Wechsler Adult Intelligence 
Scale score (r=-0.54, p=0.0004, n=40) (Petrou et al., 2012). However these results may 
have been strongly influenced by 4 PDD subjects with high levels of brain Aβ and 
cognitive impairment. 
In a DLB-only group (n=18), Gomperts et al. (Gomperts et al., 2012) found increased 
Aβ ligand binding to be associated with lower MMSE (p<0.001) scores and worse 
semantic memory (p=0.001). No such association was found in PDD, PD, PD-MCI or 
controls. A study with 11 DLB subjects found that amyloid positive subjects had 
significantly lower MMSE scores than amyloid negative subjects (14.4 v 25.3; p=0.046) 
(Siderowf et al., 2014). Other studies found no relationship between Aβ and MMSE 
(Edison et al., 2008; Shimada et al., 2013) or dementia severity measured by CDR 
(Kantarci et al., 2012b) in DLB. 
 
One longitudinal study in 46 PD subjects with either MCI or no cognitive impairment 
found that baseline increased precuneus 
11
C-PiB binding was related to decline in 
executive function (p=0.035), weakly related to decline in visuospatial function 
(p=0.06), and associated with a greater likelihood of transition to MCI or dementia 
(p=0.035) (Gomperts et al., 2013). 
In summary, there is conflicting evidence surrounding the association of amyloid 
deposition with increased cognitive impairment in LB disorders. Where correlation has 
been reported, it has generally been modest, and often in samples containing disparate 
diagnostic groups. Further research is needed to clarify the association of amyloid 
deposition with cognitive impairment in each of the LB disorders.    
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3.5.2 Parkinsonism 
In DLB and PDD, but not PD, higher relative Aβ ligand binding in the striatum 
(adjusted for overall binding) was associated in one study with better motor 
performance as measured by the UPDRS (DLB: r=-0.87, p=0.01, n=8; PDD: r=-0.90, 
p=0.005, n=7) (Gomperts et al., 2008). Other studies have found no correlation between 
global cortical (Maetzler et al., 2009; Foster et al., 2010; Kantarci et al., 2012b; 
Shimada et al., 2013) or precuneus (Gomperts et al., 2012) Aβ binding and motor 
impairment. However, these studies did not report specifically assessing relative striatal 
binding. A longitudinal study found that baseline striatal or precuneus amyloid ligand 
binding in PD and PD-MCI did not predict future motor deterioration (Gomperts et al., 
2013). 
 
3.5.3 Hallucinations and visuospatial ability 
In the two studies which have reported this, no relationship has been found between 
mean cortical (Kantarci et al., 2012b) or occipital (Gomperts et al., 2008) Aβ binding 
and hallucinations. 
In DLB, PDD and PD, but not AD or controls, relative parietal/posterior cingulate (but 
not occipital) binding was associated with impaired visuoperceptual ability as measured 
by the Benton visual form discrimination test (Gomperts et al., 2008). 
 
3.5.4 Fluctuations 
Fluctuations, measured using the Mayo Fluctuations Questionnaire, were not found to 
be associated with an increased Aβ ligand binding in DLB or PDD in two studies 
(Foster et al., 2010; Kantarci et al., 2012b). 
 
3.5.5 RBD 
No studies have reported investigating an association between RBD and Aβ ligand 
binding. 
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3.5.6 Disease onset, progression and treatment response 
The first study of amyloid PET in DLB found that increased Aβ binding was correlated 
with a shorter time between the onset of cognitive impairment and diagnosis of DLB 
(r=-0.75, p=0.01, n=10), with no such relationship  seen in AD (Rowe et al., 2007). 
Maetzler et al. (Maetzler et al., 2009) found that in a combined DLB and PDD group, 
Aβ positive patients had an older age at onset of parkinsonism and dementia and had 
lower MMSE scores. The authors suggested that this may be an effect of increasing Aβ 
with increasing age, or that cortical Aβ deposition is associated with different disease 
mechanisms resulting in an older age of onset and more rapid clinical progression. 
In a small group of treatment naïve patients, Graff-Radford et al. (2012) found that after 
treatment with acetylcholinesterase inhibitors Aβ positive patients (n=3)  tended to 
remain stable or decline, whereas Aβ negative patients (n=4) tended to remain stable or 
improve. 
 
3.5.7 Relationship with genetics, imaging findings and other biomarkers 
An early study found the apolipoprotein (APOE) ε4 genotype was associated with 
increased 
11
C-PiB binding across groups (including relatively large groups of AD and 
controls) but not within diagnostic groups (Rowe et al., 2007). Similarly, in a large 
study, Gomperts et al. (Gomperts et al., 2012) found that APOE ε4 genotype and 11C-
PiB binding were correlated across the entire cohort (DLB, PDD, PD-MCI, PD, 
controls; r=0.49, p<0.0001). In a study involving DLB, PDD and PD subjects 
11
C-PiB 
binding and CSF APOE levels were positively correlated (r
2
=0.42, p<0.0001) 
(Vijayaraghavan et al., 2014). The Aβ positive group (all of whom had dementia) were 
found to have increased rates of the APOE ε4 allele and lower CSF Aβ-42 
concentrations compared with Aβ negative patients (Maetzler et al., 2009). These 
results are consistent with findings in AD subjects, those with MCI and apparently 
healthy older controls, that the APOE ε4 genotype is robustly associated with increased 
Aβ binding (Drzezga et al., 2009; Fleisher et al., 2013).  
Shimada et al. (2013) examined the association between 
11
C-PiB binding and cortical 
atrophy in a combined PDD/DLB group compared with AD and healthy controls. They 
found that of 6/15 PDD/DLB patients were 
11
C-PiB positive. Compared to 
11
C-PiB 
negative controls (
11
C-PiB positive controls were excluded) the 
11
C-PiB positive 
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PDD/DLB group demonstrated significant cortical atrophy, particularly in temporal and 
parietal areas, whereas the 
11
C-PiB negative group did not. Using volume of interest 
analysis, the 
11
C-PiB positive PDD/DLB group had lower parahippocampal grey matter 
volume than 
11
C-PiB negative PDD/DLB subjects. There were no differences between 
the two groups in cognitive tests. Atrophy was not correlated with Aβ ligand binding in 
any group. The authors commented that Aβ deposition in PDD/DLB appeared to be 
associated with cortical atrophy in a pattern similar to that seen in AD, though the level 
of atrophy itself was not correlated with amyloid load and likely due to down-stream 
effects. 
 
Four studies have compared amyloid imaging scans with 
18
F-FDG PET in Lewy body 
disorders. One small study (n=3), found corresponding hypometabolism and amyloid 
deposition in several cortical areas (Claassen et al., 2011). Two studies in DLB and 
PDD reported brain hypometabolism (in areas such as the occipital and posterior 
parietotemporal lobes) in the absence of Aβ deposition and suggested that the two 
processes do not appear directly related, similar to the apparent dissociation between 
structural MR measures of atrophy and PET hypometabolism in DLB (Jokinen et al., 
2010; Kantarci et al., 2012b; Sinha et al., 2012). Consistent with this, a recent study 
compared PiB positive (n=5) and negative (n=5) DLB subjects and found very similar 
levels of brain metabolism in both groups (Ishii et al., 2015). Loss of white matter 
integrity in the parieto-occipital region in DLB has also been found to be independent of 
Aβ pathology (Nedelska et al., 2015b).  
 
3.6 Reports of post-mortem examination after amyloid PET imaging 
The first post-mortem report of a patient with DLB who had had an amyloid PET scan 
was by Bacskai et al. (2007). They found that amyloid imaging findings corresponded 
to post-mortem Aβ levels in brain homogenates measured using enzyme-linked 
immunosorbent assays. Much of the Aβ burden on imaging was due to cerebral Aβ 
angiopathy. 
 
Burack et al. (2010) examined 3 patients with PDD, 2 of whom had extensive cortical 
11
C-PiB uptake in PET scans before death. Both were found to have abnormal levels of 
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cortical Aβ (predominantly diffuse plaques) post-mortem. All cortical areas with PET 
mean cortical binding potential greater than 0.2 had severe plaque burden post-mortem. 
The case with no raised Aβ binding had minimal Aβ plaques but abundant cortical 
Lewy bodies, suggesting there is no significant binding of 
11
C-PiB to LBs during 
amyloid PET scans. 
 
Kantarci et al. (2012b) reported 3 cases of DLB with ante-mortem amyloid imaging. 
One had raised cortical 
11
C-PiB binding (
11
C-PiB retention ratio >1.6) and two had 
borderline binding (
11
C-PiB retention ratio 1.4-1.6). The case with raised 
11
C-PiB had 
sparse neuritic plaques but frequent diffuse plaques. The two borderline cases had 
sparse or moderate neuritic plaques (the level of diffuse plaques was not mentioned). 
The case with raised 
11
C-PiB underwent quantitative comparison of amyloid deposition 
measured by  
11
C-PIB PET and post-mortem image analysis of immunostains of 
corresponding regions (Kantarci et al., 2012c). There was a strong correlation between 
11
C-PiB retention (18 months ante-mortem) and post-mortem Aβ density in the 17 ROIs 
analysed (r=0.899; p < 0.0001). Lewy body and tau density did not correlate with 
11
C-
PiB retention. 
Ikonomovic et al. (2012) examined a case of probable DLB with a negative 
11
C- PiB 
PET scan. Although post-mortem examination did identify Aβ plaques, they were 
infrequent and primarily diffuse rather than neuritic. The authors commented that the 
level of amyloid deposition necessary to elicit a positive 
11
C-PiB PET scan is not yet 
clear. Post-mortem Aβ42 concentration in brain homogenates correlated with 
11
C-PiB 
retention in the ante-mortem PET scan (r=0.72, p=0.009), corroborating the finding of 
Kantarci et al. (2012b) above. 
 
3.7 Discussion 
3.7.1 Differences between diagnostic groups 
In summary, all Lewy body disorders are generally associated with lower mean cortical 
Aβ ligand binding than AD. DLB is usually associated with higher mean cortical Aβ 
binding than PDD, PD or controls. There are no significant differences between PDD, 
PD and controls. When Aβ is present, the pattern of deposition in LB disorders may be 
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similar to that seen in AD, with deposition in frontal, parietal and cingulate areas, along 
with the striatum.  
Two studies used 
18
F-labelled tracers (Villemagne et al., 2011; Siderowf et al., 2014), 
all other studies used 
11
C-PiB. The pattern of cortical binding with 
18
F-Florbetaben was 
almost identical to that of 
11
C-PiB (Villemagne et al., 2011). 
 
Differences between diagnostic groups are more evident when subjects are classified as 
Aβ positive or negative based on visual rating or a quantitative threshold for tracer 
binding.  AD has higher rates of amyloid positive scans than DLB, which in turn has 
higher rates than PDD (Ossenkoppele et al., 2015; Petrou et al., 2015). The difference 
between DLB and PDD is unlikely to be due to age, which was very similar between the 
two groups in this analysis (Petrou et al., 2015). However, a confounding effect of 
APOE genotype cannot be ruled out. Interestingly, the observed rates in PD-MCI may 
be lower than those seen in other types of MCI, and even in healthy controls of the same 
age (Petrou et al., 2015). From these findings we can conclude that whilst Aβ deposition 
in itself is neither necessary nor sufficient for the development of dementia in LB 
disorders, the presence of Aβ is more common in those with dementia, and relatively 
rare in those without dementia. These findings mirror results from post-mortem studies 
that have found greater Aβ deposition in DLB than PDD or PD (Harding and Halliday, 
2001; Ballard et al., 2006; Jellinger and Attems, 2008; Fujishiro et al., 2010; Walker et 
al., 2015a), and higher deposition in PDD than PD (Harding and Halliday, 2001; 
Compta et al., 2011; Irwin et al., 2012). 
 
High levels of cortical Aβ are unusual in PD. Petrou et al. (Petrou et al., 2012) found 
that most of the small number of patients with Aβ positive PET scans in a PD cohort 
identified for being at risk of dementia actually, on closer examination, already had 
dementia. Similarly, in a post-mortem study of 129 cases of PD, 17 of 20 of patients 
that had Aβ plaque pathology rated CERAD grade B or C (Mirra et al., 1991) had 
dementia (85% v. 54% in the overall group) (Kempster et al., 2007). In another 
neuropathological study of 200 patients with an initial diagnosis of PD, higher CERAD 
scores were found almost exclusively in patients who developed dementia (CERAD 
scores PD: B=3%, C=0%; PDD: B=51%, C=33%) (Jellinger et al., 2002).  
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Diffuse neocortical or limbic Lewy body pathology is generally seen as the main 
substrate of dementia in LB disorders (Aarsland et al., 2005; Emre et al., 2007; Irwin et 
al., 2012). The findings above suggest that the presence of Aβ confers a higher risk for 
the development of dementia in LB disorders. A possible explanation for this is that the 
combination of cortical Aβ and Lewy body pathology may have synergistic effects. 
Some post-mortem studies have found that increased Aβ is associated with increased α-
synuclein levels in the brain in Lewy body disorders and AD (Pletnikova et al., 2005; 
Lashley et al., 2008; Compta et al., 2011), although other studies have contradicted this 
(Ballard et al., 2004; Aarsland et al., 2005) 
Interestingly, Aβ promotes the formation of α-synuclein oligomers and polymers in 
vitro (Masliah et al., 2001). Experiments in transgenic mice expressing human Aβ, tau 
and α-synuclein peptides have shown that the presence of Aβ increases the formation of 
α-synuclein neuronal inclusions (Masliah et al., 2001) and α-synuclein increases the 
deposition of both Aβ and tau (Clinton et al., 2010). 
Thus, in LB disorders, the presence of significant Aβ may lead to a synergistic 
interaction with α-synuclein, resulting in widespread deposition of α-synuclein and Aβ, 
leading to cognitive impairment. This hypothesis may help explain the infrequency of 
significant Aβ deposition in PD without cognitive impairment and the increased rates of 
Aβ seen in DLB compared with PDD, as DLB by definition demonstrates dementia (an 
indicator of widespread neurodegeneration) earlier in the disorder. The apparent 
synergistic interaction between Aβ and α-synuclein is a possible target for therapeutic 
intervention, given our ability to identify the subset of Lewy body disease sufferers with 
Aβ deposition using PET imaging. 
 
3.7.2 Relationship of Aβ to clinical picture 
In imaging studies cognitive impairment has correlated positively with Aβ ligand 
binding across diagnostic groups (Gomperts et al., 2008; Villemagne et al., 2011). This 
may simply reflect that Aβ burden is high in AD and DLB and low in PD and controls. 
More interestingly, Aβ binding may be correlated with cognitive impairment in Lewy 
body dementia only-groups (Maetzler et al., 2009; Foster et al., 2010) and may predict 
cognitive decline in PD and PD-MCI (Gomperts et al., 2013). Some pathological studies 
support these findings. Patients with a combination of DLB and AD pathology post-
mortem have been found to have had worse cognitive function (Nelson et al., 2009), 
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more severe dementia (Serby et al., 2003) and a faster rate of cognitive decline (Kraybill 
et al., 2005) than those with ‘pure’ DLB pathology. A correlation between cognitive 
impairment and Aβ deposition in PD and PDD groups has been found (Mattila et al., 
2000; Harding and Halliday, 2001; Compta et al., 2011), although this link did not 
survive regression modelling in some studies (Mattila et al., 2000). 
Conversely, other studies have found no correlation of MMSE with CERAD score in 
PD with or without cognitive impairment (Aarsland et al., 2005; Braak et al., 2005), and 
AD pathology in PDD has been found not to affect performance on MMSE or other 
neuropsychological tests (Sabbagh et al., 2009). 
 
Imaging studies have found suggestive links between increased Aβ ligand binding and 
older onset of motor impairment and dementia (Maetzler et al., 2009), and a shorter 
interval between the onset of motor impairment and cognitive impairment (Rowe et al., 
2007). There have been various, often contradictory pathological findings about the 
association of Aβ deposition with disease onset and progression in LB disorders. 
Increased Aβ burden post-mortem has been associated with older age of onset and 
shorter survival in DLB, PD and PDD (Jellinger et al., 2002); and shorter duration of 
parkinsonism prior to the onset of dementia in PDD and DLB (Ballard et al., 2004; 
Ballard et al., 2006; Selikhova et al., 2009; Fujishiro et al., 2010; Compta et al., 2011). 
Other studies found no correlation between Aβ burden age of onset, disease duration 
and age of death in DLB (Ballard et al., 2004; Nelson et al., 2009) or PD (Lashley et al., 
2008); rate of decline in PD or PDD (Aarsland et al., 2005); or the interval between 
motor and dementia symptoms in PDD (Irwin et al., 2012). Some even found increased 
Aβ to be associated with longer disease duration in PD, although with higher dementia 
scores (Mattila et al., 2000). A large epidemiological study (Aarsland et al., 2007) found 
that the occurrence of dementia in PD was a function of age, and age of onset had no 
effect above this. Thus, in some studies (Fujishiro et al., 2010; Compta et al., 2011) the 
shorter duration of parkinsonism before dementia observed in Aβ positive patients could 
simply be a function of their older age. 
 
Findings from amyloid imaging studies can drive hypotheses that should then be tested 
in other imaging studies as well as pathological studies. Similarly, pathological findings 
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(from which most of our current knowledge of the Aβ in LB disorders derives) will 
drive hypotheses in future imaging studies. Some other positive findings from these 
early imaging studies that should be tested in future studies include the links between 
striatal Aβ and Parkinsonism; parietal/posterior cingulate Aβ and visuoperceptual 
ability; and Aβ ligand binding, APOE genotype and CSF Aβ-42. Further studies are also 
needed to corroborate the finding that the other core symptoms of DLB, visual 
hallucinations and fluctuating cognition, are not related to Aβ deposition. 
 
Based on current data it is not possible to make any firm conclusions on the influence of 
Aβ pathology on disease progression and clinical phenotype in Lewy body disorders. 
There are a few reasons for this. Aβ imaging studies have thus far, with two exceptions, 
been cross sectional rather than longitudinal. Studies vary in image acquisition, 
processing and analysis; clinical and imaging outcome measures used; cut off points for 
Aβ positive and negative cases; recruitment source (i.e. movement disorder or memory 
clinics); entry criteria for subjects; and processing of results (e.g. the removal of 
control/PDD subjects with raised amyloid from analysis (Edison et al., 2008; Maetzler 
et al., 2008; Shimada et al., 2013)). Few studies have tested the same hypotheses using 
comparable outcome measures. Many studies also suffered from low sample sizes and 
sub-optimal measures such as the MMSE, which may not be sensitive to cognitive 
changes in LB disorders. These problems, and a tendency in some studies to report the 
results of statistical tests without summary data, prevented any quantitative meta-
analysis of the results. Large-scale, prospective studies are needed to properly 
investigate the effect of Aβ burden on the onset, progression, severity and character of 
symptoms in LB disorders. 
 
Neuropathological studies suffer from similar inconsistencies (e.g. in the use of grading 
rather than fully quantitative measures to assess brain pathology). Comparison between 
imaging and pathological studies is difficult as amyloid PET measures both diffuse and 
neuritic plaques, as well as amyloid angiopathy, whereas most pathological studies 
focus solely on neuritic plaques. Although 
11
C-PiB has higher affinity for neuritic 
plaques, diffuse plaques account for most of the in vivo binding in LB disorders 
(Burack et al., 2010; Kantarci et al., 2012c). 
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3.7.3 Issues with PET amyloid imaging 
Some authors have questioned the ability of PET amyloid imaging to adequately 
quantify amyloid burden, highlighting problems with current PET amyloid imaging 
technology including partial volume effects and non-specific binding of amyloid 
radioligands (Moghbel et al., 2012). 
PET imaging has a relatively low resolution compared with MRI. This results in a 
relatively large voxel size. Given the thinness of the cerebral cortex, partial volume 
effects (where a voxel contains signal from both grey and white matter, or grey matter 
and CSF, for instance) are possible (Moghbel et al., 2012). This is further complicated 
by the presence of significant cortical atrophy in a proportion of subjects with cognitive 
impairment. Although this problem is by no means unique to PET amyloid imaging, it 
does raise doubts about the ability of PET imaging to accurately quantify amyloid 
burden in dementia (Villemagne et al., 2012). Despite this, the use of partial volume 
correction has been found not to significantly affect quantitative measures of amyloid 
ligand binding (Knesaurek et al., 2013). Few of the studies reviewed here used such 
correction measures (Table 3.1).  
Amyloid radioligands, particularly 
18
F-labelled ligands, have high non-specific white-
matter binding (Rowe and Villemagne, 2011). Studies comparing PiB binding (in vitro 
and in vivo) with amyloid burden measured by immunohistochemistry have 
demonstrated that PiB does not give a direct quantitative measure of cortical amyloid 
burden (Bacskai et al., 2007; Svedberg et al., 2009). Similarly, a study comparing in 
vivo PiB binding with amyloid burden post-mortem found cases where the precuneus 
was observed to have the highest PiB retention, despite other brain areas having 
markedly greater amyloid burden quantified by stereological assessment (Driscoll et al., 
2012). It should be noted that, despite this, there was a strong correlation between 
11
C-
PiB binding and post-mortem amyloid burden in the precuneus, anterior cingulate and 
posterior cingulate, though not the hippocampus or orbitofrontal cortex (Driscoll et al., 
2012). Thus, although ligand retention and amyloid burden are correlated in different 
brain areas within one subject (Kantarci et al., 2012c) and between subjects (Clark et 
al., 2011; Driscoll et al., 2012), amyloid PET cannot be said to precisely quantify 
amyloid burden in each particular brain area. These issues should be borne in mind 
when interpreting and discussing amyloid PET findings. 
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Importantly, amyloid imaging ligands do not appear to bind significantly to cortical LBs 
in vitro (Fodero-Tavoletti et al., 2012), and have been shown to accurately measure 
amyloid load in vivo in the presence of other pathologies, including LB (Burack et al., 
2010; Dugger et al., 2014) 
  
3.7.4 Tau pathology 
Neuropathological studies have found that NFT pathology in DLB may be associated 
with a clinical picture more similar to AD than classical DLB (Ballard et al., 2004; 
Fujishiro et al., 2008). The degree to which high Aβ binding is also associated with a 
less classical DLB clinical phenotype is of interest; such patients may have a different 
prognosis, different levels of neuroleptic sensitivity and a different response to 
treatment.  
There is a relative paucity of NFT pathology in LB disorders (Braak et al., 2005), but 
when present it is a reliable correlate of dementia (Jellinger et al., 2002; Irwin et al., 
2012). Although imaging ligands for tau are not yet widely available, there are imaging 
correlates of tau pathology. Brain atrophy on MRI, particularly in the medial temporal 
lobe has been found to be associated with post-mortem tau pathology, measured 
quantitatively with tau antibody and image analysis or semi-quantitatively using Braak 
NFT staging (Braak and Braak, 1991; Whitwell et al., 2008; Burton et al., 2009). A 
recent study has found brain atrophy in amyloid positive, but not amyloid negative 
PDD/DLB subjects (Shimada et al., 2013), despite this, atrophy was not correlated with 
PiB binding. This may be because atrophy is the result of downstream effects, either of 
tau, α-synuclein, a combination of both, or another factor. A combination of amyloid 
imaging and MRI measures of atrophy (as a surrogate measure of tau pathology) may 
be important in any study wishing to investigate the influence of AD pathology in LB 
disorders. 
 
3.8 Conclusions 
Amyloid imaging studies have demonstrated that significant Aβ deposition is present in 
a proportion of DLB and PDD patients. Significant Aβ deposition appears to be 
relatively rare in PD. Dementia often occurs in the absence of Aβ, but there is some 
evidence that amyloid may be related to the onset or progression of cognitive symptoms 
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in these disorders, though current results are not conclusive. Large scale, prospective 
amyloid imaging studies may resolve some of these unanswered questions and clarify 
the importance of Aβ in LB disorders. 
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Table 3.1. Summary of PET amyloid imaging studies including LB disease subjects (excluding neuropathological case studies) 
Study Population Scans, ligand Amyloid PET acquisition 
and image analysis 
Major findings 
Rowe et al. 
(2007) 
10 DLB 
17 AD 
9 MCI 
6 FTD 
27 controls 
 
MRI 
11
C-PIB PET 
90 min acquisition. ROI 
11
C-PIB DVR v. 
cerebellum.  Logan 
graphical analysis 
method. 
PiB burden AD>DLB>controls. 
PiB burden correlated with shorter time from onset of 
symptoms to diagnosis in DLB. 
APOE ε4 genotype linked to Aβ burden across groups. 
Edison et al. 
(2008) 
13 DLB 
12 PDD 
10 PD 
41 controls 
MRI 
11
C-PIB PET 
60-90 min 
11
C-PIB 
uptake ratio; ROI v. 
cerebellum. 
Voxel based comparison 
with threshold p<0.001. 
 
DLB more likely to show raised Aβ burden compared 
with PDD or PD. Six control subjects were excluded 
from analysis because of high cortical Aβ ligand 
binding. 
Gomperts et al. 
(2008) 
8 DLB 
7 PDD 
11 PD 
15 AD 
37 controls 
 
11
C-PIB PET 60 min DVR v 
cerebellum. Logan 
graphical analysis 
method. 
PiB binding DLB>PDD/PD/controls. 
PiB binding in DLB comparable to AD. 
In LBD (DLB+PDD) relative striatal binding was 
associated with improved performance on UPDRS. 
Johansson et al. 
(2008) 
5 PD 
16 AD 
6 controls 
 
11
C-PIB PET 
11
C-L-DOPA PET 
40-60 min ROI uptake 
ratio v. cerebellum. 
PiB retention was greater in AD than PD in all cortical 
areas and striatum. Lower in PD than control in frontal, 
parietal and cingulate areas. 
Maetzler et al. 
(2008) 
10 PDD 
6 AD 
11 controls 
 
11
C-PIB PET 
 
42-72 min ROI SUVR v. 
cerebellum. 
2/10 PDD had ‘AD-like’ pattern of amyloid deposition. 
Brainstem:posterior cingulate DVR: PDD>control, AD, 
‘AD-like’ PD. 
Maetzler et al. 
(2009) 
9 DLB 
12 PDD 
14 PD 
 
11
C-PIB PET 
 
42-72 min ROI SUVR v. 
cerebellum. 
PiB positive patients had lower CSF Aβ42, higher APOE 
ε4  allele rate, all had dementia. Within dementia, PiB 
positive had lower MMSE scores. 
Jokinen et al. 
(2010) 
11 PDD 
8 PD 
24 controls 
11
C-PIB PET 
18
F-FDG PET 
MRI 
60-90 min ROI uptake 
ratio v. cerebellum. 
No significant difference between groups in any cortical 
area. PDD more likely to show 1+ cortical areas with 
increased PiB uptake. 
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Table 3.1 Continued 
Study Population Scans, ligand Amyloid PET acquisition 
and image analysis 
Major findings 
Foster et al. 
(2010) 
6 DLB 
15 PDD 
9 PD-MCI 
8 PD 
9 controls 
 
11
C-PIB PET 
MRI 
60 min dynamic scan. 
ROI and mean cortical 
BP. Logan graphical 
analysis, cerebellum as 
reference.  
No differences in mean cortical BP or regional BPs 
between groups. 
Correlation between caudate/cortical amyloid and 
MMSE in some groups. 
Burke et al. 
(2011) 
14 DLB 
36 AD 
25 FTD 
 
11
C-PIB PET 
11
C-DTBZ PET 
 
80 min scan. ROI DVR 
v. cerebellum. Subjective 
visual assessment. 
Only moderate concordance between clinical diagnosis 
and diagnosis based on scan results. 
Claasen et al. 
(2011) 
3 DLB 
3 MSA 
12 controls 
 
11
C-PIB PET 
18
F-FDG PET 
MRI 
40-60 min acquisition. 
ROI v. cerebellum. 
Higher binding found in DLB in all areas. Most marked 
in prefrontal, parietal, temporal and precuneus. 
Villemagne et al. 
(2011) 
7 DLB 
5 PD 
30 AD 
20 MCI 
11 FTD 
4 VaD 
32 controls 
 
18
F-Florbetaben 
PET 
MRI 
 
90-110 min acquisition. 
ROI SUVR v. cerebellar 
cortex 
AD and MCI had higher neocortical and striatal binding 
than controls. No other significant differences between 
groups. 
Gomperts et al. 
(2012) 
18 DLB 
12 PDD 
14 PD-MCI 
29 PD 
85  controls 
11
C-PIB PET 
 
60 min dynamic 
acquisition. Logan 
graphical analysis 
method. ROI DVR v. 
cerebellum. 
SPM analysis corrected 
for multiple comparisons. 
DLB exhibited higher binding than other groups, 
particularly in frontal and parietal areas. No differences 
found between non-DLB groups. 
PiB burden increased in APOE ε4  genotype across 
entire cohort. 
In DLB increased PiB binding was associated with 
decreased MMSE score and poorer semantic memory. 
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Table 3.1 Continued 
Study Population Scans, ligand Amyloid PET acquisition 
and image analysis 
Major findings 
Graff-Radford et 
al. (2012) 
7 DLB 
11
C-PIB PET 
MRI 
40-60 min. ROI v. 
cerebellum. 
Partial volume 
correction. 
 
Both subjects who declined were PiB positive; all 3 
subjects who improved were PiB negative. 
Kantarci et al. 
(2012) 
21 DLB 
21 AD 
42 controls 
11
C-PIB PET 
18
F-FDG PET 
MRI 
40-60 min acquisition. 
ROI v. cerebellum. 
Voxel based comparison 
using FWE correction. 
Partial volume 
correction. 
  
DLB PiB binding was significantly lower than AD but 
significantly higher than controls. 
No relationship found between global PiB and motor 
impairment, dementia rating, visual hallucinations or 
duration of symptoms. 
Petrou et al. 
(2012) 
40 PD at 
risk for 
dementia 
11
C-PIB PET 
11
C-DTBZ PET 
MRI 
80 min acquisition. 
Logan graphical analysis 
method. 
DVR v. cerebellum. 
 
Cortical PiB was inversely correlated with overall 
cognitive score and WAIS score. 
Ossenkoppele et 
al. (2012) 
66 AD 
30 MCI 
15 SMC 
18 FTD 
5 DLB 
 
11
C-PIB PET 
18
F-FDG PET 
MRI 
90 min dynamic scan. 
ROI BP v. cerebellum. 
For 12 patients 60-90 
min SUVR ROI v 
cerebellum. 
11
C-PIB PET contributed to diagnostic process in 86% 
of patients, mainly used to rule out AD. 
 
Shimada et al. 
(2013) 
8 DLB 
7 PDD 
13 AD 
22 controls 
 
11
C-PIB PET 
MRI
 
90 min dynamic scan. 
Logan graphical analysis 
method. 
ROI DVR v. cerebellum. 
PiB positive LBD subjects demonstrated cortical 
atrophy compared with controls; greater atrophy in 
parahippocampal regions than PiB negative LBD 
subjects. 
Gomperts et al. 
(2013) 
35 PD 
11 PD-MCI 
11
C-PIB PET 
 
60 min dynamic scan. 
Logan graphical analysis 
method.  DVR v. 
cerebellum. 
Higher PiB retention at baseline associated with 
progression to MCI or dementia and with deterioration 
in executive function. 
Motor deterioration not linked to baseline striatal or 
precuneus amyloid burden.  
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BP = binding potential; DTBZ = dihydrotetrabenazine; DVR = distribution volume ratio; FDG = fluorodeoxyglucose; FWE = family-wise 
error; MRI = magnetic resonance imaging; PET = positron emission tomography; PIB = Pittsburgh compound B; ROI = region of interest; 
SMC = subjective memory complaint; SPM = statistical parametric mapping; SUVR = standardised uptake value ratio. 
Table 3.1 Continued  
Study Population Scans, ligand Amyloid PET acquisition 
and image analysis 
Major findings 
Campbell et al. 
(2013) 
10 DLB 
43 PD/PDD 
35 AD 
67 controls 
11
C-PIB PET 
MRI 
60 min dynamic scan. 
ROI and cortical BP. 
Logan graphical analysis, 
cerebellum as reference.  
 
Pattern of deposition of amyloid in LB disease was 
more similar to that seen in controls to the pattern seen 
in AD 
Edison et al. 
(2013) 
11 PDD 
8 PD 
24 controls 
11
C-PIB PET 
18
F-FDG PET 
MRI 
11
C-PK11195 PET 
 
90 min acquisition. ROI 
DVR v. cerebellum.  
No difference between PD and PDD in cortical binding. 
PD, but not PDD, had greater binding than controls. 
No significant difference between controls and PD or 
PDD in a voxel-based analysis 
Vijayaraghavan 
et al. (2014) 
9 DLB 
9 PDD 
10 PD 
11
C-PIB PET 
18
F-FDG PET 
CSF markers 
 
42-72 min ROI SUVR v. 
cerebellum. 
11
C-PiB binding and CSF APOE levels were positively 
correlated 
Ishii et al. (2015) 10 DLB 
10AD 
11
C-PIB PET 
18
F-FDG PET 
50-70 min ROI SUVR v 
cerebellum.  
Visual rating. 
 
There are no differences in cortical metabolism between 
amyloid positive and amyloid negative DLB cases 
Nedelska et al. 
(2015a) 
30 DLB 
30 AD 
60 controls 
 
11
C-PIB PET 
18
F-FDG PET 
 
40-60 min ROI SUVR v 
cerebellar grey matter 
AD patients had higher Aβ binding than DLB. 
Loss of parieto-occipital white matter integrity in DLB 
is independent of Aβ deposition. 
Siderowf et al. 
(2015) 
11 DLB 
5 PD 
10AD 
5 controls 
18
F-Florbetapir 
PET 
 
50-60 min Cortical 
SUVR v cerebellum 
Visual rating 
AD>PD in all cortical regions 
AD>DLB in parietal and anterior cingulate areas only. 
DLB>controls in posterior cingulate only. 
Amyloid positive DLB had lower MMSE than amyloid 
negative. NB: broad range (MMSE 4-28) 
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4 Chapter 4   Prodromal Dementia with Lewy Bodies: Aims, Hypotheses 
and Methods 
4.1 Aims 
The aim of this project is to characterise the phenotype of prodromal DLB. Patients with 
MCI who appear at risk of developing dementia with Lewy bodies will have a thorough 
baseline clinical and neuropsychological assessment and 
123
I-FP-CIT dopaminergic 
imaging. They will then be reviewed annually for conversion to dementia. The baseline 
assessment of those that develop DLB can then be examined to identify predictors of 
conversion to DLB. 
This thesis will examine the baseline data of this project to investigate the potential 
utility of 
123
I-FP-CIT imaging as a biomarker for prodromal DLB. A comparison will be 
made between those with normal 
123
I-FP-CIT scans and those with abnormal scans. 
Visual rating of 
123
I-FP-CIT images will be compared with semi-quantitative analysis of 
striatal 
123
I-FP-CIT binding to investigate whether visual rating is correlated with 
overall striatal binding. 
 
4.2 Hypotheses 
4.2.1 Primary Hypotheses 
123
I-FP-CIT imaging is a biomarker of Lewy body disease, therefore those with MCI 
and an abnormal 
123
I-FP-CIT scan will be more likely to have prodromal DLB than 
those with normal scans, and will have a phenotype similar to that seen in established 
DLB. This will be evidenced by: 
1. The 
123
I-FP-CIT abnormal group will have more core and suggestive diagnostic 
features of DLB 
2. The 
123
I-FP-CIT abnormal group will have higher scores in scales measuring these 
features 
3. The 
123
I-FP-CIT abnormal group will have worse visuospatial and executive function, 
but better memory on neuropsychological tests 
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4. The 
123
I-FP-CIT abnormal group will have a higher frequency of other features 
associated with DLB e.g. anosmia, postural hypotension and constipation 
 
4.2.2 Secondary Hypothesis 
The pattern of nigrostriatal dopaminergic denervation in prodromal DLB will be similar 
to that seen in established DLB, and therefore: 
5. Measures of asymmetry of 
123
I-FP-CIT binding between the left and right striata will 
be low in the entire cohort. 
 
4.3 Methods 
4.3.1 Participants 
Participants were recruited prospectively from NHS Trusts in the North of England. 
Patients were identified through direct referral from their treating teams; through the 
Dementias and Neurodegenerative Diseases Research Network (DeNDRoN) Research 
Case Register and through screening patient notes based on Mental Health Cluster, an 
instrument for categorising NHS Mental Health patients based on the type of illness 
they have and its severity (Department of Health, 2013). Patients categorised as ‘Cluster 
18’ were screened. This refers to people with ‘Cognitive Impairment (low need)’ and is 
the Cluster most likely to be used for people with MCI.  
All subjects needed to have sufficient English to complete cognitive testing. All subjects 
gave their written informed consent to take part in the study. The study received ethical 
approval from the National Research Ethics Service Committee North East - Newcastle 
& North Tyneside 2 (Research Ethics Committee Identification Number 12/NE/0290). 
 
4.3.2 Inclusion/exclusion criteria 
Subjects were ≥60 years old and fulfilled the NIAAA clinical criteria for MCI (Albert et 
al., 2011) – concern regarding change in cognition, impairment in one or more 
cognitive domains, preservation of independence of function with minimal aids or 
assistance and not demented. In addition, all subjects had at least one symptom 
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suggesting they might have Lewy body disease. This included the core and suggestive 
features of DLB (spontaneous motor parkinsonism, cognitive fluctuations, recurrent 
visual hallucinations, REM sleep behaviour disorder, severe neuroleptic sensitivity), as 
well as other symptoms that may be more likely in Lewy body disease, such as auditory 
hallucinations and delusions. Given the concern that a large proportion of people with 
DLB are not identified during life the inclusion criteria were deliberately made broader 
to try and capture these patients. Thus patients were also included if they appeared to be 
developing a core or suggestive feature of DLB, though the full symptom was not yet 
present. Examples of this would be a rest tremor without other parkinsonian features, 
marked visual illusions or visuospatial dysfunction, daytime sleepiness that did not 
amount to fluctuations or new onset sleep disturbance without a clear RBD phenotype.  
Subjects were excluded if they had an MMSE score <20; CDR score of >0.5; if they had 
developed parkinsonism more than one year prior to cognitive impairment or if they had 
evidence of clinical stroke or a serious neurological or mental condition that would 
affect their performance in study assessments. The ‘one year rule’ was used because 
patients developing parkinsonism more than one year prior to cognitive impairment 
would be classified as PDD rather than DLB if they progressed to dementia. 
 
4.3.3 Baseline cognitive and clinical assessment 
Volunteers underwent a thorough clinical and neuropsychological assessment to 
determine the symptoms they experienced and their severity.  
 
4.3.4 Clinical assessment 
Subjects were assessed by a doctor (PD) to confirm the diagnosis of MCI and suitability 
for the study. This included a neurological examination and the motor subscale of the 
Revised Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) to quantify the 
degree of parkinsonism present (Goetz et al., 2008). The degree of physical comorbidity 
was rated using the Cumulative Illness Rating  Scale for Geriatrics (CIRS-G) (Miller et 
al., 1992). 
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North-East Visual Hallucinations Interview  
The North-East Visual Hallucinations Interview (NEVHI) is a semi-structured interview 
that screens for hallucinations and investigates the emotions, cognitions and behaviours 
associated with hallucinations (Mosimann et al., 2008). 
 
Epworth Sleepiness Scale 
The Epworth Sleepiness Scale (ESS) asks volunteers to rate their likelihood of falling 
asleep or dozing from 0 (never) to 3 (high chance) in eight different situations (Johns, 
1991). Patients with DLB score higher in this test than those with AD or normal 
controls (Boddy et al., 2007). 
 
Geriatric Depression Scale  
The 15 Item Geriatric Depression Scale (GDS) consists of 15 ‘yes’ or ‘no’ questions 
assessing the presence of symptoms of depression (D'Ath et al., 1994). A cut-off of 5/6 
gives a sensitivity of 86% and a specificity of 74% when compared with ICD-10 
diagnosis (Almeida and Almeida, 1999). 
 
Gastroparesis Cardinal Symptom Index  
The Gastroparesis Cardinal Symptom Index (GCSI) is a rating scale of 9 symptoms of 
delayed stomach emptying (gastroparesis) grouped into three domains 
(nausea/vomiting, fullness/early satiety and bloating) (Revicki et al., 2003). 
 
Lewy body symptom questionnaire 
All subjects also had the Lewy body symptom questionnaire (LBSQ). This is a list of 49 
symptoms based on the Lewy Body Dementia Association’s Comprehensive Lewy 
Body Dementia Symptom Checklist (Lewy Body Dementia Association, 2014) along  
with other symptoms known to be associated with Lewy body disease. Some questions 
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were added after the start of the study. The symptoms of dry/painful eyes, double 
vision, difficulty reading because words and letters seem to move around the page and 
misjudging objects were added in light of new evidence (n=51) (Jefferis et al., 2013). 
The symptoms poor balance, frequent falls and weak voice were added following a 
revision of the Lewy Body Dementia Association’s checklist (n=43) (Lewy Body 
Dementia Association, 2014). 
 
4.3.5 Neuropsychological tests 
Addenbrooke’s Cognitive Examination Revised  
The Addenbrooke’s Cognitive Examination Revised (ACE-R) is a 100-point 
examination, divided into five domains – orientation/attention, memory, verbal fluency, 
language and visuospatial function (Mioshi et al., 2006). It has been shown to have 
good sensitivity and specificity for the identification of dementia. Mean scores of MCI 
subjects are intermediate between dementia and normal controls. 
 
Verbal fluency 
Letter and category fluency were tested. In letter fluency subjects must generate as 
many words (excluding proper nouns) beginning with the letter ‘F’ in one minute. This 
is then repeated for the letters ‘A’ and ‘S’.  Category fluency was tested as part of the 
ACER by asking the subjects to name as many animals as they could in one minute. 
Category fluency is impaired in both DLB and AD, whereas some studies have reported 
that letter fluency is more severely affected in DLB (Lambon Ralph et al., 2001). 
 
Trailmaking test 
The trail-making test consists of two parts. In part A, subjects must connect numbered 
circles in ascending order using a pen. In part B, the sheet contains circles with numbers 
and letters. These must be connected in an alternating fashion: 1-A-2-B-3-C etc. Part A 
primarily assesses visuoperceptual abilities and attention, whereas part B also tests 
working memory and task-switching (Sanchez-Cubillo et al., 2009). Those with autopsy 
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confirmed Lewy body pathology take longer to complete Part B than those with 
Alzheimer’s disease, those with combined pathology have intermediate scores (Kraybill 
et al., 2005). 
 
Graded Naming 
The Graded Naming Test requires subjects to recognise and name monochrome 
drawings of 30 objects (McKenna and Warrington, 2007). Most studies have found to 
be naming to be similarly impaired in DLB and AD (Troster, 2008), though a large 
study found greater impairment in DLB (Ferman et al., 2006) 
 
Rey AVLT 
The Rey Auditory Verbal Learning Test (AVLT) (Rey, 1964) involves the subject 
trying to recall 15 words that are read out to them at a rate of one word per second (List 
A). They are given five trials, with the number of correct responses recorded after each 
trial (Trials 1-5). There is then a single trial with a new list of 15 words (List B). 
Following this the subject is asked to recall as many words as possible from the original 
list (Trial 6). After a 30 minute break the subject is again asked to recall as many words 
as possible from the list A (Delayed Recall). A list of 50 words is then read out, with the 
subject asked to identify those words that were on List A. The number of List A words 
correctly identified is recorded. 
People with DLB score lower on the Rey AVLT than controls, but higher than those 
with AD (Ferman et al., 2006). 
 
4.3.6 Computerised cognitive tests 
Computerised tests were performed using a laptop computer with 36cm screen placed 
approximately at eye-level. Patients held one or two response paddles depending on the 
test. All tests were operated through MATLAB and developed in Newcastle University 
by Michael Firbank, apart from the motion task which was developed by David Salmon 
and colleagues in UC San Diego. These tests aim to measure specific cognitive domains 
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that are known to be affected in DLB: visuospatial function and executive functions 
such as attention, processing speed and decision-making. 
 
Simple and choice reaction time (Figure 4.1) 
Simple Reaction Time (SRT): A white ‘V’ on a black background was presented to the 
participant 30 times in varying intervals. Each time the participant pressed the paddle as 
quickly as possible. The number of correct responses, average response time and 
standard deviation of response time were recorded. 
Choice Reaction Time (CRT): A white arrow pointing to the right ‘>’ or the left ‘<’ was 
presented to the patient, who had to press a paddle corresponding to ‘right’ or ’left’ each 
time. The number of correct responses, errors, average response time and standard 
deviation of response time were recorded. 
 
 
The SRT and CRT both involve seeing a stimulus and physically responding to it. The 
CRT also contains another task – identifying the stimulus (‘right’ or ‘left’) and choosing 
an appropriate response based on this. The time taken to do this is called the Cognitive 
Processing Time and can be calculated as below: 
𝐶𝑜𝑔𝑛𝑖𝑡𝑖𝑣𝑒 𝑃𝑟𝑜𝑐𝑒𝑠𝑠𝑖𝑛𝑔 𝑇𝑖𝑚𝑒 = 𝐶ℎ𝑜𝑖𝑐𝑒 𝑅𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑇𝑖𝑚𝑒 − 𝑆𝑖𝑚𝑝𝑙𝑒 𝑅𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑇𝑖𝑚𝑒 
 
  
Figure 4.1. Visual stimuli presented in the (A) simple reaction time and (B) choice 
reaction time tasks. 
A B 
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Compared to those with AD, people with DLB have been found to have longer reaction 
times indicating worse attention, greater variability in reaction times indicating greater 
fluctuation in attention, more errors in the CRT indicating impaired decision-making 
and longer cognitive processing times indicating slower processing speed (Ballard et al., 
2001). 
 
Digit vigilance (Figure 4.2) 
360 pseudorandom numbers were presented on screen at a rate of 2/second. Each time 
the number ‘9’ appeared the patient pressed a paddle in their hand. A pale number ‘9’ 
remained onscreen throughout.  The number of correct responses, average response time 
and standard deviation of response time were recorded. DLB is associated with longer 
response times, greater variability in response times and fewer correct responses than 
AD (Ballard et al., 2001).  
  
Figure 4.2. The digit vigilance task. The bright number in the centre of the screen 
changed at a rate of 2/s. When it became a ‘9’ subjects had to press a paddle as quickly 
as possible 
 
Power of attention 
Power of attention (Rowan et al., 2007) is a summary measure of attention that 
combines the reaction times in the SRT, CRT and digit vigilance tasks. It is calculated 
as follows: 
Power of attention =  Simple Reaction Time + Choice Reaction Time + Digit Vigilance 
Response Time 
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Line angle discrimination (Figure 4.3) 
In this task of visuospatial function participants were presented with an angle at the top 
of the screen. At the bottom of the screen two angles were presented, one of which was 
the same as the top angle. Participants pressed ‘left’ or ‘right’ to select the option that 
they thought matched with the angle at the top of the screen. The difficulty modified 
based on the participant’s responses. The program produced an estimate of the angle the 
participant could discriminate in degrees, where lower scores indicated better angle 
discrimination. People with DLB perform more poorly at this task than those with AD 
indicating worse visuospatial function (Wood et al., 2013). 
 
Motion task (Figure 4.4) 
In the motion task moving white dots were presented on the screen for 1 second. A 
proportion of the dots were either moving horizontally to the right or to the left (signal). 
The rest of the dots were moving randomly (noise). The participant had to decide if the 
signal dots were moving to the right or the left. The program modified difficulty based 
on the participant’s responses; the output was a threshold of the proportion of dots in the 
signal that the participant required to identify the direction of movement. Salmon and 
colleagues have found that people with DLB perform worse than those with AD in this 
task. 
 
Figure 4.3. The angle discrimination task. Subjects had to choose which of the lower 
angles matched the angle at the top of the screen. 
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Figure 4.4. The motion task. Arrows are for illustration and were not present during 
the task. Subjects had to identify if the ‘signal’ dots (indicated with green arrows) were 
moving right (A) or left (B) amidst ‘noise’ dots (indicated with red arrows) moving in 
random directions. 
 
4.3.7 Carer rating scales 
NPI 
The Neuropsychiatric Inventory assesses the frequency and severity of ten 
neuropsychiatric symptoms, as well as the level of carer distress caused by these 
symptoms (Cummings et al., 1994). DLB cases have been found to score higher than 
AD cases in domains such as hallucinations, apathy and loss of appetite in the early 
stages of the disease (Ricci et al., 2009). 
  
Cognitive Fluctuations Scales 
The recently developed Dementia Cognitive Fluctuations Scale (DCFS) enquires about 
four symptoms (variation in function, daytime sleepiness, daytime lethargy and overall 
level of consciousness) that were shown to differentiate DLB from AD (Lee et al., 
2014). Two further symptoms (staring into space and disorganised speech) were also 
rated (Ferman et al., 2004). 
The Clinician Assessment of Fluctuation (CAF) consists of two screening questions to 
identify impaired alertness and variation in levels of confusion. If present, these are then 
A B
A 
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rated on a scale of 0-4 for severity and duration. These two scores are then multiplied to 
give an overall score (Walker et al., 2000a). Patients with DLB score higher than AD in 
this assessment (O'Brien et al., 2014a). 
 
Mayo Sleep Questionnaire 
The Mayo Sleep Questionnaire (MSQ) is a carer-rated scale to identify REM sleep 
behaviour disorder (Boeve et al., 2011). It involves questions relating to the presence of 
RBD and other causes of sleep disturbance, such as sleep apnoea. It can only be carried 
out with an informant that lives with the patient. The first question relates to the acting 
out dreams and has a sensitivity of 98% and specificity of 74% for the identification of 
RBD when compared with polysomnography (Boeve et al., 2011). 
 
Assessments of level of function 
The Lawton Instrumental Activities of Daily Living Scale (IADL) (1969) measures a 
patient’s current ability to perform eight tasks, regardless of whether the person 
regularly performs these tasks or not. The maximum score possible is 8, representing 
full function; the minimum possible score is 0, representing the highest level of 
functional impairment. 
The Clinical Dementia Rating Scale (CDR) (Hughes et al., 1982) involves a clinician 
rating the subject’s level of impairment in six domains of function. Unlike the IADL 
scale, the rating is based on clinical judgement of the decline in function due to 
cognitive impairment, and not due to other factors such as physical impairment. An 
overall score can be calculated using an algorithm (Morris, 1993). A score of 1-3 is 
consistent with dementia; a score of 0.5 is consistent with MCI or dementia. A score of 
0 is not consistent with dementia. The scores in each domain can be added to give a 
‘sum of boxes score’. 
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4.3.8 Presence of core and suggestive features of Lewy body disease 
The presence or absence of core or suggestive features of Lewy body disease was 
determined by the reviewing clinician (PD) based on the clinical interview and carer 
questionnaires. These were rated using the definitions in the diagnostic criteria for 
dementia with Lewy bodies (McKeith et al., 2005). These definitions are not fully 
operationalised and require some clinical judgement. The definitions used and scales 
that informed the decision are recorded in Table 4.1. 
 
Table 4.1. Definitions of core and suggestive symptoms of Lewy body disease 
Symptom Definition Scales used 
Fluctuations Fluctuating cognition with pronounced variations in 
attention and alertness 
CAF 
DCFS 
Visual 
hallucinations 
Recurrent visual hallucinations that are typically well 
formed and detailed 
NEVHI 
Parkinsonism Spontaneous features of parkinsonism, usually two or 
more of the following symptoms: rest tremor, rigidity, 
bradykinesia, parkinsonian gait, postural instability 
UPDRS 
RBD Report of appearing to act out dreams – vocalising, 
flailing limbs and moving around the bed 
MSQ 
Neuroleptic 
sensitivity 
Severe reaction to neuroleptic medication e.g. acute 
onset or exacerbation of parkinsonism and impaired 
consciousness 
n/a 
 
4.3.9 123I- FP-CIT SPECT imaging 
Subjects were given 85mg Potassium Iodate thyroid protection 1 hour prior to the 
intravenous injection of 185MBq 
123
I-2h-carbomethoxy-3h-(4-iodophenyl)-N-(3-
fluoropropyl)-N-nortropane (FP-CIT; GE Healthcare). Subjects were imaged using a 
dual-detector gamma camera (Siemens Symbia S) with a low-energy high-resolution 
collimator. One-hundred and twenty 25 second projections were taken over 360° on a 
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128 x 128 matrix with slice thickness of (3.9mm). Image reconstruction was performed 
using ramp-filtered back-projection with a Butterworth filter (order 13, cut-off 0.3 
cycles cm
-1
) to produce the transverse sections. The reconstructed images, uncorrected 
for gamma ray attenuation, were subsequently transferred in the DICOM format to a 
personal computer for further analysis. 
 
4.3.10 SPECT visual rating 
Images were independently visually assessed by four raters (Alan Thomas, Sean 
Colloby, Jim Lloyd and Paul Donaghy) and classified into one of four categories 
(Figure 4.5) (Benamer et al., 2000): 
0 - Normal 
1 - Unilateral reduction in putamen 
2 - Bilateral reduction in putamen 
3 - Bilateral reduction in caudate and putamen 
 
0 
 
1 
 
2 
 
3 
 
Figure 4.5. Visual Rating of FP-CIT scans (Benamer et al., 2000) 
0 - Normal. Normal tracer uptake bilaterally in putamen and caudate nuclei and largely 
symmetric 
1 - Unilateral reduction in putamen. Asymmetric uptake with normal or almost normal 
putamen activity in one hemisphere and with a more marked reduction in the 
contralateral putamen 
2 - Bilateral reduction in putamen. Significant bilateral reduction in putamen uptake 
with activity confined to the caudate nuclei. 
3 - Bilateral reduction in caudate and putamen. Virtually absent uptake bilaterally 
affecting both putamen and caudate nuclei with relatively increased background 
activity. 
Images are from study participants. 
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Following this a consensus panel was held to discuss scans in which there was not full 
agreement and decide on a consensus rating.  
 
4.3.11 SPECT quantification 
Files were processed in NifTI format using SPM 8 (www.fil.ion.ucl.ac.uk/spm/ 
software/spm8/). Each image was positioned with the anterior commissure 
approximately at point 0,0,0. Each scan was spatially registered to a FP-CIT template 
image in Montreal Neuroimaging Initiative (MNI) space using the ‘Normalise: Estimate 
and Write’ function, preserving concentrations with trilinear interpolation and a cubic 
voxel size of 2mm. The registered images were then resliced using the ‘Realign:Reslice’ 
function.  
An FP-CIT SPECT template previously developed in Newcastle was used establish 
striatal ROIs (Colloby et al., 2004). The template was developed by co-registering the 
scans of 33 normal healthy controls to a MRI brain template image in MNI space. 
Thresholding of the template image was applied to produce bilateral striatal regions of 
interest (ROI) for automated analysis (Figure 4.6). A large occipital ROI was also 
manually drawn to assess non-specific binding. Both ROI maps were then applied to 
each subject’s registered FP-CIT image using ITK-SNAP (www.itksnap.org), where 
uptake values for left striatum, right striatum and occipital activity were obtained. The 
striatal:occipital binding ratio was calculated as follows: 
𝑀𝑒𝑎𝑛 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝐿𝑒𝑓𝑡 𝑆𝑡𝑟𝑖𝑎𝑡𝑢𝑚 + 𝑀𝑒𝑎𝑛 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑅𝑖𝑔ℎ𝑡 𝑆𝑡𝑟𝑖𝑎𝑡𝑢𝑚
2 × 𝑀𝑒𝑎𝑛 𝑂𝑐𝑐𝑖𝑝𝑖𝑡𝑎𝑙 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦
 
 
The Asymmetry Index between the striata was calculated as follows: 
𝐻𝑖𝑔ℎ𝑒𝑟 𝑆𝑡𝑟𝑖𝑎𝑡𝑎𝑙 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 − 𝐿𝑜𝑤𝑒𝑟 𝑆𝑡𝑟𝑖𝑎𝑡𝑎𝑙 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦
𝑀𝑒𝑎𝑛 𝑆𝑡𝑟𝑖𝑎𝑡𝑎𝑙 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦
× 100% 
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4.3.12 Statistics 
Statistical analysis was completed using IBM SPSS Statistics 22 software. Normality 
was tested using the Shapiro-Wilk test. Comparisons between groups were carried out 
using t-tests or Mann-Whitney U tests depending on normality of the data. χ2 or 
Fischer’s Exact tests were used for categorical variables depending on cell size. 
Correlation was carried out using Pearson’s (for normally distributed data) or Kendall’s 
tau (for non-normal data) correlation. Interrater and intrarater reliability in 
123
I-FP-CIT 
SPECT visual rating was assessed using the Kappa statistic. A mean of all pair-wise 
kappa values was used to summarise agreement between the four raters.  
A value of p≤ 0.05 was set as the threshold for statistical significance, uncorrected for 
multiple comparisons. 
Statistical power was difficult to calculate for this analysis as the likelihood of a 
positive FP-CIT scan in this population was unknown. If 33% of participants had an 
abnormal scan a total sample size of 51 would be sufficient to detect differences 
between the groups with a large effect size (≥0.8) with a statistical power of 0.8. 
  
 
Figure 4.6. Striatal and occipital regions of interest overlaid on an MRI brain 
template image. 
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5 Chapter 5   Prodromal Dementia with Lewy Bodies: Results and 
Discussion 
5.1 Recruitment 
A large number of potential participants were screened for study suitability. 
Approximately 220 were approached, of whom 62 agreed to enter the study. Four 
participants were later found to be unsuitable, four withdrew and another died prior to 
completing the baseline assessment. 
Table 5.1. Group demographics and symptom profile in the 
prodromal DLB study (SD in brackets) 
 
N 53  
Mean age (years) 76.3 (7.7)  
Gender (% female) 40  
Mean years of education 11.6 (2.7)  
Mean MMSE score 26.5 (2.2)  
Mean ACE-R score  78.5 (10.8)  
ACE-R Attention/Orientation 17.1 (1.3)  
ACE-R Memory 15.8 (5.1)  
ACE-R Fluency 8.4 (3.1)  
ACE-R Language 23.1 (3.0)  
ACE-R Visuospatial 14.1 (2.1)  
MDS-UPDRS 22.4 (15.3)  
Hoehn and Yahr Stage 0.74 (1.2)  
6-point UPDRS Score 2.9 (2.8)  
Fluctuations (%) 37  
Visual Hallucinations (%) 17  
Parkinsonism (%) 32  
RBD (%) 43  
Neuroleptic sensitivity (%) 0  
Abnormal FP-CIT SPECT (%) 36  
Mean total core and suggestive features 1.7 (1.3)  
Subjects with at least 1 core feature (%) 64  
Subjects with at least 1 suggestive feature (%) 55  
Subjects with at least 1 core and suggestive feature (%) 43  
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5.2 Group demographics and symptom profile 
53 patients completed baseline assessment. The mean age was 76.3 years, 40% of the 
group was female and the mean MMSE was 26.5 (Table 5.1). 
On average each patient had a mean of 1.7 (median 2) core or suggestive features of 
DLB. 13 patients (25%) had no symptoms that reached the threshold of a core or 
suggestive feature after a thorough clinical assessment (Table 5.2). 
The most common diagnostic feature was REM sleep behaviour disorder (43%) 
followed by fluctuations (37%; Figure 5.1). No patient reported sensitivity to 
antipsychotics though only two patients (4%) were currently taking an antipsychotic 
medication.  
 
 
Table 5.2. Number of core and suggestive features of 
LB disease in the prodromal DLB study subjects 
No. of core or suggestive features Frequency (n) 
0 13 
1 9 
2 22 
3 4 
4 2 
5 3 
 
 
5.3 123I-FP-CIT SPECT visual rating 
19 volunteers (36%) had an abnormal FP-CIT scan on visual rating (Figure 5.2). 8 
subjects had grade 1 (unilateral loss in the putamen), 8 had grade 2 (bilateral putamen 
loss) and 3 had grade 3 (universal loss). 
There was full agreement between the four raters in 35/53 scans (66%). The mean 
Kappa between the raters was 0.62 (substantial agreement). 
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Figure 5.1. Frequency of each core and suggestive feature of Lewy body disease 
in the prodromal DLB study. 
Figure 5.2. Frequency of FP-CIT SPECT visual rating grade in the 
prodromal DLB study. 34 subjects had a normal scan (64%), 19 
(36%) had an abnormal scan (n=8 Grade 1, n=8 Grade 2, n=3 Grade 3). 
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5.4 Comparison of FP-CIT normal and abnormal subjects 
5.4.1 Demographics 
Those with abnormal scans were of similar age to those with normal scans but were 
more likely to be male (89% v. 46%; p=0.001) and to be taking medications for 
parkinsonism (32% v 6%; p=0.02).  Rates of severe co-morbidity measured by the 
CIRS-G were low in both groups, with few domains rated as category 3 
(severe/constant significant disability) and none at category 4 (severe impairment in 
function).  The FP-CIT abnormal group tended towards slightly lower overall levels of 
co-morbidity than the FP-CIT normal group (CIRS-G 8.0 v 10.2; p=0.08). There were 
no differences between those with normal and abnormal scans in terms of prescription 
of cholinesterase inhibitors or loss of function measured by the CDR or IADL scales 
(Table 5.3). 
 
Table 5.3. Demographics of FP-CIT normal and abnormal groups 
 FP-CIT Normal 
Mean  (SD) 
FP-CIT Abnormal 
Mean  (SD) 
 
p 
n 34 19 - 
Age 76.7 (8.5) 75.6 (6.1) 0.63 
Gender (% female) 56 11 0.001 
Number of years education 11.4 (2.7) 12.0 (2.7) 0.15 
Cholinesterase Inhibitor prescribed (%) 38 42 0.78 
Levodopa prescribed (%) 6 32 0.02 
CDR total Score 0.4 (0.2) 0.5 (0.1) 0.36 
IADL Total (n=47) 6.5 (1.6) 6.1 (2.0) 0.59 
CIRS-G Total score 10.2 (4.3) 8.0 (4.6) 0.08 
Average CIRS domains at Level 3 0.5 (0.7) 0.3 (0.6) 0.11 
Average CIRS domains at Level 4 0 - 0 - - 
 
5.4.2 Presence of core and suggestive features of LB disease 
The presence or absence of core and suggestive symptoms of LB disease was 
determined for each volunteer as described in section 4.3.8. All volunteers with an 
abnormal FP-CIT scan also had at least one other LB feature (Figure 5.3). The majority 
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of those with normal FP-CIT scans had zero or one LB feature. The average number of 
features (not including abnormal FP-CIT scan) in the abnormal scan group was 1.9 
compared with 1.0 in those with normal scans (p<0.01). The specific symptoms 
associated with an abnormal scan were parkinsonism (58% v 18%; p=0.003) and REM 
sleep behaviour disorder (68% v 29%; p=0.006; Figure 5.4). There were no differences 
between the groups in the rate of cognitive fluctuations (Abnormal v normal = 42% v 
35%; p=0.62) or visual hallucinations (Abnormal v normal = 21% v 15%; p=0.71). 
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Figure 5.4. The proportion of subjects experiencing core and suggestive features of 
LB disease in the normal and abnormal FP-CIT groups. Those with abnormal scans 
were significantly more likely to experience parkinsonism (58% v 18%; p=0.003) and 
REM sleep behaviour disorder (68% v 29%; p=0.006). 
Figure 5.3. The number of core and suggestive clinical features of 
LB disease experienced by subjects in the normal and abnormal FP-
CIT groups.  
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5.4.3 Cognitive tests 
One patient could not complete the Rey AVLT. Two patients could not complete Trails 
A, 22 could not complete Trails B. 
There were no differences between those with normal and abnormal scans in the ACE-R 
or any of its cognitive subdomains (Table 5.4). There were no differences in memory 
measured by the Rey AVLT, verbal fluency measured by the ‘FAS’ test or word 
retrieval measured by the graded naming test. There were no differences in executive 
function measured by the Trails B, but this test had a significant floor effect, with 58% 
of those with abnormal and 38% of those with normal  FP-CIT SPECT being unable to 
complete the test within 5 minutes (Tombaugh et al. 2004).  
 
 
Table 5.4. Cognitive test scores in FP-CIT normal and abnormal groups. 
 FP-CIT Normal FP-CIT Abnormal  
 Mean (SD) Mean (SD) p 
MMSE 26.4 (2.4) 26.7 (1.7) 0.65 
ACE-R total 78.4 (12.0) 78.5 (8.6) 0.97 
ACE-R attention and orientation  16.9 (1.4) 17.4 (1.1) 0.22 
ACE-R memory  15.6 (5.5) 16.2 (4.4) 0.70 
ACE-R fluency  8.9 (3.0) 7.6 (3.0) 0.15 
ACE-R language  22.8 (3.5) 23.6 (1.7) 0.96 
ACE-R visuospatial  14.2 (2.1) 13.8 (2.2) 0.60 
Rey AVLT Trial 1 3.9 (1.8) 4.0 (1.7) 0.85 
Rey AVLT Trial 6 3.9 (3.5) 4.6 (3.4) 0.47 
Rey AVLT Delay 3.2 (3.8) 3.8 (3.4) 0.38 
Rey AVLT Recognition 11.6 (2.7) 11.3 (2.6) 0.65 
Verbal Fluency (FAS) score 30.4 (15.8) 29.4 (14.3) 0.94 
Trails A (s) 64.4 (34.9) 76.7 (41.0) 0.34 
Trails B (s) 134.6 (72.3) 158.6 (72.5) 0.25 
Failed to complete Trails B (%) 38 58 0.17 
Graded naming test 16.9 (7.5) 16.6 (5.7) 0.87 
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5.4.4 Computerised tests of cognitive function 
One patient could not complete the digit vigilance task due to double vision. Computer 
errors resulted in the loss of data for one patient in the reaction time tests and seven 
patients in the angle discrimination task. 
There were no differences between the groups in simple reaction time, choice reaction 
time, or the variation in these measures assessed by standard deviation (Table 5.5). 
Cognitive processing time did not differ between the groups. Those with abnormal 
scans were more likely to make errors on the choice reaction time task. They also 
tended towards being more likely to miss a stimulus in the digit vigilance test, though 
their response times were not different to the normal group. There was no difference in 
power of attention between the two groups. 
There were no differences between the groups on the two measures of visuospatial 
function – the angle and motion tasks. 
 
 
Table 5.5. Computerised Cognitive Test Scores in FP-CIT normal and abnormal 
groups. 
 FP-CIT Normal 
Mean  (SD) 
FP-CIT Abnormal 
Mean  (SD) 
 
p 
Simple Reaction time (ms) 452.6 (214.0) 388.4 (135.2) 0.43 
Simple reaction time SD (ms) 158.8 (149.6) 96.2 (71.7) 0.26 
Choice reaction time (ms) 774.7 (338.1) 709.1 (197.5) 0.89 
Choice reaction time SD 202.2 (149.6) 194.3 (87.0) 0.54 
Choice reaction time number of errors 1.7 (1.7) 3.8 (6.1) 0.03 
Cognitive processing time 322.1 (239.0) 320.7 (116.2) 0.27 
Digit vigilance number got (max 36) 32.4 (5.0) 29.9 (5.3) 0.053 
Digit vigilance mean time (ms) 566.6 (73.8) 581.5 (65.2) 0.48 
Digit vigilance SD (ms) 109.5 (44.5) 113.2 (37.7) 0.76 
Digit vigilance false positives 4.7 (6.5) 2.9 (2.8) 0.38 
Power of attention (ms) 1793 (556) 1670 (373) 0.78 
Angle discrimination threshold (
o
) 23.2 (18.1) 22.2 (14.3) 0.60 
Motion Task Threshold 0.72 (0.25) 0.64 (0.30) 0.47 
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5.4.5 Symptom scales 
Six patients did not have a carer or informant to complete the carer questionnaires. 21 
did not have a cohabitee to complete the MSQ, though a collateral history could be 
obtained from another family member in some cases to allow a clinical diagnosis of 
RBD (Figure 5.1). Two patients did not have a postural BP measurement. 
There were no differences between the groups in any NPI domain. There was no 
evidence of any difference in the severity of hallucinations measured by the NEVHI or 
depressive symptoms measured by the GDS (Table 5.6). 
 
 
The abnormal group tended towards higher scores on one fluctuations scale, the CAF 
(2.5 v 1.1; p=0.07) but not the DCFS (7.8 v 7.3; p=0.40). They also tended toward 
increased daytime sleepiness measured by the Epworth Sleepiness scale (9.4 v 7.3; 
p=0.06). 
Table 5.6. Symptom Scales in FP-CIT normal and abnormal groups 
 FP-CIT Normal 
Mean  (SD) 
FP-CIT Abnormal 
Mean  (SD) 
 
p 
DCFS total 7.3 (3.1) 7.8 (3.3) 0.40 
Clinician Assessment of Fluctuation 1.1 (2.1) 2.5 (3.4) 0.07 
Epworth Sleepiness scale 7.3 (5.5) 9.4 (4.3) 0.06 
MSQ RBD Question (% yes) 50 (n=14) 61 (n=18) 0.53 
NPI total 12.5 (11.1) 11.2 (10.4) 0.72 
NPI Distress total 6.5 (7.0) 5.7 (7.5) 0.48 
GDS 3.5 (3.3) 3.2 (2.4) 0.76 
NEVHI 3.0 (4.4) 2.9 (3.8) 0.90 
GCSI total 0.4 (0.6) 0.1 (0.3) 0.12 
MDS-UPDRS 18.6 (13.1) 29.2 (17.0) 0.02 
Hoehn and Yahr Stage 0.5 (1.1) 1.2 (1.3) 0.04 
6-point UPDRS score 2.3 (2.3) 4.1 (3.2) 0.01 
Standing - Lying Systolic BP 3.8 (20.1) -10.1 (22.7) 0.01 
Standing - Lying Diastolic BP 5.0 (8.9) -4.0 (11.0) 0.003 
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There were no differences between the groups on the MSQ Question 1 which has 
proven reliability for the identification of RBD. However 21 subjects (40%) did not 
have an appropriate informant to complete the questionnaire, and these were almost 
entirely in the FP-CIT normal group (n=20/21). 
Unsurprisingly the abnormal FP-CIT SPECT group scored higher on the MDS-UPDRS 
(29.2 v 18.6; p=0.02) and Hoehn and Yahr (1.2 v 0.5; p=0.04) scales. They also had a 
small but statistically significant drop in postural BP, compared to the rise seen in the 
normal group (systolic (mmHg): -10.1 v 3.8, p=0.01; diastolic (mmHg): -4.0 v 5.0, 
p=0.003). 
 
5.4.6 Symptom questionnaire 
Those with abnormal scans were more likely to report parkinsonian symptoms such as 
shuffling (68% v 29%; p=0.006), drooling (58% v 29%; p=0.04), loss of sense of smell 
(53% v 24%; p=0.03) and change in posture (79% v 35%; p=0.04). They also reported 
the symptoms of RBD (involuntary movements in sleep 74% v 26%, p=0.001; Acting 
out dreams 58%v 29%, p=0.04; crying out in sleep 63% v 24%, p=0.004)) and insomnia 
(42% v 15%; p=0.04). They tended towards being more likely to report constipation 
(53% v 29%; p=0.09), slowness of movement (68% v 44%; p=0.09) and a change in 
handwriting (74% v 50%; p=0.09; Figures 5.5 and 5.6).
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Figure 5.5. Cognitive, parkinsonian and psychiatric symptoms in FP-CIT normal and 
abnormal groups. (*=p<0.05; **=p<0.01)) 
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5.5 Charactieristics of FP-CIT binding assessed by quantification. 
Fully-automated quantification was successful in 51/53 scans. In one scan the patient 
was incorrectly positioned, resulting in the edge of the bounding box being close to the 
striata. This was satisfactory for visual rating but SPM was unable to successfully 
realign the scan. In another scan realignment failed because there was exceptionally low 
uptake in both striata and therefore insufficient signal to allow realignment. 
 
FP-CIT positive patients had a lower mean striatal:occipital FP-CIT binding ratio 
compared to those with normal scans (1.61 v 2.10; p<0.001; Figure 5.7). Visual rating 
grade was inversely correlated with mean striatal binding (Kendall’s tau B correlation 
co-efficient = -0.59; p<0.001). There was some overlap in striatal binding between those 
with normal and abnormal scans (Figure 5.8). There was no correlation of mean striatal 
binding with age (Pearson’s r=-0.06; p = 0.69).  
 
Figure 5.7. Quantification of striatal binding relative to non-specific occipital binding 
in FP-CIT normal and abnormal groups. FP-CIT abnormal patients had a lower mean 
striatal:occipital FP-CIT binding ratio compared to those with normal scans (1.61 v 2.10; 
p<0.001) 
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Figure 5.8. Comparison of striatal FP-CIT binding and visual rating grade in the 
prodromal DLB study. Visual rating grade was correlated with striatal binding (Kendall’s 
tau B correlation co-efficient = -0.59; p<0.001). 
Figure 5.9. Comparison of mean striatal uptake with asymmetry in the 
prodromal DLB study. Few subjects had significant asymmetry and there was no 
significant difference in asymmetry between those with normal and abnormal 
scans (2.7% v 5.1%; p=0.16) 
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There was little asymmetry between the left and right striata in the group, with only one 
patient having an asymmetry index above 10% (Figure 5.9). The mean asymmetry 
index score was 2.7% in the normal group and 5.1% in the abnormal group (p=0.16). 
 
5.6 Comparison of genders 
Given the unexpectedly large difference in the proportion of males and females 
classified as FP-CIT abnormal, a comparison of males and females was carried out. 
 
5.6.1 Demographics  
Table 5.7. Demographics in males and females in the prodromal DLB study 
 Male 
Mean  (SD) 
Female 
Mean  (SD) 
 
P 
n 32 21 - 
Age 74.1 (7.4) 79.7 (7.0) 0.008 
Number of years education 12.2 (2.9) 10.6 (1.9) 0.018 
ACE-R total 79.3 (11.2) 77.2 (10.2) 0.50 
Cholinesterase inhibitor prescribed (%) 41 38 0.85 
Levodopa prescribed (%) 19 10 0.46 
CDR total 0.4 (0.2) 0.5 (0.2) 0.82 
IADL 6.2 (1.8) 6.6 (1.6) 0.42 
CIRS-G total 9.0 (5.1) 10.1 (3.3) 0.34 
MDS-UPDRS 21.4 (17.4) 23.9 (11.8) 0.19 
Hoehn and Yahr stage 0.8 (1.2) 0.7 (1.3) 0.77 
6-point UPDRS score 3.0 (3.1) 2.8 (2.4) 0.81 
Mean Striatal:Occipital Ratio 1.80 (0.3) 2.13 (0.3) 0.001 
Total Core and Suggestive symptoms (/5) 1.5    (1.1) 1.0    (0.9) 0.09 
 
Females were on average almost five years older than males. There were no differences 
between the genders in MDS-UPDRS score or Hoehn and Yahr Stage, though males 
were almost twice as likely to be taking medications for parkinsonism (p=0.46; Table 
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5.7). There were no differences between the groups in MCI severity measured by CDR 
and IADL scores and comorbidity measured by the CIRS-G. 
 
5.6.2 Presence of core and suggestive features of LB disease and striatal FP-CIT 
binding 
Males were more likely to have a positive FP-CIT scan (53% v 10% p=0.001), and 
semi-quantified striatal binding was significantly higher in females (2.13 v 1.80; p= 
0.001; Figure 5.11). Males were more likely to have RBD (59% v 19%; p=0.004) and 
approached having more core and suggestive features than females (exluding FP-CIT 
imaging; 1.5 v 1.0; p=0.09; Figure 5.10). There were no significant differences between 
the genders in the presence of fluctuations, visual hallucinations or parkinsonism.  
 
 
 
 
 
 
Given the gender disparity in FP-CIT imaging it could be concluded that either fewer 
females than males in our study have LB disease, or that females with early LB disease 
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Figure 5.10. Frequency of core and suggestive features of Lewy body disease in males 
and females in the prodromal DLB study. Males were more likely to have a positive FP-
CIT scan (53% v 10% p=0.001) and RBD (59% v 19%; p=0.004). There were no significant 
differences between the genders in the presence of fluctuations, visual hallucinations or 
parkinsonism 
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show less nigrostriatal denervation. If females are more likely to have a substantia 
nigra-sparing form of LB disease, then FP-CIT negative females in our cohort should be 
more likely to have prodromal DLB than FP-CIT negative males. A post-hoc analysis 
was carried out to investigate if FP-CIT negative females had a clinical profile more 
similar to DLB compared with FP-CIT negative males. 
 
 
 
 
5.7 Comparison of males and females with normal FP-CIT scans 
5.7.1 Demographics  
As with the whole sample, females were older than males and had fewer years in 
education (Table 5.8). There were no differences between the genders in the 
prescription of cholinesterase inhibitors or medications for parkinsonism and no 
difference in severity of MCI or the presence of comorbidities. 
 
Figure 5.11. Comparison of Striatal FP-CIT binding in males and 
females in the prodromal DLB study. Striatal binding was significantly 
higher in females (2.13 v 1.80; p= 0.001). 
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5.7.2 Core and suggestive features of DLB 
There was no difference between the two groups in mean number of core and suggestive 
symptoms (male 1.0 v female 0.95; p=0.86). There were no significant differences in 
the rates of any symptom (p≥0.20), though males had relatively high rates of 
fluctuations and RBD, but low rates of visual hallucinations and parkinsonism (Figure 
5.12). 
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Table 5.8. Demographics of FP-CIT negative males and females 
 Male 
Mean  (SD) 
Female 
Mean  (SD) 
 
p 
n 15 19 - 
Age 73.1 (8.6) 79.6 (7.4) 0.02 
Number of years education 12.4 (3.1) 10.5 (2.0) 0.04 
Cholinesterase inhibitor prescribed (%) 33 42 0.60 
Levodopa prescribed (%) 0 11 0.49 
CIRS-G total score 10.1 (5.4) 10.3 (3.4) 0.91 
CDR total Score 0.4 (0.2) 0.5 (0.2) 0.34 
IADL 6.4 (1.6) 6.6 (1.6) 0.57 
Figure 5.12. Rates of core and suggestive symptoms in FP-CIT negative males and 
females. There were no significant differences in the rates of any symptom (p≥0.20). 
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5.7.3 Cognitive tests 
There was no difference between the groups in global cognitive function assessed by the 
ACER, but FP-CIT negative females had lower scores in the visuospatial domain (13.6 
v 14.9; p=0.04).There was no difference between the groups in memory, verbal fluency, 
executive function measured by Trails B or naming (Table 5.9).  
To account for demographic differences between the genders, linear regression was 
carried out with age, years in education and gender as independent variables. Gender 
was not associated with differences in any cognitive test (p>0.20 in all cases) including 
the ACE-R visuospatial domain (β=-0.22, p=0.26, n=34). 
 
 
Table 5.9. Cognitive Tests in FP-CIT negative males and females 
 Male Female  
 Mean (SD) Mean (SD) p 
MMSE  26.3 (2.8) 26.4 (2.1) 0.86 
ACE-R total  79.0 (14.1) 78.0 (10.4) 0.80 
ACE-R attention and orientation 16.7 (1.7) 17.1 (1.2) 0.78 
ACE-R memory  15.7 (6.0) 15.5 (5.3) 0.89 
ACE-R fluency  9.1 (3.5) 8.7 (2.8) 0.72 
ACE-R language  22.5 (4.2) 23.0 (2.9) 0.76 
ACE-R visuospatial  14.9 (1.9) 13.6 (2.1) 0.04 
Rey AVLT Trial 1 3.9 (2.3) 3.8 (1.4) 0.97 
Rey AVLT Trial 6 4.0 (3.7) 3.9 (3.3) 0.99 
Rey AVLT Delay 3.1 (4.6) 3.3 (3.1) 0.42 
Rey AVLT Recognition 11.2 (3.2) 11.8 (2.3) 0.71 
Verbal Fluency (FAS) score 34.6 (15.4) 27.1 (15.8) 0.17 
Trails A (s) 59.3 (34.9) 68.4 (35.3) 0.32 
Trails B (s) 137.9 (90.5) 131.2 (52.5) 0.75 
Failed to complete Trails B (%) 33 42 0.60 
Graded naming test 17.4 (9.9) 16.5 (5.1) 0.34 
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5.7.4 Computerised tests of cognitive function 
FP-CIT negative females had slower reaction times than males in the simple reaction 
time (489ms v 404ms; p=0.006) and the digit vigilance (593ms v 534ms; p=0.002) 
tasks, and approached having a worse overall power of attention (1849ms v 1720 ms 
(p=0.06). There was no difference in choice reation time, variability of reaction times, 
or numbers of mistakes in the reaction time and vigilance tasks. Females had worse 
visuospatial function both in the angle discrimination (31.6 v 11.4; p=0.001) and motion 
(threshold 0.80 v 0.63; p=0.04) tasks (Table 5.10).  
Linear regression was again carried out with age, years in education and gender as 
independent variables. The association of gender with a difference in digit vigilance 
time (β=0.48, p=0.02, n=34) and angle discrimination threshold (β=0.51, p=0.02, n=29) 
remained. There was no significant association in simple reaction time (β=0.32, p=0.10, 
n=33), motion task threshold (β=0.30, p=0.19, n=34) or any other computerised test 
variable. 
 
Table 5.10. Computerised Tests in FP-CIT negative males and females 
 Male Female  
 Mean (SD) Mean (SD) p 
Simple Reaction time (ms) 403.8 (216.0) 488.6 (210.9) 0.006 
Simple reaction time SD correct (ms) 116.4 (100.0) 190.1 (173.6) 0.13 
Choice reaction time (ms) 784.8 (392.3) 767.4 (303.1) 0.32 
Choice reaction time SD 225.0 (189.1) 185.3 (115.1) 0.87 
Choice reaction time number of errors 1.5 (1.6) 1.8 (1.8) 0.63 
Cognitive processing time 381.0 (319.8) 278.7 (151.6) 0.42 
Digit vigilance number got (max 36) 32.9 (4.9) 32.0 (5.1) 0.58 
Digit vigilance mean time (ms) 533.7 (55.8) 592.6 (77.1) 0.02 
Digit vigilance SD (ms) 96.6 (34.0) 119.6 (49.8) 0.14 
Digit vigilance false positives 4.5 (3.3) 4.9 (8.3) 0.23 
Power of attention (ms) 1720 (578) 1849 (548) 0.06 
Angle discrimination threshold (
o
) 11.4 (8.3) 31.6 (18.6) 0.001 
Motion Task Threshold 0.63 (0.28) 0.80 (0.21) 0.04 
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5.7.5 Symptom scales 
There were no differences between the groups in the NPI or in specific measures of 
fluctuations, sleepiness, hallucinations or gastroparesis (Table 5.11). Females recorded 
more depressive symptoms on the GDS (4.5 v 2.3; p=0.047) and significantly higher 
MDS-UPDRS scores (23.3 v 12.7; p=0.004). There was no difference between the 
groups in lying and standing BP. Only 10 males and 4 females had a suitable informant 
to complete the MSQ, so this was not included in the statistical analysis. There were no 
significant differences in any NPI subscale, though 21% of informants for females 
reported delusions compared with 0% for males (p=0.07). 
Linear regression with age, years in education and gender as independent variables 
found no association between age and any variable in Table 5.11 including GDS score 
(β=.31, p=0.10, n=34), MDS-UPDRS score (β=0.28, p=0.14, n=34) or 6-point UPDRS 
score (β-0.17, p=0.40, n=34). 
 
Table 5.11. Symptom Scales in FP-CIT negative males and females 
 Male Female  
 Mean (SD) Mean (SD) p 
DCFS total  7.4 (3.3) 7.2 (3.0) 0.95 
Clinician Assessment of Fluctuation 0.9 (1.9) 1.4 (2.3) 0.70 
NPI total 13.3 (12.7) 11.8 (9.7) 0.73 
NPI Distress total  6.1 (6.9) 6.9 (7.3) 0.57 
GDS 2.3 (1.9) 4.5 (3.9) 0.047 
NEVHI 2.5 (3.9) 3.4 (4.8) 0.66 
Epworth Sleepiness scale 6.1 (4.4) 8.3 (6.2) 0.23 
GCSI total 0.3 (0.7) 0.4 (0.5) 0.18 
MDS-UPDRS 12.7 (12.0) 23.3 (12.2) 0.004 
Hoehn and Yahr stage 0.1 (0.5) 0.8 (1.4) 0.30 
6-point UPDRS score 1.6 (2.0) 2.8 (2.5) 0.02 
Standing - Lying Systolic BP 5.1 (13.6) 2.7 (24.9) 0.88 
Standing - Lying Diastolic BP 6.4 (7.3) 3.8 (10.2) 0.41 
 
 
97 
 
5.7.6 Symptom questionnaire 
FP-CIT negative females were more likely to report frequent falls (40% v 0%; p=0.02), 
a change in posture (53% v 13%; p=0.02) and dizziness (74% v 27%; p=0.01). They 
tended toward being more likely to have auditory hallucinations (26% v 0%; p=0.053) 
and to have difficulty moving around due to misjudging objects (38% v 6%; p=0.07; 
Figures 5.13 and 5.14). 
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0% 20% 40% 60% 80% 100%
Memory
Problem Solving
Planning
Fluctuating Attention
Disorganised speech
Confusion
Rigidity/stiffness
Shuffling walk
Tremor
Slowness of movement
Change in handwriting
Slack facial expression
Drooling
Loss of smell
Balance
Frequent falls
Change in posture
Weak voice
Seeing things
Hearing things
Other hallucinations
Depression
Apathy
Delusions
Anxiety
male
female
* 
* 
Figure 5.13. Cognitive, parkinsonian and psychiatric symptoms in FP-CIT negative 
males and females. (*=p<0.05) 
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0% 20% 40% 60% 80% 100%
Vivid dreams
Nightmares
Involuntary movements in sleep
Acting out dreams
Cried out in sleep
Excessive daytime sleepiness
Transient loss of consciousness
Insomnia
Restless legs
Dizziness
Sensitivity to heat or cold
Sexual dysfunction
Urinary incontinence
Constipation
Dry painful eyes
Double vision
Difficulty reading
Misjudging objects
S/E: Parkinsonism
S/E: Increased confusion
S/E: Increased hallucinations
S/E:  Increased sleepiness
S/E: Increased dizziness or fainting
Male
Female
* 
Figure 5.14. Sleep, autonomic and visual symptoms in FP-CIT negative males and 
females. (S/E = side effects to medications; *=p<0.05) 
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5.8 Discussion 
The primary hypothesis in this analysis was that 
123
I-FP-CIT imaging is a biomarker for 
prodromal DLB and will therefore be associated with a clinical profile similar to that 
seen in established DLB, albeit in a less severe form.  
 
5.8.1 Hypothesis 1: The 123I-FP-CIT abnormal group will have more core and 
suggestive diagnostic features of DLB 
The presence or absence of the diagnostic features of DLB was determined by the 
reviewing clinician (PD). Abnormal 
123
I-FP-CIT imaging was indeed associated with an 
increased number of core or suggestive features of DLB, particularly parkinsonism and 
RBD. All subjects with an abnormal scan were found to have at least one other core or 
suggestive feature of DLB. This supports the hypothesis that 
123
I-FP-CIT imaging is a 
biomarker of Lewy body pathology in the MCI phase.  
 
5.8.2 Hypothesis 2: The 123I-FP-CIT abnormal group will have higher scores in scales 
measuring these features 
Revised UPDRS (MDS-UPDRS) scores were higher in the abnormal 
123
I-FP-CIT group. 
However an affirmative answer to the RBD screening question of the Mayo Sleep 
Questionnaire was common in both groups. 
Despite the absence of clinically detected differences in the rate of cognitive 
fluctuations, scores in the Clinician Assessment of Fluctuation and Epworth Sleepiness 
scales approached being significantly greater in those with abnormal scans. However, 
similar proportions of both groups had clinically significant scores. Only 3 in the 
normal group and 4 in the abnormal group scored above the CAF threshold of ≥5 
(Walker et al., 2000a). A higher proportion (8 normal, 10 abnormal) scored above an 
Epworth Sleepiness Scale threshold of ≥10 previously found to differentiate DLB from 
Controls (Boddy et al., 2007). Long-term follow-up will ascertain if lower thresholds in 
these scales can identify fluctuations in prodromal LB disease. It should be noted that 
other conditions such as vascular cognitive impairment may be associated with 
fluctuation (Walker et al., 2000a), limiting the specificity of these scales. The dementia 
cognitive fluctuations scale did not detect any difference between the groups. There 
were no differences between the groups in the Visual Hallucination Inventory.  
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In summary, the two specific features associated with abnormal 
123
I-FP-CIT imaging 
were parkinsonism and RBD. 
123
I-FP-CIT imaging is a measure of nigrostriatal 
dopaminergic nerve degeneration, thought to be the direct cause of parkinsonism in 
DLB and therefore the association between the two is unsurprising. RBD is also thought 
to be caused by brainstem LB pathology (Boeve et al., 2007). Thus it seems that 
123
I-
FP-CIT imaging may be a biomarker of brainstem LB pathology more widely. The 
reticular activating system, including the midbrain reticular formation, is thought to be 
an important factor in fluctuations in DLB (Ferman et al., 2014). This may explain a 
tendency toward increased severity of fluctuating cognition and daytime sleepiness in 
the abnormal 
123
I-FP-CIT group. Despite this, fluctuations were not more common in 
the 
123
I-FP-CIT abnormal group. There were also no differences in visual hallucinations 
between the two groups. There are at least two potential explanations for these findings: 
 
1. Some cases of prodromal DLB do not display significant substantia nigra pathology. 
The Braak hypothesis suggests that Lewy body pathology progresses in a predictable 
sequence from the brainstem to subcortical structures and finally to the neocortex 
(Braak et al., 2003). We know from post-mortem studies that this does not hold in all 
cases, and limbic and cortical areas can be affected without involvement of the 
substantia nigra (Zaccai et al., 2008). Furthermore, the severity of synucleinopathy in 
the brain is only weakly correlated with substantia nigra neuronal loss in DLB (Beach et 
al., 2009). 
 Visual hallucinations are associated with LB disease in the amygdala, parahippocampal 
gyrus and temporal cortex (Harding et al., 2002). Fluctuating cognition has also been 
associated with cortical LB pathology (Schneider et al., 2012). Thus, in cases with 
neocortical involvement and relatively little brainstem LB pathology hallucinations and 
cognitive fluctuations would be expected to be common, and parkinsonism, RBD and 
abnormal 
123
I-FP-CIT imaging relatively rare. This would explain the absence of any 
difference in rates of hallucinations and fluctuations between the 
123
I-FP-CIT normal 
and abnormal groups. Therefore 
123
I-FP-CIT imaging may detect prodromal LB disease 
in cases with brainstem involvement and symptoms such as parkinsonism and RBD. 
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123
I-FP-CIT imaging may not be useful in detecting other patterns of LB pathology with 
early cortical involvement and symptoms such as hallucinations and fluctuations. 
 
2. Some visual hallucinations and fluctuations in our group were caused by non-Lewy 
body pathology. 
Symptoms such as visual hallucinations, fluctuations and parkinsonism are 
characteristic of DLB, but can occur in other disorders such as AD and vascular 
dementia (Walker et al., 2000b; Ferman et al., 2013a; Kaur et al., 2013).Thus it seems 
probable that some of the cohort with normal FP-CIT scans  may have visual, cognitive 
or motor symptoms mimicking LB features but not caused by LB pathology. One 
potential factor would be vascular disease. This is supported by the finding of higher 
CIRS-G scores in the domains of ‘Heart’ and ‘Vascular’ in the 123I-FP-CIT normal 
group (CRIS-G Heart+Vascular: Normal 2.3 ±1.6, Abnormal 1.3 ±1.5; p=0.04), though 
MRI assessment of cerebrovascular disease was not included in this study. 
 
Each of the two explanations above is probably true for a proportion of those with 
normal 
123
I-FP-CIT scans i.e. some of those with normal scans have a substantia nigra 
sparing pattern of LB deposition, others do not have LB disease at all but have 
symptoms such as parkinsonism, hallucinations, fluctuations and RBD caused by other 
pathology such as vascular disease. The proportion of 
123
I-FP-CIT normal participants 
in this cohort that actually have prodromal DLB will be established in longitudinal 
follow-up. 
 
5.8.3 Hypothesis 3: The 123I-FP-CIT abnormal group will have worse visuospatial 
and executive function, but better memory on neuropsychological tests 
We hypothesised that abnormal 
123
I-FP-CIT imaging would be associated with the 
typical DLB cognitive profile of decreased attention, executive and visuospatial 
function, but relatively preserved memory. No differences were detected between the 
two groups in any ACER subdomain, memory measured by the Rey AVLT delayed 
recall or recognition, attention/executive function measured by the Trails Test, verbal 
fluency or graded naming. Executive dysfunction was common in the overall cohort, 
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with 38% of those with normal and 58% of those with abnormal scans being unable to 
complete Trails B. Computerised tests of cognition did find some evidence of executive 
dysfunction with increased errors in the choice reaction time task in the abnormal 
123
I-
FP-CIT group, along with a tendency towards decreased attention in the digit vigilance 
task. Features previously found in DLB such as visuospatial dysfunction (Wood et al., 
2013), slowed cognitive processing, longer reaction times and increased variation in 
reaction times (Ballard et al., 2001) were not seen in the 
123
I-FP-CIT abnormal group. 
We cannot say at this point whether the full neuropsychological profile of DLB is not 
expressed in the prodromal stage, or whether it is not discernible here due to a 
proportion of those in the 
123
I-FP-CIT normal group having prodromal DLB, that is 
having Lewy body disease but without sufficient substantia nigra involvement to 
become abnormal on 
123
I-FP-CIT imaging. The neuropsychological scales used often 
show clear differences between established DLB and AD, but may not be sensitive to 
changes in the early stages of LB disease, where cognitive deficits are by definition 
milder than those seen in established disease. 
 
5.8.4 Hypothesis 4: The 123I-FP-CIT abnormal group will have a higher frequency of 
other features associated with DLB e.g. anosmia, postural hypotension and 
constipation 
 
5.8.4.1 Olfactory system 
The olfactory system thought to be one of the earliest sites of LB deposition (Beach et 
al., 2009) and decreased sense of smell has been found to be an early symptom of DLB 
(Chiba et al., 2012; Fujishiro et al., 2013b). Consistent with this, loss of sense of smell 
was found to be more common in the FP-CIT abnormal group. 
 
5.8.4.2 Peripheral autonomic Nervous System 
The peripheral autonomic nervous system is susceptible to early involvement in LB 
disease (Minguez-Castellanos et al., 2007) and orthostatic dizziness and hypersalivation 
have been reported as early symptoms in DLB (Chiba et al., 2012). The 
123
I-FP-CIT 
abnormal group were more likely to report drooling but not dizziness, though they did 
have a significantly greater fall in blood pressure on standing. The magnitude of this fall 
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(10/4 mmHg) may not be clinically significant. Other autonomic symptoms such as 
sexual dysfunction, urinary incontinence and sensitivity to heat or cold were relatively 
common in both groups.  
 
5.8.4.3 Enteric System 
LBs can be found in the enteric nervous system in the early stages of LB disease and in 
asymptomatic individuals. Constipation has previously been reported to be significantly 
more common in DLB than AD in a survey carried out in Japan (47% v. 16%) (Chiba et 
al., 2012). There was no significant difference in the rates of constipation between the 
123
I-FP-CIT abnormal and normal groups in this cohort (53% v 29%). This may reflect a 
lack of specificity of constipation as a marker of LB pathology in populations with high 
background rates of constipation, compared with the low rate of 17% of healthy older 
people in the Japanese cohort. 
Delayed gastric emptying is common in established PD (Heetun and Quigley, 2012) but 
symptoms of delayed gastric emptying measured by the GCSI were very infrequent in 
both groups in our cohort, with only two subjects scoring above the threshold of 1.90. 
 
5.8.4.4 Visual Symptoms 
Visual symptoms such as dry/painful eyes, double vision, difficulty reading and 
misjudging objects have been reported in DLB (Jefferis et al., 2013) but these did not 
differentiate the 
123
I-FP-CIT normal and abnormal groups. 
 
5.8.4.5 Neuropsychiatric Symptoms 
Depression is a supportive feature for the diagnosis of DLB (McKeith et al., 2005) and 
has been reported to be more common in DLB than AD (Ballard et al., 1999; Boot et 
al., 2013b). Despite this, the 
123
I-FP-CIT abnormal group did not score higher on the 
GDS. There were no differences between the groups in NPI overall score or carer 
distress. 
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The 
123
I-FP-CIT normal group were more likely to report ‘other hallucinations’ 
(olfactory, gustatory or tactile; 21% v. 0%). The reason for this increased incidence is 
not yet clear but may be related to the pathological heterogeneity of the 
123
I-FP-CIT 
normal group. 
 
In summary, the above evidence shows that hyposmia and drooling are more common 
in those with abnormal 
123
I-FP-CIT imaging, supporting the hypothesis that it is a 
biomarker of prodromal DLB. There were no differences between the groups in other 
autonomic, enteric, visual and neuropsychiatric symptoms. In general, most symptoms 
associated with LB disease were relatively common in the 
123
I-FP-CIT normal group. A 
lack of specificity may limit the usefulness of these symptoms to identify people with 
prodromal DLB but their presence may increase confidence in the diagnosis of DLB in 
clinical settings, particularly in the early stages of dementia (Donaghy and McKeith, 
2014).   
Quantitative measures of dysfunction may be more useful in differentiating normal 
ageing from pathological changes. Abnormal olfaction measured by the University of 
Pennsylvania Smell Identification Test and abnormal colour vision measured by the 
Farnsworth-Munsell test are both associated with an increased hazard ratio for the 
development of DLB in people with idiopathic RBD (Postuma et al., 2015a). The same 
authors found that using abnormalities in olfaction, colour vision and motor function to 
select patients could increase the three year conversion to neurodegenerative disease 
from 30% to 60%. Research is beginning to emerge on the utility of similar tests in MCI 
cohorts, with the Cross-Cultural Smell Identification Test differentiating DLB-MCI 
from AD-MCI with an area under the receiver operating characteristic of 0.84 (Yoon et 
al., 2015). A similar battery to that developed by Postuma et al. for RBD could be 
developed for use in MCI cohorts to identify those at highest risk of conversion to DLB. 
 
5.8.5 Hypothesis 5: Measures of asymmetry of 123I-FP-CIT binding between the left 
and right striata will be low in the entire cohort. 
There was little asymmetry in striatal binding in the cohort. Only one subject had an 
asymmetry index greater than 10%. This is similar to reports in established DLB, and 
different to the asymmetrical binding pattern often seen in PD (Walker et al., 2004). 
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This poses some difficulties in the visual classification of scans. The mildest grade of 
abnormality in PD is defined as asymmetry in the putamina (Benamer et al., 2000). If a 
more symmetrical pattern of loss occurs in DLB than PD, early disease may be more 
difficult to visualise. Quantitative measures may be helpful to detect subtle, symmetrical 
decline in 
123
I-FP-CIT  binding. This is somewhat complicated by natural variation in 
123
I-FP-CIT binding and differences associated with age and gender. Good data on 
normal ranges are beginning to become available from large-scale studies of normal 
cohorts (Varrone et al., 2013), but to apply these to study cohorts requires scanning and 
processing procedures that replicate those used to acquire the normal data.  
Those with abnormal 
123
I-FP-CIT scans unsurprisingly had lower overall striatal 
binding than those with normal scans and visual rating grade was inversely correlated 
with striatal binding. That said, there was significant overlap between those with normal 
and abnormal scans and no evidence of a clear ‘intermediate’ group between those with 
normal and abnormal scans. Longitudinal follow-up may allow us to identify a 
threshold of binding that identifies individuals at risk of developing DLB based on our 
quantification methods. 
 
5.8.6 Gender differences 
More than half of males (53%), but few females (10%) had an abnormal 
123
I-FP-CIT 
scan. This degree of difference was unexpected. Despite being older, females had 
123
I-
FP-CIT binding ratios 18% higher than males on average, larger than the approximately 
10% difference noted a normal cohort (Varrone et al., 2013). Varrone et al. suggested 
this may be due to differences in striatal size, with females having the same number of 
dopamine transporters as males, but smaller striata, resulting in higher 
123
I-FP-CIT 
uptake per unit volume. However an expected 10% difference in striatal binding would 
not seem sufficient to explain a five-fold greater likelihood of an abnormal scan on 
visual rating. In addition, RBD was found to be significantly more common in males 
than females (59% v 19%). These results suggest that either females in our study are 
less likely to have prodromal DLB than males, or that females with prodromal DLB are 
less likely to have brainstem involvement, and therefore less likely to have RBD or a 
positive FP-CIT scan. 
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A meta-analysis of epidemiological studies found DLB to be equally common in males 
and females (Vann Jones and O'Brien, 2014). If LB disease is equally common in males 
and females in our cohort, we would expect that a greater proportion of the 
123
I-FP-CIT 
normal females have prodromal DLB than the 
123
I-FP-CIT normal males. A post-hoc 
comparison was carried out to test this hypothesis.  
We expected that 
123
I-FP-CIT normal females would have a more ‘Lewy body’ 
phenotype than males if this hypothesis was correct. However, there were no differences 
between 
123
I-FP-CIT normal males and females in the number of core or suggestive 
features present. Females did score higher on the MDS-UPDRS, but there were no 
differences in quantitative scales for other core and suggestive features. Females 
recorded slower reaction times in tests of attention. It is not clear if this was due to 
attentional deficit or motor impairment. Females consistently scored lower on 
visuospatial tasks (ACE-R visuospatial subdomain, angle task and motion task). There 
was no evidence of executive dysfunction measured by Trails B or the choice reaction 
time test. 
Females with normal FP-CIT had higher scores on the GDS and were more likely to 
report dizziness, but there was no difference in postural BP change, other autonomic 
symptoms such as constipation or other associated symptoms such as hyposmia and 
drooling. 
123
I-FP-CIT normal females were older than 
123
I-FP-CIT normal males by an average of 
6.5 years. This may be a factor in the differences in visuospatial function, reaction times 
and MDS-UPDRS scores between the genders. However, females did have slower 
response times in the digit vigilance tasks and worse visuospatial function on the angle 
discrimination task even after linear regression to account for the effect of age and years 
in education. In any case there was no clear pattern of increased LB features in the 
female group. This suggests that in our overall cohort males were more likely to have 
LB disease than females. Alternatively, females may have a less clear LB phenotype in 
the prodromal stage of DLB, with fewer core and suggestive features (RBD in 
particular) and greater visuospatial dysfunction. This remains speculative, and 
longitudinal follow-up is needed establish whether or not this is the case. 
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5.9 Strengths and limitations of study 
This is the first cohort that we are aware of that specifically examines the phenotype of 
people with MCI who are at risk of developing DLB. The cohort is well characterised 
both clinically and neuropsychologically. As there is little evidence for the presentation 
of prodromal DLB this study is by nature exploratory. We have been inclusive in our 
selection criteria in an effort not to exclude different presentations of prodromal DLB. 
Recruiting patients with symptoms that do not reach the threshold of core or suggestive 
features of DLB may increase the heterogeneity of the cohort, but will also allow us to 
chart the development of these features in some subjects. Longitudinal follow-up will 
clarify which subjects are in the prodromal stages of DLB. 
No statistical correction was made for multiple comparisons. In this exploratory study 
priority was given to reducing the likelihood of type II errors, where potentially 
clinically significant findings remain undetected. Our positive findings require 
confirmation in independent cohorts. 
The 
123
I-FP-CIT normal and abnormal groups were very similar in age and overall 
cognitive function, enabling a direct comparison between the groups. This has allowed 
us to conclude that 
123
I-FP-CIT is a biomarker of prodromal DLB, though the sensitivity 
and specificity of this marker will not be clear until longitudinal follow-up is complete. 
40% of the cohort was treated with cholinesterase inhibitors. This reflects a willingness 
from some clinicians to treat visual hallucinations and fluctuations with cholinesterase 
inhibitors in the absence of dementia, and also a trend towards earlier treatment of 
cognitive impairment over the past several years. During screening for this study we 
found that in some cases a diagnosis of dementia was made by clinical teams despite 
recording an absence of any functional impairment. For the purposes of this study we 
applied the NIAAA criteria for MCI to determine suitability to participate (Albert et al., 
2011). Those on treatment with cholinesterase inhibitors had similar levels of functional 
impairment measured by the IADL and CDR scales (CDR in those on treatment = 0.48 
v. 0.42 in those not on treatment (p= 0.32); IADL = 5.8 v. 6.7 (p= 0.14)). 
We included subjects with MMSE ≥20 provided they satisfied NIAAA criteria for MCI 
i.e. preservation of independence with minimal aids or assistance. Whilst many people 
with an MMSE score between 20 and 25 will have dementia, some are not yet 
functionally impaired, and their relatively low score may reflect low prior educational 
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attainment. Those with MMSE <25 (n=9) had similar levels of functional impairment to 
those with scores ≥25 (n=44). CDR in those with MMSE<25 = 0.50 v. 0.43 in those 
with MMSE ≥25 (p=0.54); IADL = 6.3 v 6.3 (p=0.80). 
 
A complete dataset was not possible in all participants, principally due to the absence of 
a suitable informant, and in some cases due to technical errors in the computerised tests. 
Only two 
123
I-FP-CIT scans failed automatic quantification. One of these was clearly 
abnormal, with extremely low binding. Such cases would not pose any problem in 
clinical practise. The other subject was incorrectly positioned in the scanner. 
Clinical assessment was carried out prior to 
123
I-FP-CIT reporting, preventing the 
biasing of clinical assessment. However, in some cases the clinician was aware of the 
123
I-FP-CIT result e.g. if a scan had been carried out as part of their routine care prior to 
assessment.  
 
5.10 Future directions 
Longitudinal follow-up of this cohort will determine the sensitivity and specificity of 
123
I-FP-CIT imaging in prodromal DLB, along with the diagnostic utility of the other 
neuropsychological and clinical scales assessed. We may be able to identify clinical 
phenotypes that reflect emergent core or suggestive features of LB disease e.g. visual 
phenomena such as misidentification or passage hallucinations preceding fully formed 
visual hallucinations. 
In established DLB 
123
I-FP-CIT imaging has a sensitivity of 89% and a specificity of 
81% (O'Brien et al., 2014b). Sensitivity could be expected to be lower in prodromal 
DLB as nigrostriatal pathology and neuronal loss will be less well developed. The 
prevalence of LB features, in particular RBD, in the 
123
I-FP-CIT normal group suggests 
that some of this group also have LB disease. Semi-quantitative analysis may identify 
subtle abnormalities not detected by visual rating.  
The pattern of signal loss in the striatum may differ between DLB and PD, with less 
asymmetry and a lower caudate:putamen binding ratio in DLB (Walker et al., 2004; 
Marquie et al., 2014). The relative lack of brain structural information contained in a 
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123
I-FP-CIT image makes automated analysis of striatal subdivisions difficult. We plan 
to do this using semi-automated software with user-positioning of caudate and putamen 
templates. This will allow us to ascertain whether a particular pattern of loss is seen in 
early LB disease. However, the evidence from established DLB suggests that losses are 
global, rather than being restricted to the putamen (Walker et al., 2004). This will affect 
the visual rating of scans. We found good agreement on visual rating (mean Kappa = 
0.62) but many scans were considered difficult to rate due to a mild general decrease in 
striatal binding in the absence of any more localised signal loss. This is more difficult to 
visualise than the unilateral loss in the putamen seen in the early stages of PD. The 
development of thresholds for normal binding using semi-quantitative analysis may 
help to identify when overall striatal binding has decreased. 
 
More work is needed to investigate other potential biomarkers of prodromal DLB. 
Biomarkers that investigate structures affected early in the disease process may be the 
most useful. The peripheral autonomic nervous system can be investigated using MIBG 
imaging of cardiac sympathetic denervation (Fujishiro et al., 2012). Biopsies of 
peripheral nerves in the skin or gut may allow us to directly identify αSyn pathology 
(Beach et al., 2010; Wang et al., 2013). We plan to examine cardiac MIBG and skin 
autonomic nerve αSyn as potential markers of LB disease in the near future. Findings in 
RBD suggest that olfactory and visual dysfunction, as well as subtle motor impairments 
may be markers of prodromal LB disease. No one biomarker is likely to prove sensitive 
and specific enough in isolation. A two-stage process may be necessary, where initial 
sensitive, non-invasive and inexpensive markers (e.g. visual/olfactory/motor function 
tests, symptom questionnaires) are used to identify patients at risk and then a second 
more specific but potentially more expensive or invasive test (e.g. 
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I-FP-CIT imaging, 
biopsy) is used to confirm the presence of LB disease. 
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6 Chapter 6   Amyloid Imaging Aims, Hypotheses and Methods 
6.1 Aims 
The aim of this project is to determine the prevalence and pattern of amyloid deposition 
in DLB, and whether amyloid deposition influences clinical phenotype. Subjects had a 
thorough baseline clinical and neuropsychological assessment followed by amyloid PET 
imaging using Florbetapir. Where possible subjects also had an MRI scan. 
 
6.2 Hypotheses 
6.2.1 Primary hypotheses 
1. The proportion of DLB patients with positive amyloid scans on visual rating will be 
greater than controls and less than AD. 
2. Semiquantitative measures of amyloid deposition will be greater in DLB than 
controls and less than AD. 
 
6.2.2 Secondary hypotheses 
We will test if amyloid deposition is associated with a clinical phenotype with 
similarities to AD, and faster disease progression. 
3. Amyloid positive DLB cases will have greater memory impairment and less 
visuospatial, attention and executive impairments than amyloid negative DLB cases. 
4. Amyloid positive DLB cases will score lower in scales measuring hallucinations, 
fluctuations and parkinsonism 
5. Amyloid positive DLB cases will have smaller hippocampi than amyloid negative 
cases 
6. Amyloid positive DLB cases will have a shorter duration of illness than amyloid 
negative cases 
 
We will also examine correlations between clinical measures and amyloid binding in 
DLB.  
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6.3 Methods 
6.3.1 Participants 
Participants were recruited prospectively from NHS Trusts in the North of England. 
Patients were identified through direct referral from their treating teams; through the 
Dementias and Neurodegenerative Diseases Research Network (DeNDRoN) Research 
Case Register and through screening patients’ notes in memory clinics. Control subjects 
were recruited through the DeNDRoN Case Register or were partners of participants.  
All subjects needed to have sufficient English to complete cognitive testing. All subjects 
with capacity gave their written informed consent to take part in the study. In the case of 
subjects with dementia who lacked capacity their participation in the study was 
discussed with a consultee. The study received ethical approval from the National 
Research Ethics Service Committee North East - Newcastle & North Tyneside 2 
(Research Ethics Committee Identification Number 13/NE/0064). 
 
6.3.2 Inclusion/exclusion criteria 
Dementia subjects were ≥60 years old and had a diagnosis of probable DLB or probable 
AD confirmed by two clinicians based on current diagnostic criteria (McKeith et al., 
2005; McKhann et al., 2011), with an MMSE score ≥12. Subjects taking anti-
cholinesterase drugs or memantine were stable for three months before baseline 
assessment. Control patients had an MMSE ≥26 and no signs of dementia. 
Subjects were excluded if they had a major concurrent psychiatric illness; severe 
physical illness that would limit their ability to fully participate in the study; 
contraindications to PET imaging; history of other significant neurological illness 
including stroke; medications that may significantly interfere with cognitive testing (e.g. 
high dose benzodiazepines), previous experimental treatment with an amyloid-targeting 
agent or current treatment with any other investigational agent. AD and control patients 
were excluded if they had had a diagnosis of Parkinson’s disease.  
 
6.3.3 Baseline cognitive and clinical assessment 
The clinical and neuropsychological assessments carried out in this study are listed in 
table 6.1. The assessment was identical to that carried out in the Prodromal Study (see 
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sections 4.3-4.7) with the following exceptions: The Bristol Activities of Daily Living 
Scale (BADLS) (Bucks et al., 1996) was used in this study. This rates a person’s ability 
to perform 20 daily tasks on a scale from 0 (able to perform task or not applicable) to 3 
(unable to perform task). A maximum score of 60 represents the highest level of 
functional impairment. The Northeast Visual Hallucinations Inventory, Clinical 
Dementia Rating Scale, Epworth Sleepiness Scale and Mayo Sleep Questionnaire were 
not used in this study. 
 
Table 6.1. Clinical and neuropsychological assessment in the amyloid imaging 
study 
Clinical Assessment Cognitive Assessment 
Revised Unified Parkinson’s disease 
Rating Scale Motor Sub-scale 
Addenbrooke’s Cognitive Examination - 
Revised 
 
Neuropsychiatric Inventory FAS Verbal Fluency 
 
Geriatric Depression Scale 
 
Trail-making Test A and B 
 
Clinician Assessment of Fluctuations 
 
Graded Naming Test 
 
Dementia Cognitive Fluctuations Scale Rey Auditory Verbal Learning Test 
  
Functional Assessment Computerised Tests 
Instrumental Activities of Daily Living 
Scale 
 
Simple and choice reaction time 
 
Bristol Activities of Daily Living Scale 
 
Digit vigilance 
 
 Line angle discrimination 
 
 Motion Task 
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6.3.4 Imaging 
PET 
Subjects were given a 370MBq intravenous injection of 
18
F-Florbetapir (Amyvid) 30-50 
minutes prior to scanning. Subjects were imaged using a PET-CT scanner in list mode 
(Siemens Biograph-40) for 15 minutes (3 x 5 minute frames), 30-50 minutes after 
injection. Images were reconstructed using iterative reconstruction (4 iterations, 16 
subsets), with a 168x168 matrix size, 2.04x2.04mm pixel size, 3mm slice thickness, and 
3mm post-reconstruction Gaussian filter. Attenuation correction was performed utilising 
CT scan data.  
 
CT 
CT scans were obtained immediately before the PET images. CT dose was minimised 
using the Siemens CAR Dose 4D protocol with 50mAsec target dose, 0.5sec gantry 
rotation time, 0.8mm beam pitch, 0.6mm slice thickness and scan duration of 19 
seconds. Images were reconstructed with 3mm slice thickness to match the PET images. 
For subjects without MR imaging, CT scans were also reconstructed with a 1mm slice 
thickness for use as a background scan for visual rating. 
 
MRI 
MRI scans were performed in all subjects unless contraindicated. Scans were acquired 
on a 3T whole body MR scanner (Achieva scanner; Philips Medical Systems), with 
body coil transmission and eight channel head coil receiver. Images acquired included a 
3D sagittal magnetisation-prepared rapid gradient echo (MPRAGE) sequence (repetition 
time 8.3ms, echo time 4.6ms, flip angle 8
o
, inversion delay 1250 ms, imaging time 
4.5mins). The sagittal acquisition matrix was 216x240, giving a voxel size of 
1x1x1mm.  
 
6.3.5 Image processing 
MRI and PET images were analysed in NifTI format, using SPM 8 
(www.fil.ion.ucl.ac.uk/spm/software/spm8/). Each image was manually repositioned 
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with the anterior commissure approximately at point 0,0,0. A mean PET image was 
obtained by co-registering the three 5 minute scans.  This mean scan was then co-
registered with the native space MRI. MRI images were segmented into white matter, 
grey matter and CSF. Grey and white matter images were smoothed using a 4mm full 
width half-maximum Gaussian kernel.  Region of interest (ROI) maps were developed 
to mirror those used in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
(Landau and Juagust, 2014) using the MarsBar (www.marsbar.sourceforge.net) region 
map (Table 6.2) (Tzourio-Mazoyer et al., 2002). ADNI regions were used because this 
study represents the largest cohort of Florbetapir PET images to date and so was felt to 
be the most robust validated dataset as a comparator. From this cohort thresholds for 
abnormal levels of amyloid deposition have been developed that can be easy transferred 
to other datasets such as this cohort.  
 
In addition to the frontal, temporal, parietal, cingulate and cerebellar areas used in 
ADNI, striatal and occipital regions were also included (Figure 6.1). These maps were 
transformed into native space for each subject. Cortical and white matter areas within 
these regions were identified using a threshold of 0.5 on the smoothed grey and white 
matter segmentation images. Mean PET uptake values within the ROIs were then 
determined. Standardised uptake volume ratios (SUVR) were calculated for each region 
by dividing mean PET uptake in the region by mean PET uptake in the cerebellum. The 
cerebellum has been the usual reference region for cross-sectional data in ADNI (Jagust 
et al., 2015). No partial volume correction was made as this has been found not to 
significantly change images  (Knesaurek et al., 2013). 
   
Figure 6.1. Regions of interest used in amyloid imaging. Frontal (teal), cingulate 
(orange), temporal (green), parietal (blue), occipital (red) and cerebellar (navy) areas are 
displayed. 
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Hippocampal volumes were obtained from the MPRAGE scan using a fully-automated 
script in SPM which has been validated against manual tracing and used in many other 
studies (Firbank et al., 2008). This script spatially normalises the MRI image to 
Table 6.2. Cortical regions of interest  and corresponding MarsBar regions 
Region of interest MarsBar Regions 
Frontal lobe Superior frontal gyrus  
Middle frontal gyrus  
Inferior frontal gyrus  
Supplementary motor area  
Paracentral lobule  
Gyrus rectus  
Olfactory cortex 
Temporal lobe Superior temporal gyrus 
Herschel gyrus 
Middle temporal gyrus  
Inferior temporal gyrus 
Parietal lobe Superior parietal gyrus 
Inferior parietal, but supramarginal and angular gyri 
Angular gyrus 
Supramarginal gyrus 
Precuneus (middle and superior areas) 
Cingulate lobe Anterior cingulate and paracingulate gyri 
Median cingulate and paracingulate gyri 
Posterior cingulate gyrus 
Precuneus (inferior area) 
Occipital lobe Superior occipital gyrus 
Middle occipital gyrus 
Inferior occipital gyrus 
Cuneus 
Calcarine fissure and surrounding cortex  
Lingual gyrus 
Fusiform gyrus 
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standard space, following which grey matter pixels are identified within a predefined 
hippocampal region to segment the hippocampi.  
 
6.3.6 Visual rating 
Images were reviewed by 5 raters (John O’Brien, Michael Firbank, George Petrides, 
Jim Lloyd and Paul Donaghy), all of whom had completed training in amyloid image 
reading. Raters were blinded to all clinical data. Six scans were duplicated in the dataset 
to test intrarater reliability.  Scans were classified as positive or negative based on the 
method developed by the manufacturer (Eli Lilly, 2012), summarised as follows. 
Images were viewed in transaxial orientation (with access to other views where 
necessary) in a black-white scale. The occipital, temporal, parietal and frontal areas 
were reviewed and classified as normal if the signal from the cortex was less than the 
signal from the white matter (clear grey white contrast) and abnormal where there was a 
reduction or loss of grey-white contrast, or where the signal from the grey matter was 
greater than the white matter.  Subjects were classified as amyloid positive if there were 
two or more brain regions (each larger than a single gyrus) with reduced or absent grey-
white contrast or one area in which grey matter activity clearly exceeded white matter 
(Figure 6.2). All scans were rated independently, following which a consensus meeting 
was held to discuss those scans in which there was disagreement (defined as a 3/2 split) 
on whether the scan was positive or negative and a final decision reached. 
 
6.3.7 Statistics 
Statistical analysis was completed using IBM SPSS Statistics 22 software. Normality 
was tested using the Shapiro-Wilk test. Comparisons between diagnostic groups were 
carried out using one-way ANOVA or Kruskall-Wallace tests depending on normality 
of the data. Where significant, post hoc pairwise comparisons were carried out using the 
Tukey’s Test or Mann-Whitney U tests with a Bonferroni correction (α=0.05). 
Comparisons between amyloid positive and negative DLB cases were carried out using 
t-tests or Mann-Whitney U tests. χ2 or Fischer’s Exact tests were used for categorical 
variables depending on cell size. 
Correlation was carried out using Pearson’s r (for normally distributed data) or 
Kendall’s tau (for non-normal data) correlation. Linear regression was used to adjust for 
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the effect of age and years in education on specific variables when correlation was 
observed. Interrater and intrarater reliability in amyloid PET scan visual rating were 
assessed using the Kappa statistic. A mean of all pair-wise kappa values was used to 
summarise agreement between the five raters. Unless otherwise stated, a p value of 
≤0.05 was set as the threshold for statistical significance, uncorrected for the number of 
statistical tests performed. 
 
 
The primary aim of this study is to compare amyloid binding in DLB subjects with AD 
and controls. Sample sizes of DLB (n=20), control (n=10) and AD (n=10) would be 
sufficient to detect differences with an effect size of >1.1 with statistical power of 0.8. 
The difference between these diseases in Florbetapir binding is not yet known. 
However, using the effect sizes reported with another 
18
F-labelled ligand, Florbetaben, 
this study would be powered to find differences between AD and DLB (effect size = 
1.8) but perhaps not differences between DLB and controls (effect size = 0.8) 
(Villemagne et al., 2011). This sample size would have a power of 0.78 to detect 
differences in the proportion of amyloid positive scans between DLB and AD given the 
expected rates of 50% in DLB, 90% in AD and 25% in controls (Ossenkoppele et al., 
A 
 
B 
  
Figure 6.2. Examples of negative (A) and positive (B) amyloid PET imaging scans. 
A displays the normal contrast between high white matter binding (dark) and low grey 
matter binding (light) seen in controls and some DLB patients. B shows loss of grey-
white contrast in a subject with AD. 
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2015). This sample size would not be sufficient to reliably detect the expected 
difference between DLB and controls (power=0.29). 
Comparisons will be made between amyloid positive and negative DLB cases. A 
sample size of 20 (n=10 in each group) would be sufficient to detect large differences 
between the groups (effect size >1.3) with statistical power of 0.8.  
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7 Chapter 7   Amyloid Imaging Results and Discussion 
7.1 Recruitment 
A large number of clinical notes were screened to identify patients with DLB and AD. 
141 dementia patients were approached to participate in the study, of whom 40 agreed 
to enter. Four patients scored below the threshold for MMSE, another patient was found 
to have an atypical presentation of AD and was excluded. One patient had a major 
stroke and another withdrew before completing baseline. One patient did not tolerate 
PET imaging. In total, 32 subjects with dementia (22 DLB and 10 AD) completed 
baseline amyloid PET imaging, 29 of them  also had an MRI scan. Two of the DLB 
participants were unable to have an MRI due to the presence of pacemakers. One AD 
participant failed to tolerate MR imaging. Subjects without MR imaging were included 
in the visual rating but not in the quantification of amyloid PET images. 15 control 
subjects also completed baseline PET and MRI imaging successfully. 
 
7.2 Comparison of DLB, AD and controls 
7.2.1 Demographics 
Table 7.1. Demographics of DLB, AD and controls 
 Control AD DLB  
 Mean (SD) Mean (SD) Mean (SD) p 
n 15 10 22 - 
Age 75.2 (6.9) 75.9 (5.2) 76.5 (6.4) 0.84 
Gender (% female) 27 20 18 0.70 
Years in education  12.4 (3.0) 11.7 (2.8) 11.0 (3.2) 0.47 
MMSE 29.0 (1.1) 20.2 (5.0) 20.3 (4.7) <0.001
a,c
 
CIRS-G 6.3 (3.5) 7.0 (3.1) 11.2 (4.0) 0.001
a,b
 
CIRS-G Neurological 0.2 (0.8) 0 (0.0) 1.1 (1.2) 0.003
a,b
 
CIRS-G Heart + Vascular 2.2 (1.3) 0.9 (1.2) 2.0 (1.8) 0.09 
AChI/Memantine (%) 0 100 100 - 
Levodopa (%) 0 0 55 - 
a = significant difference DLB v control; b = significant difference DLB v AD; c = 
significant difference AD v control. Post-hoc Tukey’s Test, α=0.05. 
AChI=acetylcholinesterase inhibitor. 
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Demographic variables are shown in Table 7.1. There were no significant differences 
between control, AD and DLB subjects in age, gender or number of years in education. 
There was no difference between AD and DLB cases in overall cognitive function 
measured by the MMSE. DLB cases scored higher on the CIRS-G scale of co-
morbidity. There was no significant difference in CIRS-G heart + vascular subscores. 
As expected, the DLB group scored higher than AD or controls in the neurological 
subscore (which included parkinsonism). All dementia patients were taking a 
cholinesterase inhibitor or memantine. 55% of DLB patients were on levodopa 
treatment for parkinsonism. 
 
7.2.2 Cognitive tests 
2 AD and 12 DLB failed to complete Trails A; 7 AD and 18 DLB failed to complete 
trails B. Therefore trails data was not analysed. One AD and one DLB subject did not 
wish to complete the Rey AVLT.  
DLB subjects scored significantly worse than controls on every test except Rey AVLT 
recognition (DLB 11.4 v Control 12.9; p=0.31).  AD subjects scored worse than 
controls on every test except the FAS, and in this test the difference was only 
marginally above the threshold for significance (p=0.051). 
Overall cognitive function was very similar between AD and DLB (mean ACE-R = 
60.3 v 59.7; p=0.99). DLB scored higher than AD in the ACE-R memory domain, and 
approached a significantly higher score in the Rey AVLT recognition test (11.4 v 7.4; 
p=0.06). There were no other differences between the two groups in any other cognitive 
test (Table 7.2). 
 
7.2.3 Computerised tests of cognitive function 
Nine patients did not have angle task data due to a computer error (4 DLB, 2 AD, 3 
controls). A further 5 DLB subjects were unable to complete this task. One AD and four 
DLB subjects could not complete the digit vigilance task. Eight DLB subjects could not 
complete the motion task. One DLB subject did not complete the reaction time task. 
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Table 7.2. Cognitive tests in DLB, AD and controls 
 Control AD DLB  
 Mean (SD) Mean (SD) Mean (SD) p 
ACE-R Total 94.7 (2.8) 60.3 (17.8) 59.7 (16.7) <0.001
a,c
 
ACE-R Attention/Orientation 18.0 (0.0) 12.7 (4.0) 12.6 (3.40 <0.001
a,c
 
ACE-R Memory 23.6 (1.9) 7.7 (3.7) 12.1 (5.7) <0.001
a,b,c
 
ACE-R Fluency 12.0 (1.5) 6.4 (3.9) 5.6 (3.2) <0.001
a,c
 
ACE-R Language 25.4 (0.9) 21.6 (5.0) 21.1 (3.3) <0.001
a,c
 
ACE-R Visuospatial 15.7 (0.6) 11.9 (3.7) 8.8 (3.7) <0.001
a,c
 
Rey AVLT Trial 1 5.7 (1.7) 1.8 (1.6) 2.2 (2.3) <0.001
a,c
 
Rey AVLT Trial 6 9.1 (2.7) 0.4 (1.3) 2.2 (2.3) <0.001
a,c
 
Rey AVLT Delay 8.3 (2.7) 0.4 (0.7) 1.6 (2.1) <0.001
a,c
 
Rey AVLT Recognition 12.9 (1.8) 7.4 (4.2) 11.4 (2.4) <0.01
c
 
Verbal Fluency (FAS) score 50.1 (12.8) 29.8 (16.4) 21.6 (15.1) <0.001
a
 
Graded Naming Test 24.1 (2.3) 14.0 (7.8) 13.9 (7.9) <0.001
a,c
 
a = significant difference DLB v control; b = significant difference DLB v AD; c = 
significant difference AD v control. Post-hoc Tukey’s Test, α=0.05. 
 
 
DLB subjects were slower and showed greater variability in reaction times in the simple 
reaction time (SRT), choice reaction time (CRT) and digit vigilance tasks and overall 
power of attention compared with controls (Table 7.3). They also demonstrated worse 
visuospatial function on the angle discrimination and motion tasks. There were no 
significant differences between DLB and AD subjects in any test, though in every 
measurement apart from CRT errors and cognitive processing time their scores were 
worse than AD. This difference approached significance in the digit vigilance task (digit 
vigilance number correct DLB=21.2, AD=30.9, p=0.08; digit vigilance time 
DLB=736ms, AD=587ms, p=0.09). 
Two DLB subjects had a high false positive rates in the digit vigilance task (>72), but 
excluding these subjects did not change the overall result. Four DLB subjects had a 
negative cognitive processing time, suggesting a learning effect following the SRT task 
resulting in faster responses to the CRT task than the SRT task. 
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Table 7.3. Computer tests in DLB, AD and controls 
 Control AD DLB  
 Mean (SD) Mean (SD) Mean (SD) p 
SRT (ms) 341 (53) 424 (148) 767 (567) <0.01
a
 
SRT SD (ms) 67 (29) 208 (218) 569 (693) <0.001
a,c
 
SRT number correct 29.6 (0.8) 29.0 (0.9) 27.2 (3.6) 0.02
a
 
CRT (ms) 564 (68) 962 (466) 1105 (537) <0.001
a,c
 
CRT SD (ms) 107 (36) 322 (212) 527 (479) <0.001
a,c
 
CRT errors 1.6 (1.8) 6.2 (7.8) 5.4 (4.7) 0.03
a,c
 
Cognitive Processing Time (ms) 223 (63) 539 (404) 338 (442) 0.03
c
 
Digit vigilance number correct 35.5 (1.0) 30.9 (5.3) 21.2 (7.4) <0.001
a,c
 
Digit vigilance time (ms) 516 (54) 587 (111) 736 (183) <0.001
a
 
Digit vigilance SD (ms) 69 (33) 172 (127) 258 (130) <0.001
a,c
 
Digit vigilance false positives 1.1 (1.1) 6.0 (4.8) 19.9 (30.1) <0.001
a,c
 
Power of attention (ms) 1421 (143) 1848 (519) 2604 (822) <0.001
a 
Angle Task (
o
) 8.4 (3.3) 25.5 (22.4) 43.3 (31.6) 0.001
a
 
Motion Task 0.56 (0.30) 0.80 (0.27) 0.96 (0.07) <0.01
a
 
SRT =simple reaction time, CRT = choice reaction time. a = significant difference DLB v 
control; b = significant difference DLB v AD; c = significant difference AD v control. Post-
hoc Tukey’s Test, α=0.05. 
 
 
7.2.4 Symptom scales 
One DLB participant did not have carer distress scores for the NPI as he lived alone. 
Other questionnaires were filled out by a member of day hospital staff who knew him 
well. 
Unsurprisingly DLB subjects scored higher than AD subjects in the CAF and DCFS 
fluctuations scales, and also in the Geriatric Depression Scale (Table 7.4). DLB cases 
scored higher in the NPI hallucination domain, and approached higher scores in the 
depression domain. No other NPI domain approached significant difference (p>0.2). 
DLB cases had greater functional impairment measured by the IADL and BADL scales. 
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Table 7.4. Symptom scales in DLB, AD and controls 
 AD DLB  
 Mean (SD) Mean (SD)   p 
CAF 1.4 (3.0) 6.5 (4.6) <0.01 
DCFS total 7.0 (3.2) 11.7 (3.3) <0.01 
Geriatric depression scale 1.4 (1.2) 4.4 (2.2) <0.001 
NPI total hallucinations  0.0 (0.0) 2.8 (2.9) 0.001 
NPI total depression 0.2 (0.4) 1.6 (1.8) 0.06 
NPI total 10.2 (8.8) 19.3 (16.2) 0.11 
NPI distress total 4.7 (5.0) 8.1 (9.0) 0.35 
BADL 11.8 (7.6) 21.7 (12.1) 0.03 
IADL 4.4 (1.4) 2.9 (1.9) 0.04 
 
 
7.2.5 Parkinsonism, autonomic and enteric function 
 
Table 7.5. Parkinsonism, orthostatic BP changes and gastroparesis in DLB, AD and 
controls 
 Control AD DLB  
 Mean (SD) Mean (SD) Mean (SD) p 
MDS-UPDRS 5.3 (3.1) 12.9 (4.8) 47.5 (18.5) <0.001
a,b
 
Hoehn and Yahr Stage 0  0  2.2 (1.3) <0.001
a,b
 
6-point UPDRS 0.8 (0.4) 2.0 (1.5) 7.9
 
 (3.6) <0.001
a,b
 
Systolic BP change (mmHg) 7.0 (17.6) 8.9 (19.6) -11.7 (23.3) 0.01
a,b
 
Diastolic BP change (mmHg) 9.0 (8.2) 8.1 (11.2) -0.6
 
 (10.5) 0.02
a
 
GCSI 0.19 (0.36) 0.25 (0.44) 0.41 (0.46) 0.10 
(a = significant difference DLB v control; b = significant difference DLB v AD; c = 
significant difference AD v control. Post-hoc Tukey’s Test, α=0.05) 
 
Three DLB patients did not have postural BP checked as they were unable to stand. As 
expected DLB cases had higher score in the UPDRS, 6-point UPDRS and Hoehn & 
Yahr Scale (Table 7.5). They had a significantly greater fall in systolic BP than AD and 
controls, and a significantly greater fall in diastolic BP than controls. There were no 
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differences between the groups in GCSI scores. Only one patient in the entire cohort 
scored above the threshold for abnormality on the GCSI. 
 
7.3 Imaging results 
7.3.1 Visual rating 
There was absolute consensus between all five raters in 35/53 scans and majority read 
(4:1) in 9, with only 9 scans needing discussion at the consensus meeting. The mean 
kappa in the group was 0.65, indicating a good level interrater reliability. Intrarater 
reliability was also good, with a kappa of 0.66. 
All AD subjects scans were visually rated as amyloid positive, a significantly greater 
proportion than DLB (46%; p<0.01; n=32, Fisher’s Exact Test)) and control subjects 
(20%; p<0.001; n=25, Fisher’s Exact Test). The difference between DLB and controls 
was not significant (p=0.11; χ2=2.54; df=1, n=37).  
 
7.3.2 Semiquantification of amyloid PET scans 
 
Table 7.6. Regional amyloid binding relative to cerebellum in DLB, AD and controls 
 Control AD DLB  
 Mean (SD) Mean (SD) Mean (SD)     p 
Parietal 1.12 0.17 1.42 0.13 1.23 0.21 <0.01
c
 
Frontal 1.13 0.18 1.50 0.19 1.24 0.22 <0.01
b,c
 
Temporal 1.13 0.15 1.44 0.19 1.23 0.20 <0.01
b,c
 
Cingulate 1.20 0.22 1.55 0.19 1.31 0.24 <0.01
b,c
 
Occipital 1.10 0.12 1.30 0.15 1.18 0.15 <0.01
c
 
Striatal 1.13 0.13 1.41 0.18 1.19 0.16 <0.01
b,c
 
Mean Cortical 1.14 0.18 1.48 0.17 1.25 0.21 <0.01
c
 
Visual Rating positive (%) 20 100 46 <0.001
b,c 
APOE ε4 allele present (%) 33 90 68 0.01a,c 
Hippocampal Volume (mL) 2.75 0.35 1.59 0.50 2.25 0.55 <0.001
a,c
 
a = significant difference DLB v control; b = significant difference DLB v AD; c = 
significant difference AD v control. Post-hoc Tukey’s Test, α=0.05 
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There were no significant differences in normalised amyloid binding in any region 
between DLB and controls (Table 7.6; Figure 7.1). AD cases had greater binding than 
controls in all regions, and greater binding than DLB in frontal, temporal and cingulate 
cortices and the striatum. Mean cortical binding (p=0.053) and parietal binding (p=0.06) 
showed a trend approaching statistical significance, being greater in AD than DLB. 
 
 
 
 
 
 
The APOE  ε4 allele was more common in DLB (68%) and AD (91%) than control 
subjects (33%; DLB v control p=0.04, χ2=4.36, df=1, n=37; AD v control p=0.01, n=25, 
Fisher’s Exact Test). The difference between AD and DLB was not statistically 
significant (p=0.38, n=32, Fisher’ Exact Test). Across the entire cohort, presence of the 
APOE ε4 allele was associated with positive visual rating of the amyloid PET scan 
(83% v 42%; p=0.004; χ2=8.33; df=1, n=47). 
DLB and AD had smaller hippocampi than controls, DLB approached having 
significantly larger hippocampi than AD (2.25 v 2.75mL; p=0.06; Table 7.6).  
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Cortical
Control AD DLB
Figure 7.1. Amyloid ligand binding in six brain regions and overall cortical binding 
(normalised to whole cerebellum reference region) in DLB, AD and controls. Error 
bars represent standard deviation. (*=AD>control; **=AD>DLB & control; p<0.05) 
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7.3.3  Pattern of amyloid deposition 
 
Table 7.7. Regional amyloid binding relative to mean cortical binding in DLB, AD and 
controls 
 Control AD DLB  
 Mean (SD) Mean (SD) Mean (SD) p 
Relative parietal 0.98 0.03 0.97 0.04 0.98 0.05 0.51 
Relative frontal 0.99 0.02 1.01 0.02 0.99 0.03 0.07 
Relative temporal 0.99 0.03 0.97 0.02 0.99 0.04 0.40 
Relative cingulate 1.04 0.04 1.05 0.03 1.04 0.03 0.81 
Relative occipital 0.97 0.07 0.88 0.07 0.95 0.07 0.01
c
 
Relative striatal 1.00 0.07 0.95 0.07 0.96 0.09 0.34 
Frontal:Occipital Ratio 1.02 0.08 1.15 0.12 1.05 0.09 0.01
b,c
 
a = significant difference DLB v control; b = significant difference DLB v AD; c = 
significant difference AD v control. Post-hoc Tukey’s Test, α=0.05 
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Figure 7.2. Relative amyloid ligand binding in six brain regions relative to overall 
cortical binding, and frontal:occipital binding ratio in DLB, AD and controls. Error 
bars represent standard deviation (* = significant AD v control;   ** = significant AD v 
DLB & control; p<0.05). 
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To compare the pattern of amyloid deposition across disease categories binding in each 
region was compared to overall mean cortical binding in that individual (Table 7.7, 
Figure 7.2). Relative occipital binding differed across groups, being significantly lower 
in AD compared with controls (p=0.01) and approaching significance compared with 
DLB (p=0.06). In a post-hoc analysis frontal:occipital ratio was found to be greater in 
AD than DLB or controls (AD v DLB p=0.03; AD v controls p=0.01). When only 
amyloid positive DLB cases were included the difference was not statistically 
significant (DLB 1.09 v AD 1.15; p=0.21). 
 
7.3.4 Comparison of visual rating and quantification 
A comparison of visual rating and quantification can be seen in figure 7.3. Scans with a 
cortical SUVR>1.11 are classed as amyloid positive in ADNI (Landau and Juagust, 
2014). When this was compared with visual rating there was agreement in 36/44 cases 
(kappa 0.64; p<0.001). Seven subjects visually rated as negative were above the ADNI-
defined SUVR threshold of 1.11 (4 DLB, 3 controls). One DLB subject was visually 
rated as positive but had a cortical SUVR below threshold. 
 
 
 
 
Figure 7.3. A comparison of visual rating and quantification of amyloid 
imaging. The horizontal line reflects the ADNI-defined cut off of 1.11. 
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7.4 Comparison of amyloid positive and negative DLB cases based on visual 
rating 
7.4.1 Demographics 
There were no differences between amyloid negative and amyloid positive DLB 
subjects in age, gender, overall cognitive function, prescription of levodopa or presence 
of the APOE  ε4 gene (Table 7.8). Amyloid positive cases had significantly more years 
in education (12.7 v 9.5; p=0.01). There were no significant differences in duration of 
illness measured by time since diagnosis or duration of memory impairment. Two DLB 
subjects were unable to give a date of onset of memory problems, and did not have a 
carer that was able to do so. 
 
Table 7.8. Demographics and duration of illness in amyloid positive and negative 
DLB subjects 
 Amyloid 
negative 
Amyloid 
positive 
 
 Mean (SD) Mean (SD) p 
n 12 10 - 
Age 75.8 (6.3) 77.2 (6.7) 0.63 
Gender (% female) 17 20 1.00 
Years in education 9.5 (2.5) 12.7 (3.2) 0.01 
MMSE 19.6 (3.6) 21.2 (5.9) 0.46 
CIRS-G 11.6 (4.4) 10.8 (3.7) 0.87 
AChI/Memantine (%) 100 100 na 
Levodopa (%) 50 60 0.69 
Time since diagnosis (months) 31.3 (26.1) 20.8 (13.7) 0.27 
Duration memory impairment (months) 71.6 (43.8) 62.4 (55.9) 0.41 
APOE ε4 Allele Present (%) 58 80 0.38 
AChI=acetylcholinesterase inhibitor    
 
7.4.2 Cognitive tests 
There were no differences between the two groups in any ACE-R cognitive domain, 
memory measured by the Rey AVLT or graded naming (Table 7.9). The amyloid 
positive group scored significantly higher on the FAS verbal fluency test (28.0 v 16.3; 
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p=0.02). The FAS test is known to vary according to educational level (Tombaugh et 
al., 1999). When multiple linear regression was used with years in education and the 
presence or absence of amyloid as independent variables there was no effect of amyloid 
imaging result on FAS score (β=0.16; p=0.48), though years in education approached 
having a significant effect (β=0.46; p=0.051). 
 
Table 7.9. Cognitive tests in amyloid positive and negative DLB subjects 
 Amyloid negative Amyloid positive  
 Mean (SD) Mean (SD) p 
ACE-R Total 57.7 (14.8) 62.1 (19.3) 0.55 
ACE-R Attention/Orientation 11.8 (2.8) 13.7 (4.0) 0.19 
ACE-R Memory 12.4 (5.5) 11.8 (6.2) 0.81 
ACE-R Fluency 4.8 (2.8) 6.5 (3.6) 0.22 
ACE-R Language 20.7 (3.7) 21.5 (2.8) 0.92 
ACE-R Visuospatial 8.9 (2.6) 8.6 (4.9) 0.86 
Rey AVLT Trial 1 1.9 (1.9) 2.6 (2.8) 0.51 
Rey AVLT Trial 6 2.3 (1.9) 2.0 (2.8) 0.50 
Rey AVLT Delay 1.3 (1.4) 1.9 (2.8) 1.00 
Rey AVLT Recognition 11.2 (2.7) 11.8 (1.9) 0.57 
Verbal Fluency (FAS) score 16.3 (13.7) 28.0 (14.8) 0.02 
Graded Naming Test 13.8 (8.2) 14.1 (8.1) 0.92 
*Data uncorrected for years in education 
 
7.4.3 Computerised tests of cognitive function 
Amyloid negative subjects had much slower simple reaction times than amyloid 
positive (998ms v 473ms; p=0.049; Table 7.10). Variation in reaction time approached 
significance (837ms v 211ms; p=0.06). There were no differences in the digit vigilance 
task, a very similar test to the SRT, and no differences in the choice reaction task, 
overall power of attention or the angle discrimination task. Both groups had poor scores 
in the motion task, particularly the amyloid negative group (amyloid negative 0.99 v 
amyloid positive 0.90; p=0.10). 
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Given the association of education level with cognitive test scores linear regression was 
carried out with amyloid imaging result and years in education as independent variable 
for each cognitive and computerised tests in tables 7.9 and 7.10. Only digit vigilance 
false positive rate (β=0.57; p=0.04) showed a significant effect of amyloid deposition. 
The ACE-R memory subdomain (β=-0.41; p=0.06) and cognitive processing time 
(β=0.46; p=0.08) showed a trend towards significance. 
 
Table 7.10. Computer tests in amyloid positive and negative DLB subjects 
 Amyloid negative Amyloid positive  
 Mean (SD) Mean (SD) p 
SRT (ms) 988 652 473 220 0.05 
SRT SD (ms) 837 792 211 294 0.06 
SRT number correct 26.5 4.3 28.2 2.5 0.51 
CRT (ms) 1246 628 918 334 0.19 
CRT SD (ms) 592 552 440 377 0.65 
CRT errors 5.0 5.3 6.0 4.0 0.46 
Cognitive Processing Time (ms) 258 515 445 319 0.35 
Digit vigilance number correct 18.1 7.8 23.6 6.4 0.12 
Digit vigilance time (ms) 751 172 724 200 0.70 
Digit vigilance SD (ms) 241 144 271 124 0.63 
Digit vigilance false positives 7.0 7.4 30.2 37.5 0.06 
Power of attention (ms) 2727 (973) 2116 (571) 0.13 
Angle Task (
o
) 49.1 34.4 36.6 29.7 0.50 
Motion Task 0.99 0.02 0.92 0.09 0.10 
*Data uncorrected for years in education. SRT =simple reaction time, CRT = choice 
reaction time. 
 
 
7.4.4 Symptom scales 
There were no differences between the groups in scores on the fluctuation or depression 
scales (Table 7.11). There was also no difference in NPI overall score, any NPI 
subdomain, NPI distress score or functional impairment measured by the BADL or 
IADL scales. 
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Table 7.11. Symptom scales in amyloid positive and negative DLB subjects 
 Amyloid negative Amyloid positive  
 Mean (SD) Mean (SD) p 
CAF 5.8 (4.5) 7.4 (4.9) 0.38 
DCFS total 12.4 (3.3) 10.9 (3.3) 0.30 
Geriatric depression scale 4.6 (2.7) 4.2 (1.5) 0.68 
NPI total hallucinations  2.8 (2.7) 2.7 (3.2) 0.72 
NPI total depression 1.4 (1.6) 1.7 (2.2) 1.00 
NPI total 17.0 (9.3) 22.1 (22.1) 0.77 
NPI distress total 5.8 (6.4) 11.1 (11.3) 0.35 
BADL 22.8 (12.3) 20.3 (12.4) 0.77 
IADL 2.9 (1.9) 2.9 (2.0) 0.98 
 
 
7.4.5 Parkinsonism, autonomic and enteric function 
There were no differences between the groups in levels of parkinsonism or orthostatic 
blood pressure changes (Table 7.12). The amyloid negative group approached having 
more symptoms of gastroparesis but as previously mentioned only one patient had a 
clinically significant score. 
 
Table 7.12. UPDRS, orthostatic blood pressure changes and GCSI in amyloid 
positive and negative DLB subjects 
 Amyloid negative Amyloid positive  
 Mean (SD) Mean (SD) p 
MDS-UPDRS 45.3 (15.2) 50.1 (22.3) 0.56 
Hoehn and Yahr Stage 2.1 (1.4) 2.3 (1.2) 0.92 
6-point UPDRS 7.0 (2.8) 8.9 (4.3) 0.23 
Systolic BP change (mmHg) -8.9 (23.5) -14.9 (24.0) 0.59 
Diastolic BP change (mmHg) 1.5 (9.0) -2.9 (12.0) 0.37 
GCSI 0.57 (0.56) 0.22 (0.21) 0.06 
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7.4.6 Hippocampal volume 
There was no difference in hippocampal volume between the amyloid positive and 
negative groups (positive 2.25 v negative 2.26 mL; p=0.96). Mean cortical amyloid was 
inversely correlated with hippocampal volume in the DLB group (Pearson’s r=-0.573; 
p=0.008) but not AD (r=0.06; p=0.87) or controls (r=0.38; p=0.16). This association did 
not survive linear regression with age as an independent variable (β=-0.22; p=0.25). 
 
7.5 Correlation of amyloid binding with clinical picture in DLB 
We tested correlations between amyloid binding and clinical phenotype that had 
previously been reported. These analyses are based on correlations within DLB subjects 
only. 
 
7.5.1 Overall cognitive function and cortical or striatal binding 
There was no correlation between mean cortical or striatal binding and overall cognitive 
function measured by the MMSE or ACE-R, or functional impairment measured by the 
BADL and IADL scales (p>0.3 for all correlations). 
 
7.5.2 Memory 
Higher mean cortical amyloid binding was associated with lower ACE-R retrograde 
memory scores (questions on current and past UK Prime Ministers and USA Presidents) 
(Kendall’s tau = -0.38; p=0.03). This association was strengthened after linear 
regression with age and years in education (β=-0.58; p=0.01). Correlation between 
cortical binding and overall ACE-R memory subscore approached significance 
(Pearson’s r=-0.418; p=0.07), indicating a trend towards lower memory scores in 
amyloid positive subjects. When entered into regression with age and years in education 
this association was significant (β=-0.50; p=0.02). There was no significant correlation 
between amyloid and memory assessed by the Rey AVLT delayed recall or recognition. 
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7.5.3 Parkinsonism and striatal binding 
There was a positive correlation between striatal amyloid binding and 6-point UPDRS 
score (Pearson’s r=0.48; p=0.03), this correlation held after linear regression with age 
(Coefficient=0.61; p=0.008). There was no relationship between striatal binding and 
total UPDRS score (Pearson’s r=0.25; p=0.28) or Hoehn & Yahr Stage (Kendall’s tau=-
0.13; p=0.47). Contrary to a previous report (Gomperts et al., 2008), relative striatal 
binding did not show any correlation with parkinsonism, (UPDRS: Pearson’s r=0.20; 
p=0.41).  
 
7.5.4 Visuospatial function and parietal, cingulate, occipital binding 
There was a negative correlation between scores on the visuospatial subdomain of the 
ACE-R and relative cingulate binding (Pearson’s r=-0.49; p=0.03) but a positive 
correlation with relative parietal binding (Pearson’s r=0.47; p=0.04). Only the positive 
correlation with parietal binding held after regression with age and years in education 
(p=0.01). There was no significant relationship between the computerised tasks of 
visual function and cortical binding in the parietal, cingulate or occipital areas. 
 
7.6 Discussion 
7.6.1 Clinical and neuropsychological characteristics of participants  
DLB and AD groups were well matched for age, gender, level of education and overall 
cognitive function. DLB subjects performed better than those with AD in the ACE-R 
memory sub-score, but there were no other significant differences between DLB and 
AD in any other cognitive test. This was likely due to the relatively low numbers in the 
cohort, particularly of AD patients. Although not significant, the DLB group had worse 
visuospatial function and attention in almost every test of these domains. The Trail-
making Test was not effective in measuring executive function in this cohort due to a 
marked floor-effect. Only 22% of the dementia cases were able to successfully complete 
Trails B.  
The DLB group scored higher in scales measuring the severity of core features of DLB: 
hallucinations, fluctuations and parkinsonism. This is unsurprising, as these patients are 
diagnosed as DLB based on the presence of these symptoms. Depression is a supportive 
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feature of DLB in the consensus diagnostic criteria (McKeith et al., 2005), and the DLB 
group were found to have higher GDS scores than the AD group. 
 
7.6.2 APOE genotype 
A recent large genetic study including 667 pathologically confirmed DLB cases 
confirmed APOE genotype as a strong risk factor in DLB (Bras et al., 2014). As has 
previously been reported, the APOE ε4 genotype was more common in AD and DLB 
than controls (Kobayashi et al., 2011), though the rates here were higher in all groups 
than previously reported. Kobayashi et al. and a recent meta-analysis of amyloid 
imaging (Ossenkoppele et al., 2015) found the APOE ε4 allele in 40-50% of DLB cases 
compared with 68% in this cohort. This may be partly explained by the higher APOE ε4 
allele frequencies observed in more northern parts of Europe compared to southern 
Europe (Lucotte et al., 1997) but selection bias may be a more important factor. 
Anecdotally we notice that participants are often motivated to take part in research 
because other family members have suffered from dementia. Therefore we may be more 
likely to recruit people with a genetic predisposition towards dementia, such as the 
APOE ε4 allele. 
 
7.6.3 Hypothesis 1: The proportion of DLB patients with positive amyloid scans on 
visual rating will be greater than controls and less than AD. 
When amyloid PET scans were visually rated 100% of AD cases were amyloid positive, 
compared with 46% of DLB and 20% of controls. These figures are consistent with a 
recent meta-analysis that found 88% of AD,  51% of DLB and 24% of control cases to 
be amyloid positive (Ossenkoppele et al., 2015). The relatively even division of the 
DLB group into two halves enabled a comparison to be made between amyloid positive 
and amyloid negative cases. 
Carriers of the APOE ε4 allele were more likely to be amyloid positive across the whole 
cohort, but there was no effect of APOE ε4 in controls or DLB examined independently. 
The association between APOE ε4 and DLB may be related to the association of APOE 
ε4 with amyloid deposition, or the promotion of αSyn aggregation by APOE (Verghese 
et al., 2011). 
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7.6.4 Hypothesis 2: Semiquantitative measures of amyloid deposition will be greater 
in DLB than controls and less than AD. 
AD cases displayed the highest amyloid deposition with a mean cortical amyloid burden 
significantly greater than controls and approaching significantly greater than DLB. AD 
had greater amyloid deposition than controls in all brain areas assessed, and greater than 
DLB in frontal, temporal, cingulate and striatal regions. There was no difference 
between DLB and controls in any region, but DLB scored intermediate between AD and 
controls in every measure.  
The majority of previous studies have found significantly greater mean cortical binding 
in AD than DLB (Rowe et al., 2007; Villemagne et al., 2011; Kantarci et al., 2012b). 
One study found differences only in the parietal and posterior cingulate regions 
(Siderowf et al., 2014) and another found no differences (Gomperts et al., 2008). 
However these studies had relatively low numbers of DLB cases (n=11, and 8 
respectively) and in one study the DLB group was nine years older than the AD group 
(Gomperts et al., 2008). Similarly, amyloid binding has been found to be greater in 
DLB than controls in some studies (Edison et al., 2008; Gomperts et al., 2008; 
Gomperts et al., 2012; Kantarci et al., 2012b), with no significant differences reported 
in smaller studies (n=6-11 DLB subjects) (Foster et al., 2010; Villemagne et al., 2011; 
Siderowf et al., 2014). 
This study used 
18
F-Florbetapir, whereas previous studies have used 
11
C-PiB with one 
exception (Villemagne et al., 2011). The signal to noise ratio is greater in PiB than in 
Florbetapir (Landau et al., 2014), this may explain the lack of statistical significance 
between DLB and controls in our findings despite the relatively large sample size 
compared with previous studies.  Nevertheless we found amyloid deposition in DLB to 
be intermediate between AD and controls, which is consistent with previous research.  
Though amyloid binding was numerically higher in AD than controls and DLB in every 
cortical area, when regional binding was normalised to overall cortical binding, AD 
cases were found to have relatively low occipital binding. This has previously been 
reported in one amyloid imaging study (Gomperts et al., 2008) and is consistent with 
pathological findings or relatively low occipital Aβ load in AD compared with other 
cortical areas (Walker et al., 2015a). We calculated the frontal:occipital ratio for each 
subject and found that this was significantly higher in AD than DLB or controls. This 
did not hold when only amyloid positive DLB subjects were compared with AD, 
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suggesting that where amyloid deposition occurs in DLB the pattern is similar to that in 
AD. This is consistent with previous studies that have found similar patterns of 
deposition in amyloid positive DLB and AD (Kantarci et al., 2012b; Shimada et al., 
2013). 
 
The distribution of amyloid binding in DLB was similar to that reported in a 
neuropathological cohort diagnosed with DLB during life, but fulfilling 
neuropathological criteria for AD and DLB post mortem (Walker et al., 2015a), with 
the highest amyloid levels in the cingulate and lowest in the occipital cortex. However, 
the difference between these two areas was much higher in the neuropathological study 
(cingulate:occipital ratio 2.28 v. 1.11 in this study), most likely due to a combination of 
greater amyloid deposition in end-stage disease and an increase in signal to noise ratio 
in post mortem quantification compared with imaging studies. 
 
7.6.5 Comparison of visual rating and cortical SUVR threshold 
One scan visually rated as positive was classified as negative using the ADNI cortical 
SUVR threshold of 1.11. Four DLB and three control cases were categorised as amyloid 
positive despite being visually classified as negative. This is consistent with a previous 
report of 250 scans from a phase 1b trial in AD, which found visual rating to be more 
conservative, producing more amyloid negative results (Klein et al., 2014). The use of 
visual rating in this study is justified, as it has been shown to have diagnostic validity in 
AD, and predictive validity for the conversion of MCI to AD (Schreiber et al., 2015). 
However, quantification may detect lower levels of amyloid deposition that are 
clinically significant (Schreiber et al., 2015). As such, a comparison of those with 
amyloid above and below the ADNI threshold of 1.11 may be a more accurate measure 
of the effect of amyloid in DLB. However, as a significant majority of DLB cases fall 
above this threshold a much larger sample would be necessary to test this. 
 
7.6.6 Hippocampal volume 
AD and DLB both had smaller hippocampi (and so greater hippocampal atrophy) than 
controls. AD approached having greater atrophy than DLB. These findings are 
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consistent with previous reports of medial temporal lobe atrophy in DLB that is greater 
than controls but less than AD (Watson et al., 2009). 
 
7.6.7 Hypothesis 3: Amyloid positive DLB cases will have greater memory 
impairment and less visuospatial, attention and executive impairments than 
amyloid negative DLB cases. 
The amyloid positive group had more years in education compared to the amyloid 
negative group. Despite this there were no differences between the two groups in the 
vast majority of cognitive tests. This may be due to increased cognitive reserve in the 
amyloid positive group masking the cognitive effects of amyloid deposition (Amieva et 
al., 2014). Initial differences between the groups in verbal fluency and simple reaction 
time did not survive linear regression with years in education and visual rating as 
independent variables. This regression analysis found those with amyloid deposition to 
have significantly more digit vigilance false positive responses, and a trend toward 
slower cognitive processing in the choice reaction task and worse memory function on 
the ACE-R (but not the Rey AVLT). Overall there was no difference between the 
groups in the vast majority of cognitive tests. Similarly, amyloid imaging has previously 
been found not to correlate with cognitive impairment in AD (Jagust et al., 2009). 
This is the largest comparison of amyloid positive and negative DLB subjects to date, 
and includes significantly more neuropsychological comparisons than most previous 
reports. Despite the large number of outcome measures tested there were very few 
differences between the groups, even without correcting for multiple comparisons. We 
hypothesised that those with amyloid deposition would have a phenotype less typical of 
DLB, with some features of AD, i.e. worse memory function, less marked 
attention/executive and visuospatial dysfunction. There was no consistent evidence for 
this. Therefore, people with clinically diagnosed DLB and amyloid deposition appear to 
have the same cognitive phenotype as those without amyloid. 
 
7.6.8 Hypothesis 4: Amyloid positive DLB cases will score lower in scales measuring 
hallucinations, fluctuations and parkinsonism 
There were no differences between amyloid positive and negative DLB subjects in 
scales measuring fluctuations, hallucinations, parkinsonism, depression, other 
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neuropsychiatric symptoms and postural BP changes. Amyloid positive subjects 
approached having lower scores in the GCSI, but only one subject had a clinically 
significant score. 
We hypothesised that those with amyloid deposition would have less severe 
parkinsonism, fluctuations and hallucinations, but found no evidence for this. Consistent 
with our findings in cognitive tests we found no evidence that amyloid deposition was 
associated with a different clinical phenotype in DLB. That said, the DLB group in this 
study necessarily had core and suggestive features present, as they had received a 
clinical diagnosis of probable DLB. Our study criteria would exclude any potential 
patients with mixed amyloid and αSyn pathology but no diagnostic features of DLB. 
Neuropathological studies do not suffer from this bias. A recent study of cases with a 
post-mortem diagnosis of DLB found that all three core features of DLB were less 
frequent in cases with moderate to frequent neuritic Aβ plaques compared to those with 
no or sparse neuritic plaques (Tiraboschi et al., 2015), suggesting that Aβ may have an 
effect on the clinical profile of DLB. Despite this over 75% of cases with advanced 
neuritic plaques disease were clinically diagnosed as DLB.  
 
7.6.9 Hypothesis 5: Amyloid positive DLB cases will have smaller hippocampi than 
amyloid negative cases  
There was no difference in hippocampal volume between the amyloid positive and 
negative groups. However, hippocampal volume was inversely correlated with amyloid 
deposition. It is known that amyloid deposition increases with age (Jansen et al., 2015) 
and hippocampal volume decreases with age (Frisoni et al., 2008), therefore any inverse 
correlation between amyloid and hippocampal atrophy may be due to age. The 
association between the two variables in this cohort did not survive linear regression 
with age as an independent variable. 
Hippocampal atrophy was evident in the DLB group compared to controls but we found 
no direct link between amyloid and atrophy. Atrophy may be due to other types of 
pathology, particularly tau neurofibrillary tangles (Kantarci et al., 2012a; Nedelska et 
al., 2015a). 
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7.6.10 Hypothesis 6: Amyloid positive DLB cases will have a shorter duration of illness 
than amyloid negative cases 
Amyloid and αSyn pathology have been shown to interact synergistically in vitro and in 
mouse models (Masliah et al., 2001). It has been hypothesised that this interaction may 
result in more rapid cognitive decline in those with both pathologies. The lack of 
cognitive differences found in this study suggests that amyloid does not have a 
significant impact in the severity or pattern of cognitive impairment in DLB. However, 
there are three reasons for us to be cautious of making this conclusion. Cross-sectional 
analysis may be insensitive to detect such differences, as those with more severe 
impairment due to co-existing amyloid and αSyn may be more likely to refuse 
participation in the study.  Also, those with amyloid pathology had more years in 
education, which may have masked the effect of amyloid deposition. Finally, those with 
amyloid deposition had a shorter duration of illness (21 v 31 months). Though not 
statistically significant, this raises the possibility that those with amyloid deposition 
have declined more quickly. Cognitive tests in this cohort will be repeated after one 
year. If amyloid is associated with more rapid cognitive decline this may be detected at 
follow-up assessment. 
It is difficult to assess the rate of cognitive decline from cross-sectional imaging studies 
or retrospective pathological studies. Previous studies have used a variety of proxy 
measures for rate of cognitive decline such as the interval between motor and cognitive 
impairment, age of onset, disease duration and age of death (Jellinger et al., 2002; 
Ballard et al., 2004; Rowe et al., 2007; Maetzler et al., 2009; Nelson et al., 2009; Foster 
et al., 2010). Unsurprisingly findings differ between these heterogeneous studies, but 
longitudinal studies such as this one may be able to give a definitive answer to this 
question.  
 
7.6.11 Correlation of amyloid with clinical variables 
We tested correlations between amyloid binding and clinical variables within the DLB 
group that had previously been reported in the literature. AD and control subjects were 
excluded to avoid confounding relating to differences between diagnostic groups rather 
than the direct or indirect effects of amyloid. 
With the exception of global cognitive function (e.g. measured by the MMSE) these 
correlations had been reported in single studies without any corroboration in 
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independent cohorts and were unlikely to have been a priori hypotheses. The chance of 
Type 1 errors in these post-hoc tests is relatively high, particularly where multiple 
clinical and neuropsychological measures may be compared with multiple cortical 
regions. We sought to independently verify these findings in our cohort, with the 
expectation that we would not replicate the most of the findings. 
 
7.6.11.1 Cognitive and functional impairment  
We found no evidence to support previous findings of correlation between cortical or 
striatal binding and summary measures of cognitive or functional impairment. There 
was conflicting evidence from previous studies regarding this, and reported correlations 
were often modest. Our findings support previous research that there is no link between 
amyloid burden and overall cognition (Edison et al., 2008; Shimada et al., 2013) or 
functional impairment (Kantarci et al., 2012b) in DLB. Where correlation has been 
reported it has generally been in diagnostically heterogeneous cohorts including healthy 
controls and PD, both of which have high cognitive function and low rates of amyloid 
(Gomperts et al., 2008; Maetzler et al., 2009; Villemagne et al., 2011). Any correlation 
in these cohorts may be due to these group differences rather than the effect of amyloid 
itself. One study found an association between higher amyloid binding in the precuneus 
and lower MMSE in DLB, but the strength of the association was not reported 
(Gomperts et al., 2012). This study measured precuneus amyloid deposition because 
amyloid deposition is particularly high in this area and is highly correlated with global 
retention. Precuneus binding was not measured in our study. 
 
7.6.11.2 Semantic memory 
Few amyloid imaging studies have undertaken sufficient neuropsychological testing to 
investigate cognitive sub-domains. One study reported an association between cortical 
amyloid deposition and worse scores in tests of semantic memory, but no association 
with episodic memory (Gomperts et al., 2012).  
In our study semantic memory was tested in the ‘Retrograde Memory’ section of the 
ACE-R. This was inversely correlated with cortical amyloid deposition. It appears that 
amyloid deposition may indeed be associated with worse semantic memory, though we 
should bear in mind that the ACE-R retrograde memory assessment consists only of 
142 
 
four points (of 26 total points for memory), and is not a rigorous test of semantic 
memory.  
We also found inverse correlation between amyloid and ACE-R overall memory scores 
after regression with age and years in education as variables. However, in accordance 
with Gomperts et al. we found no association with episodic memory assessed using the 
Rey AVLT.  
 
7.6.11.3 Parkinsonism 
One previous study has reported relative striatal binding to be inversely correlated with 
UPDRS scores (Gomperts et al., 2008). The rationale for examining relative binding 
rather than overall striatal amyloid deposition was not stated.  
We found no association between relative striatal binding and UPDRS scores, or striatal 
binding (not corrected for overall binding) and overall UPDRS or Hoehn and Yahr 
stage. We did find a direct correlation between striatal binding and 6-point UPDRS 
scores, contrary to the previous report of inverse correlation between striatal binding 
and parkinsonism. The relationship between striatal amyloid deposition and motor 
impairment has not been explored in other imaging or post mortem studies. The 
findings of Gomperts et al. were in a small DLB group (n=8), and were not replicated in 
our cohort. Our finding of direct correlation is perhaps more plausible but it requires 
replication in other cohorts. 
 
7.6.11.4 Visuospatial function 
Gomperts et al. (2008) also found an association between increased amyloid in the 
parietal/posterior cingulate region relative to overall binding hand impaired 
visuoperceptual ability in the Benton Visual Form Discrimination Test. There was no 
correlation between cingulate or parietal amyloid binding and computerised tests of 
visuospatial function in our cohort, though this lacked statistical power, with data 
available for only 11 and 13 DLB patients in the angle discrimination and motion tasks 
respectively. Relative cingulate binding was associated with worse visuospatial function 
measured in the ACE-R, but this did not survive regression with age. Contrary to the 
finding of Gomperts et al. we found a surprising positive correlation between ACE-R 
visuospatial performance and relative parietal amyloid binding which did survive a 
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regression analysis. This seems biologically implausible, and may well be a Type 1 
error. Due to the small numbers of patients involved and the conflicting findings 
between our study and that of Gomperts et al. no conclusions can be drawn on the effect 
of cingulate and parietal amyloid deposition on visuospatial function in DLB. This 
should be investigated in other cohorts. 
 
7.7 Summary 
DLB was associated with a lower cortical burden of amyloid in most regions than AD. 
Though there were no statistically significant differences in amyloid deposition between 
DLB and controls, deposition in DLB was intermediate between AD and controls in all 
regions. This is consistent with previous findings in DLB. Where significant amyloid 
deposition occurs in DLB, the pattern of deposition appears grossly similar to that of 
AD. 
There were no consistent differences in the cognitive or clinical phenotype of amyloid 
positive and negative DLB cases, and no difference in hippocampal atrophy. Correlation 
between hippocampal atrophy and amyloid was likely due to the confounding effects of 
age, and other pathology such as tau may be responsible for the atrophy seen in DLB. 
These findings replicate neuropathological studies that found no influence of overall 
amyloid load on the ability to diagnose DLB in life (Tiraboschi et al., 2015; Walker et 
al., 2015a). When only neuritic plaques are considered, amyloid pathology may be 
associated with decreasing rates of core features of DLB (Tiraboschi et al., 2015), but 
amyloid imaging agents bind to diffuse amyloid plaques and vascular amyloid and so 
cannot be used to test these findings in life. 
Previous findings of  a correlation between amyloid deposition and clinical phenotype 
(Gomperts et al., 2008; Maetzler et al., 2009; Villemagne et al., 2011; Gomperts et al., 
2012) were generally not replicated in our cohort, apart from a correlation between 
semantic memory impairment and cortical amyloid deposition. This is consistent with 
other imaging studies that found no link between amyloid burden and cognitive (Edison 
et al., 2008; Shimada et al., 2013) or functional (Kantarci et al., 2012b) impairment.  
The presence of amyloid was not associated with lower cognitive scores to suggest a 
synergistic effect between amyloid and αSyn. That said, there was a non-significant 10 
month difference in disease duration between the groups which may potentially be 
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clinically relevant. Also, the amyloid positive group had more years in education, which 
is known to protect against decline in cognitive function in dementia (Amieva et al., 
2014). Longitudinal follow-up will be necessary to determine whether those with 
amyloid deposition deteriorate at a faster rate than those without amyloid. 
 
7.8 Strengths and limitations of study 
This is one of the largest studies of amyloid imaging in DLB to date. All subjects have 
had a detailed cognitive and clinical assessment. All but three subjects had an MRI, 
allowing for accurate region of interest analysis of amyloid ligand binding. As far as 
possible we followed the analysis methods used in ADNI (Landau and Juagust, 2014), 
allowing us to compare our cohort with well-defined thresholds for abnormality. The 
DLB group was sufficiently large and well balanced between amyloid positive and 
negative to allow a direct comparison between the two. 
We did not have a complete dataset for all patients due to patient inability to complete 
certain tests and computer error. This, and the low number of participants in the AD 
group may have reduced the power of the study to find differences between the AD and 
DLB groups, and between the amyloid positive and negative DLB cases. This 
particularly affected the computerised measures of visuospatial function – the angle and 
motion tasks.  Comparison with some previous studies in DLB may be impaired by the 
use of different cortical region maps to define regions of interest.  
Amyloid imaging agents, particularly 
18
F-labelled agents such as Florbetapir, have high 
nonspecific white matter binding (Rowe and Villemagne, 2011). Partial volume effects 
can occur if white matter (high signal) or CSF (low signal) are present in a voxel 
identified as predominantly grey matter. Despite this, the use of partial volume 
correction does not appear to improve the accuracy of results (Knesaurek et al., 2013) 
and is not performed in the ADNI cohort.  
Emerging evidence suggests that white-matter reference regions may be better than 
cerebellar reference regions when quantifying changes in amyloid deposition over time 
(Chen et al., 2015; Landau et al., 2015). This may be due to greater accuracy in cerebral 
white matter measurement than pontine or cerebellar areas due to their relatively 
peripheral positioning in the imaging field, or the relative stability of white matter 
compared to the cerebellum over time. We used the whole cerebellum region as this is 
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the only region that has been validated against post-mortem amyloid measurement 
(Clark et al., 2011) and is still recommended for cross-sectional comparisons (Chen et 
al., 2015). It is also the reference region used in most previous studies of amyloid 
imaging in DLB (Table 3.1). 
Results from Florbetapir are strongly correlated with those from PiB, though there is 
greater specific cortical binding in PiB (Landau et al., 2013). Amyloid ligands such as 
PiB and Florbetapir do not give a direct measure of amyloid burden and may 
overestimate binding in specific regions e.g. the precuneus (Driscoll et al., 2012). 
However, post mortem examination has confirmed that Florbetapir signal is correlated 
with amyloid density measured by immunochemistry (Clark et al., 2011). Crucially, this 
correlation does not seem to be affected by the presence of other brain pathology 
including LB disease (Dugger et al., 2014). 
 
7.9 Future directions 
Although a substantial cohort compared to other published data, we are continuing to 
recruit to this study. A larger cohort may show statistically significant differences in 
some of the trends seen in this cohort, and negate some spurious findings. There were 
few DLB subjects that were below the threshold for abnormality of quantitative 
assessment of amyloid binding. A larger cohort may allow us to compare amyloid 
positive and negative based on a quantitative threshold rather than visual rating. 
There is no evidence from this study that amyloid deposition is associated with a 
different pattern of clinical or neuropsychological impairment in DLB. We cannot 
conclude that amyloid is not associated with more rapid decline in DLB. All clinical and 
cognitive assessments will be repeated after one year. At this point any effect of 
amyloid on disease progression in DLB may be evident. In the absence of any effect of 
amyloid, the effect of APOE could be investigated, given the possibility of interaction 
between APOE and αSyn (Verghese et al., 2011). Neuropathological studies have found 
that tau is more closely related to clinical phenotype in DLB than amyloid (Merdes et 
al., 2003; Weisman et al., 2007; Walker et al., 2015a). Therefore novel tau imaging 
ligands may be more likely to identify DLB subgroups with differing symptoms and 
cognitive profiles. 
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The pattern of amyloid deposition in amyloid positive DLB and AD was similar in a 
region of interest analysis. A voxel-based analysis may be better able to identify more 
subtle differences between the two diseases within regions. 
Until in vivo synuclein imaging ligands become available, pathological studies are 
required to assess whether the presence of amyloid is associated with a lower likelihood 
of the presence of LB clinical features in the presence of αSyn pathology. This study 
found no difference in the presence of LB clinical features but this may be due to 
selection bias, as all our DLB subjects by definition have at least two diagnostic features 
of DLB. 
Dissecting the contributions of different brain pathologies to the clinical presentation 
and progression of dementia was previously only possible through post mortem studies. 
Post mortem studies by nature tend to assess late stage disease, and therefore may not 
identify the pathological processes that are important in the initial development of 
disease. Amyloid imaging allows us to examine the importance of amyloid deposition in 
vivo. Similar ligands have been developed for tau (Villemagne et al., 2015) and ligands 
are in development for the imaging of αSyn (Zhang et al., 2014). Over the coming years 
research studies using these and other ligands should shed more light on the 
pathophysiology of dementia with Lewy bodies, including interactions between 
different pathologies. 
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8 Chapter 8   Conclusions 
 
These studies investigated the association of two imaging biomarkers with clinical 
phenotype at different stages of cognitive impairment in Lewy body disease. We 
investigated the use of 
123
I-FP-CIT SPECT as a potential diagnostic biomarker of 
prodromal DLB. We used 
18
F-Florbetapir amyloid PET to examine the clinical 
implications of concurrent amyloid deposition in DLB. 
 
We found that 36% of MCI cases with Lewy body symptoms had an abnormal 
123
I-FP-
CIT scan, and those with abnormal scans had more core features of LB disease than 
those with normal scans. The relatively high frequency of abnormal scans and their 
association with symptoms suggestive of LB disease suggests that 
123
I-FP-CIT imaging 
shows promise as a potential biomarker for prodromal DLB. That said, several cases 
with normal scans also had significant LB features. Some of these may represent cases 
of prodromal DLB with relative sparing of the substantia nigra. Other diagnostic 
biomarkers will be necessary to identify such cases.  
Contrary to observations in PD, there was little asymmetry in 
123
I-FP-CIT imaging 
between the left and right striata (Walker et al., 2004). Early losses that affect the entire 
striata in both hemispheres are more difficult to visualise than focal losses, potentially 
limiting the utility of visual assessment of images, the standard method of interpreting 
clinical scans currently. Semiquantitative measurements may aid differentiation 
between normal and abnormal scans but reference ranges for these will need to take into 
account gender and age differences in FP-CIT binding (Varrone et al., 2013). We found 
even greater differences than expected between the genders in this cohort. It remains to 
be seen whether this reflects a difference in the pathophysiology of prodromal DLB 
between males and females, or simply lower rates of LB disease in females in this 
cohort.  
Longitudinal follow-up of these subjects to dementia, and eventually autopsy, will 
identify the sensitivity and specificity of visually rated 
123
I-FP-CIT scans to detect 
prodromal DLB in MCI with Lewy body symptoms. This may also aid the development 
of gender and age-specific thresholds for abnormality in semiquantified images. A very 
large sample size would be needed to determine the sensitivity and specificity of this 
148 
 
marker in a general MCI population (i.e. not selected for the presence of Lewy body 
symptoms) as only 5-10% of cases would be expected to convert to DLB in longitudinal 
follow-up (Vann Jones and O'Brien, 2014). This type of study would be extremely 
expensive and possibly unnecessary, as FP-CIT is unlikely to be used as a diagnostic 
tool in those without symptoms of Lewy body disease. A more feasible and useful study 
may be to investigate a group of LB-MCI cases alongside AD-MCI cases as a 
comparator group. 
 
Recent diagnostic criteria have highlighted the use of imaging biomarkers to increase 
diagnostic certainty in dementia (McKhann et al., 2011) and MCI related to 
Alzheimer’s disease (Albert et al., 2011).  The accurate identification of prodromal 
DLB is important for research studies wishing to investigate the pathophysiology of 
prodromal DLB and trial drugs targeting LB pathology. Postuma et al. (2015a) have 
demonstrated that the use of three simple clinical biomarkers (olfaction, colour vision 
and motor function) can help to identify subjects with RBD at high risk of developing a 
neurodegenerative disease. A similar process may be used to identify subjects with MCI 
at high risk of developing DLB.  It may be that FP-CIT has a role in this, but less 
expensive biomarkers such as olfactory dysfunction (Yoon et al., 2015) may be 
preferable where large numbers of people are being screened. A two-stage process may 
be an effective way to identify prodromal DLB, with inexpensive, sensitive markers in 
the first stage (e.g. olfactory dysfunction, mild motor impairments) followed by a 
potentially more expensive and invasive, but more specific markers in the second stage 
(Donaghy and McKeith, 2014). 
123
I-FP-CIT SPECT is a candidate for this, along with 
cardiac MIBG and nerve biopsy for the presence of αSyn (Treglia and Cason, 2012; 
Wang et al., 2013). 
 
In addition to use as diagnostic markers, imaging ligands can be used to investigate the 
pathophysiology of dementia and the effect of mixed pathology on clinical and 
cognitive features. Amyloid imaging is a useful tool to examine the effect of amyloid 
pathology in DLB, following post mortem and in vitro evidence of possible interactions 
between Aβ and αSyn (Masliah et al., 2001; Fujishiro et al., 2010). Consistent with 
other studies, we found that amyloid deposition in DLB is intermediate between AD 
and controls. The pattern of amyloid deposition in AD was different from DLB or 
149 
 
controls, with relatively high binding in frontal and low binding in occipital regions. 
However, we found that amyloid positive DLB cases may have a more ‘AD-like’ 
pattern of deposition. 
The presence of amyloid pathology had little effect on clinical phenotype in DLB, 
though longitudinal follow-up may demonstrate that amyloid deposition has an effect on 
the speed of clinical progression. Our findings, albeit on a relatively small cohort, 
suggest that recognition of DLB is not more difficult in the face of concurrent amyloid 
deposition, and conversely that there are not obvious clinical or cognitive features that 
will allow in vivo identification of amyloid pathology in DLB. However, this cross-
sectional study could not examine possible effects on disease course, which would have 
important therapeutic impact. If amyloid is associated with a faster rate of decline then 
amyloid and the interaction between amyloid and αSyn may be targets for treatment in 
DLB. If such treatments were developed, amyloid imaging would then be useful as a 
pathological biomarker to identify people who would benefit from such treatments. If 
there is no effect of amyloid on rate of progression, then such drugs would be unlikely 
to be beneficial and resources could be directed towards developing treatments that 
target other pathophysiological processes. 
Over the coming years the already available ligands for tau (Villemagne et al., 2015) 
and the prospect of ligands in the future for other pathologies such as αSyn (Zhang et 
al., 2014) will shed new light on the pathophysiology of dementia, including the effect 
of comorbid pathologies, which are present in most cases of dementia (Schneider et al., 
2007). These and other biomarkers will also be used in therapeutic studies to identify 
cohorts with specific brain pathology prior to the development of dementia and to 
monitor the effects of treatments targeting these pathologies (Hampel et al., 2014). If 
these studies identify treatments for dementia, imaging and other biomarkers will then 
be important in identifying the pathological processes present in an individual and 
deciding the specific treatment suitable for that person. 
 
  
150 
 
9 References 
 
Aarsland, D., Ballard, C., Larsen, J.P. and McKeith, I. (2001a) 'A comparative study of 
psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease 
with and without dementia', Int J Geriatr Psychiatry, 16(5), pp. 528-36. 
Aarsland, D., Ballard, C., McKeith, I., Perry, R.H. and Larsen, J.P. (2001b) 
'Comparison of extrapyramidal signs in dementia with Lewy bodies and 
Parkinson's disease', J Neuropsychiatry Clin Neurosci, 13(3), pp. 374-9. 
Aarsland, D., Ballard, C., Rongve, A., Broadstock, M. and Svenningsson, P. (2012) 
'Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia', 
Curr Neurol Neurosci Rep, 12(5), pp. 492-501. 
Aarsland, D., Ballard, C., Walker, Z., Bostrom, F., Alves, G., Kossakowski, K., Leroi, 
I., Pozo-Rodriguez, F., Minthon, L. and Londos, E. (2009) 'Memantine in 
patients with Parkinson's disease dementia or dementia with Lewy bodies: a 
double-blind, placebo-controlled, multicentre trial', Lancet Neurol, 8(7), pp. 
613-8. 
Aarsland, D., Ballard, C.G. and Halliday, G. (2004) 'Are Parkinson's disease with 
dementia and dementia with Lewy bodies the same entity?', J Geriatr Psychiatry 
Neurol, 17(3), pp. 137-45. 
Aarsland, D., Kvaloy, J.T., Andersen, K., Larsen, J.P., Tang, M.X., Lolk, A., Kragh-
Sorensen, P. and Marder, K. (2007) 'The effect of age of onset of PD on risk of 
dementia', J Neurol, 254(1), pp. 38-45. 
Aarsland, D., Perry, R., Brown, A., Larsen, J.P. and Ballard, C. (2005) 'Neuropathology 
of dementia in Parkinson's disease: a prospective, community-based study', Ann 
Neurol, 58(5), pp. 773-6. 
Aisen, P.S., Vellas, B. and Hampel, H. (2013) 'Moving towards early clinical trials for 
amyloid-targeted therapy in Alzheimer's disease', Nat Rev Drug Discov, 12(4), 
p. 324. 
Albert, M.S., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., 
Gamst, A., Holtzman, D.M., Jagust, W.J., Petersen, R.C., Snyder, P.J., Carrillo, 
M.C., Thies, B. and Phelps, C.H. (2011) 'The diagnosis of mild cognitive 
impairment due to Alzheimer's disease: recommendations from the National 
Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines 
for Alzheimer's disease', Alzheimers Dement, 7(3), pp. 270-9. 
Albin, R. and Koeppe, R. (2006) 'Rapid loss of striatal VMAT2 binding associated with 
onset of Lewy body dementia', Mov Disord, 21(2), pp. 287-8. 
Albin, R.L., Burke, J.F., Koeppe, R.A., Giordani, B., Gilman, S. and Frey, K.A. (2013) 
'Assessing mild cognitive impairment with amyloid and dopamine terminal 
molecular imaging', J Nucl Med, 54(6), pp. 887-93. 
151 
 
Almeida, O.P. and Almeida, S.A. (1999) 'Short versions of the geriatric depression 
scale: a study of their validity for the diagnosis of a major depressive episode 
according to ICD-10 and DSM-IV', Int J Geriatr Psychiatry, 14(10), pp. 858-65. 
Amieva, H., Mokri, H., Le Goff, M., Meillon, C., Jacqmin-Gadda, H., Foubert-Samier, 
A., Orgogozo, J.M., Stern, Y. and Dartigues, J.F. (2014) 'Compensatory 
mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 
years of cognitive decline', Brain, 137(Pt 4), pp. 1167-75. 
Auning, E., Rongve, A., Fladby, T., Booij, J., Hortobagyi, T., Siepel, F.J., Ballard, C. 
and Aarsland, D. (2011) 'Early and presenting symptoms of dementia with lewy 
bodies', Dement Geriatr Cogn Disord, 32(3), pp. 202-8. 
Aurora, R.N., Zak, R.S., Maganti, R.K., Auerbach, S.H., Casey, K.R., Chowdhuri, S., 
Karippot, A., Ramar, K., Kristo, D.A. and Morgenthaler, T.I. (2010) 'Best 
practice guide for the treatment of REM sleep behavior disorder (RBD)', J Clin 
Sleep Med, 6(1), pp. 85-95. 
Bacskai, B.J., Frosch, M.P., Freeman, S.H., Raymond, S.B., Augustinack, J.C., Johnson, 
K.A., Irizarry, M.C., Klunk, W.E., Mathis, C.A., Dekosky, S.T., Greenberg, 
S.M., Hyman, B.T. and Growdon, J.H. (2007) 'Molecular imaging with 
Pittsburgh Compound B confirmed at autopsy: a case report', Arch Neurol, 
64(3), pp. 431-4. 
Ballard, C., Grace, J., McKeith, I. and Holmes, C. (1998) 'Neuroleptic sensitivity in 
dementia with Lewy bodies and Alzheimer's disease', Lancet, 351(9108), pp. 
1032-3. 
Ballard, C., Holmes, C., McKeith, I., Neill, D., O'Brien, J., Cairns, N., Lantos, P., Perry, 
E., Ince, P. and Perry, R. (1999) 'Psychiatric morbidity in dementia with Lewy 
bodies: a prospective clinical and neuropathological comparative study with 
Alzheimer's disease', Am J Psychiatry, 156(7), pp. 1039-45. 
Ballard, C., McKeith, I., Burn, D., Harrison, R., O'Brien, J., Lowery, K., Campbell, M., 
Perry, R. and Ince, P. (1997) 'The UPDRS scale as a means of identifying 
extrapyramidal signs in patients suffering from dementia with Lewy bodies', 
Acta Neurol Scand, 96(6), pp. 366-71. 
Ballard, C., O'Brien, J., Gray, A., Cormack, F., Ayre, G., Rowan, E., Thompson, P., 
Bucks, R., McKeith, I., Walker, M. and Tovee, M. (2001) 'Attention and 
fluctuating attention in patients with dementia with Lewy bodies and Alzheimer 
disease', Arch Neurol, 58(6), pp. 977-82. 
Ballard, C., Ziabreva, I., Perry, R., Larsen, J.P., O'Brien, J., McKeith, I., Perry, E. and 
Aarsland, D. (2006) 'Differences in neuropathologic characteristics across the 
Lewy body dementia spectrum', Neurology, 67(11), pp. 1931-4. 
Ballard, C.G., Jacoby, R., Del Ser, T., Khan, M.N., Munoz, D.G., Holmes, C., Nagy, Z., 
Perry, E.K., Joachim, C., Jaros, E., O'Brien, J.T., Perry, R.H. and McKeith, I.G. 
(2004) 'Neuropathological substrates of psychiatric symptoms in prospectively 
studied patients with autopsy-confirmed dementia with lewy bodies', Am J 
Psychiatry, 161(5), pp. 843-9. 
152 
 
Beach, T.G., Adler, C.H., Lue, L., Sue, L.I., Bachalakuri, J., Henry-Watson, J., Sasse, 
J., Boyer, S., Shirohi, S., Brooks, R., Eschbacher, J., White, C.L., 3rd, Akiyama, 
H., Caviness, J., Shill, H.A., Connor, D.J., Sabbagh, M.N. and Walker, D.G. 
(2009) 'Unified staging system for Lewy body disorders: correlation with 
nigrostriatal degeneration, cognitive impairment and motor dysfunction', Acta 
Neuropathol, 117(6), pp. 613-34. 
Beach, T.G., Adler, C.H., Sue, L.I., Vedders, L., Lue, L., White Iii, C.L., Akiyama, H., 
Caviness, J.N., Shill, H.A., Sabbagh, M.N. and Walker, D.G. (2010) 'Multi-
organ distribution of phosphorylated alpha-synuclein histopathology in subjects 
with Lewy body disorders', Acta Neuropathol, 119(6), pp. 689-702. 
Benamer, T.S., Patterson, J., Grosset, D.G., Booij, J., de Bruin, K., van Royen, E., 
Speelman, J.D., Horstink, M.H., Sips, H.J., Dierckx, R.A., Versijpt, J., Decoo, 
D., Van Der Linden, C., Hadley, D.M., Doder, M., Lees, A.J., Costa, D.C., 
Gacinovic, S., Oertel, W.H., Pogarell, O., Hoeffken, H., Joseph, K., Tatsch, K., 
Schwarz, J. and Ries, V. (2000) 'Accurate differentiation of parkinsonism and 
essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the 
[123I]-FP-CIT study group', Mov Disord, 15(3), pp. 503-10. 
Bettens, K., Sleegers, K. and Van Broeckhoven, C. (2013) 'Genetic insights in 
Alzheimer's disease', Lancet Neurol, 12(1), pp. 92-104. 
Blanc, F., Colloby, S.J., Philippi, N., de Petigny, X., Jung, B., Demuynck, C., Phillipps, 
C., Anthony, P., Thomas, A., Bing, F., Lamy, J., Martin-Hunyadi, C., O'Brien, 
J.T., Cretin, B., McKeith, I., Armspach, J.P. and Taylor, J.P. (2015) 'Cortical 
Thickness in Dementia with Lewy Bodies and Alzheimer's Disease: A 
Comparison of Prodromal and Dementia Stages', PLoS One, 10(6), p. e0127396. 
Boddy, F., Rowan, E.N., Lett, D., O'Brien, J.T., McKeith, I.G. and Burn, D.J. (2007) 
'Subjectively reported sleep quality and excessive daytime somnolence in 
Parkinson's disease with and without dementia, dementia with Lewy bodies and 
Alzheimer's disease', Int J Geriatr Psychiatry, 22(6), pp. 529-35. 
Boeve, B.F., Molano, J.R., Ferman, T.J., Smith, G.E., Lin, S.-C., Bieniek, K., Haidar, 
W., Tippmann-Peikert, M., Knopman, D.S., Graff-Radford, N.R., Lucas, J.A., 
Petersen, R.C. and Silber, M.H. (2011) 'Validation of the Mayo Sleep 
Questionnaire to screen for REM sleep behavior disorder in an aging and 
dementia cohort', Sleep Med, 12(5), pp. 445-53. 
Boeve, B.F., Silber, M.H., Ferman, T.J., Kokmen, E., Smith, G.E., Ivnik, R.J., Parisi, 
J.E., Olson, E.J. and Petersen, R.C. (1998) 'REM sleep behavior disorder and 
degenerative dementia: an association likely reflecting Lewy body disease', 
Neurology, 51(2), pp. 363-70. 
Boeve, B.F., Silber, M.H., Parisi, J.E., Dickson, D.W., Ferman, T.J., Benarroch, E.E., 
Schmeichel, A.M., Smith, G.E., Petersen, R.C., Ahlskog, J.E., Matsumoto, J.Y., 
Knopman, D.S., Schenck, C.H. and Mahowald, M.W. (2003) 'Synucleinopathy 
pathology and REM sleep behavior disorder plus dementia or parkinsonism', 
Neurology, 61(1), pp. 40-5. 
Boeve, B.F., Silber, M.H., Saper, C.B., Ferman, T.J., Dickson, D.W., Parisi, J.E., 
Benarroch, E.E., Ahlskog, J.E., Smith, G.E., Caselli, R.C., Tippman-Peikert, M., 
153 
 
Olson, E.J., Lin, S.C., Young, T., Wszolek, Z., Schenck, C.H., Mahowald, 
M.W., Castillo, P.R., Del Tredici, K. and Braak, H. (2007) 'Pathophysiology of 
REM sleep behaviour disorder and relevance to neurodegenerative disease', 
Brain, 130(Pt 11), pp. 2770-88. 
Bombois, S., Debette, S., Bruandet, A., Delbeuck, X., Delmaire, C., Leys, D. and 
Pasquier, F. (2008) 'Vascular subcortical hyperintensities predict conversion to 
vascular and mixed dementia in MCI patients', Stroke, 39(7), pp. 2046-51. 
Bonanni, L., Perfetti, B., Bifolchetti, S., Taylor, J.P., Franciotti, R., Parnetti, L., 
Thomas, A. and Onofrj, M. (2015) 'Quantitative electroencephalogram utility in 
predicting conversion of mild cognitive impairment to dementia with Lewy 
bodies', Neurobiol Aging, 36(1), pp. 434-45. 
Bonanni, L., Thomas, A., Tiraboschi, P., Perfetti, B., Varanese, S. and Onofrj, M. 
(2008) 'EEG comparisons in early Alzheimer's disease, dementia with Lewy 
bodies and Parkinson's disease with dementia patients with a 2-year follow-up', 
Brain, 131(Pt 3), pp. 690-705. 
Booij, J. and Kemp, P. (2008) 'Dopamine transporter imaging with [(123)I]FP-CIT 
SPECT: potential effects of drugs', Eur J Nucl Med Mol Imaging, 35(2), pp. 
424-38. 
Boot, B. (2013) 'The incidence and prevalence of dementia with Lewy bodies is 
underestimated', Psychol Med, 43(12), pp. 2687-8. 
Boot, B.P., McDade, E.M., McGinnis, S.M. and Boeve, B.F. (2013a) 'Treatment of 
dementia with lewy bodies', Curr Treat Options Neurol, 15(6), pp. 738-64. 
Boot, B.P., Orr, C.F., Ahlskog, J.E., Ferman, T.J., Roberts, R., Pankratz, V.S., Dickson, 
D.W., Parisi, J., Aakre, J.A., Geda, Y.E., Knopman, D.S., Petersen, R.C. and 
Boeve, B.F. (2013b) 'Risk factors for dementia with Lewy bodies: a case-control 
study', Neurology, 81(9), pp. 833-40. 
Braak, H. and Braak, E. (1991) 'Neuropathological stageing of Alzheimer-related 
changes', Acta Neuropathol, 82(4), pp. 239-59. 
Braak, H., de Vos, R.A., Bohl, J. and Del Tredici, K. (2006) 'Gastric alpha-synuclein 
immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases 
staged for Parkinson's disease-related brain pathology', Neurosci Lett, 396(1), 
pp. 67-72. 
Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, E.N. and Braak, E. 
(2003) 'Staging of brain pathology related to sporadic Parkinson's disease', 
Neurobiol Aging, 24(2), pp. 197-211. 
Braak, H., Rub, U., Jansen Steur, E.N., Del Tredici, K. and de Vos, R.A. (2005) 
'Cognitive status correlates with neuropathologic stage in Parkinson disease', 
Neurology, 64(8), pp. 1404-10. 
Bras, J., Guerreiro, R., Darwent, L., Parkkinen, L., Ansorge, O., Escott-Price, V., 
Hernandez, D.G., Nalls, M.A., Clark, L.N., Honig, L.S., Marder, K., Van Der 
Flier, W.M., Lemstra, A., Scheltens, P., Rogaeva, E., St George-Hyslop, P., 
154 
 
Londos, E., Zetterberg, H., Ortega-Cubero, S., Pastor, P., Ferman, T.J., Graff-
Radford, N.R., Ross, O.A., Barber, I., Braae, A., Brown, K., Morgan, K., 
Maetzler, W., Berg, D., Troakes, C., Al-Sarraj, S., Lashley, T., Compta, Y., 
Revesz, T., Lees, A., Cairns, N., Halliday, G.M., Mann, D., Pickering-Brown, 
S., Dickson, D.W., Singleton, A. and Hardy, J. (2014) 'Genetic analysis 
implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of 
dementia with Lewy bodies', Hum Mol Genet, 23(23), pp. 6139-46. 
Braskie, M.N. and Thompson, P.M. (2013) 'Understanding cognitive deficits in 
Alzheimer's disease based on neuroimaging findings', Trends Cogn Sci, 17(10), 
pp. 510-6. 
Braskie, M.N. and Thompson, P.M. (2014) 'A focus on structural brain imaging in the 
Alzheimer's disease neuroimaging initiative', Biol Psychiatry, 75(7), pp. 527-33. 
Bucks, R.S., Ashworth, D.L., Wilcock, G.K. and Siegfried, K. (1996) 'Assessment of 
activities of daily living in dementia: development of the Bristol Activities of 
Daily Living Scale', Age Ageing, 25(2), pp. 113-20. 
Burack, M.A., Hartlein, J., Flores, H.P., Taylor-Reinwald, L., Perlmutter, J.S. and 
Cairns, N.J. (2010) 'In vivo amyloid imaging in autopsy-confirmed Parkinson 
disease with dementia', Neurology, 74(1), pp. 77-84. 
Burn, D.J., Rowan, E.N., Allan, L.M., Molloy, S., O'Brien, J.T. and McKeith, I.G. 
(2006) 'Motor subtype and cognitive decline in Parkinson's disease, Parkinson's 
disease with dementia, and dementia with Lewy bodies', J Neurol Neurosurg 
Psychiatry, 77(5), pp. 585-9. 
Burton, E.J., Barber, R., Mukaetova-Ladinska, E.B., Robson, J., Perry, R.H., Jaros, E., 
Kalaria, R.N. and O'Brien, J.T. (2009) 'Medial temporal lobe atrophy on MRI 
differentiates Alzheimer's disease from dementia with Lewy bodies and vascular 
cognitive impairment: a prospective study with pathological verification of 
diagnosis', Brain, 132(Pt 1), pp. 195-203. 
Cagnin, A., Busse, C., Jelcic, N., Gnoato, F., Mitolo, M. and Caffarra, P. (2015) 'High 
specificity of MMSE pentagon scoring for diagnosis of prodromal dementia 
with Lewy bodies', Parkinsonism Relat Disord, 21(3), pp. 303-5. 
Campbell, M.C., Markham, J., Flores, H., Hartlein, J.M., Goate, A.M., Cairns, N.J., 
Videen, T.O. and Perlmutter, J.S. (2013) 'Principal component analysis of PiB 
distribution in Parkinson and Alzheimer diseases', Neurology, 81(6), pp. 520-7. 
Cerami, C., Della Rosa, P.A., Magnani, G., Santangelo, R., Marcone, A., Cappa, S.F. 
and Perani, D. (2015) 'Brain metabolic maps in Mild Cognitive Impairment 
predict heterogeneity of progression to dementia', Neuroimage Clin, 7, pp. 187-
94. 
Chen, K., Roontiva, A., Thiyyagura, P., Lee, W., Liu, X., Ayutyanont, N., Protas, H., 
Luo, J.L., Bauer, R., Reschke, C., Bandy, D., Koeppe, R.A., Fleisher, A.S., 
Caselli, R.J., Landau, S., Jagust, W.J., Weiner, M.W., Reiman, E.M. and 
Alzheimer's Disease Neuroimaging Initiative (2015) 'Improved power for 
characterizing longitudinal amyloid-beta PET changes and evaluating amyloid-
155 
 
modifying treatments with a cerebral white matter reference region', J Nucl Med, 
56(4), pp. 560-6. 
Chiba, Y., Fujishiro, H., Iseki, E., Ota, K., Kasanuki, K., Hirayasu, Y. and Satoa, K. 
(2012) 'Retrospective survey of prodromal symptoms in dementia with Lewy 
bodies: comparison with Alzheimer's disease', Dement Geriatr Cogn Disord, 
33(4), pp. 273-81. 
Chirumamilla, A. and Travin, M.I. (2011) 'Cardiac applications of 123I-mIBG imaging', 
Semin Nucl Med, 41(5), pp. 374-87. 
Claassen, D.O., Josephs, K.A., Ahlskog, J.E., Silber, M.H., Tippmann-Peikert, M. and 
Boeve, B.F. (2010) 'REM sleep behavior disorder preceding other aspects of 
synucleinopathies by up to half a century', Neurology, 75(6), pp. 494-9. 
Claassen, D.O., Lowe, V.J., Peller, P.J., Petersen, R.C. and Josephs, K.A. (2011) 
'Amyloid and glucose imaging in dementia with Lewy bodies and multiple 
systems atrophy', Parkinsonism Relat Disord, 17(3), pp. 160-5. 
Clark, C.M., Schneider, J.A., Bedell, B.J., Beach, T.G., Bilker, W.B., Mintun, M.A., 
Pontecorvo, M.J., Hefti, F., Carpenter, A.P., Flitter, M.L., Krautkramer, M.J., 
Kung, H.F., Coleman, R.E., Doraiswamy, P.M., Fleisher, A.S., Sabbagh, M.N., 
Sadowsky, C.H., Reiman, E.P., Zehntner, S.P. and Skovronsky, D.M. (2011) 
'Use of florbetapir-PET for imaging beta-amyloid pathology', JAMA, 305(3), pp. 
275-83. 
Clerici, F., Del Sole, A., Chiti, A., Maggiore, L., Lecchi, M., Pomati, S., Mosconi, L., 
Lucignani, G. and Mariani, C. (2009) 'Differences in hippocampal metabolism 
between amnestic and non-amnestic MCI subjects: automated FDG-PET image 
analysis', Q J Nucl Med Mol Imaging, 53(6), pp. 646-57. 
Clinton, L.K., Blurton-Jones, M., Myczek, K., Trojanowski, J.Q. and LaFerla, F.M. 
(2010) 'Synergistic Interactions between Abeta, tau, and alpha-synuclein: 
acceleration of neuropathology and cognitive decline', J Neurosci, 30(21), pp. 
7281-9. 
Colloby, S.J., McParland, S., O'Brien, J.T. and Attems, J. (2012) 'Neuropathological 
correlates of dopaminergic imaging in Alzheimer's disease and Lewy body 
dementias', Brain, 135(Pt 9), pp. 2798-808. 
Colloby, S.J., O'Brien, J.T., Fenwick, J.D., Firbank, M.J., Burn, D.J., McKeith, I.G. and 
Williams, E.D. (2004) 'The application of statistical parametric mapping to 123I-
FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and 
Parkinson's disease', Neuroimage, 23(3), pp. 956-66. 
Colloby, S.J., Williams, E.D., Burn, D.J., Lloyd, J.J., McKeith, I.G. and O'Brien, J.T. 
(2005) 'Progression of dopaminergic degeneration in dementia with Lewy bodies 
and Parkinson's disease with and without dementia assessed using 123I-FP-CIT 
SPECT', Eur J Nucl Med Mol Imaging, 32(10), pp. 1176-85. 
Compta, Y., Parkkinen, L., O'Sullivan, S.S., Vandrovcova, J., Holton, J.L., Collins, C., 
Lashley, T., Kallis, C., Williams, D.R., de Silva, R., Lees, A.J. and Revesz, T. 
156 
 
(2011) 'Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: 
which is more important?', Brain, 134(Pt 5), pp. 1493-505. 
Craig, D., Mirakhur, A., Hart, D.J., McIlroy, S.P. and Passmore, A.P. (2005) 'A cross-
sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's 
disease', Am J Geriatr Psychiatry, 13(6), pp. 460-8. 
Cummings, J.L., Henchcliffe, C., Schaier, S., Simuni, T., Waxman, A. and Kemp, P. 
(2011) 'The role of dopaminergic imaging in patients with symptoms of 
dopaminergic system neurodegeneration', Brain, 134(Pt 11), pp. 3146-66. 
Cummings, J.L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D.A. and 
Gornbein, J. (1994) 'The Neuropsychiatric Inventory: comprehensive assessment 
of psychopathology in dementia', Neurology, 44(12), pp. 2308-14. 
D'Ath, P., Katona, P., Mullan, E., Evans, S. and Katona, C. (1994) 'Screening, detection 
and management of depression in elderly primary care attenders. I: The 
acceptability and performance of the 15 item Geriatric Depression Scale 
(GDS15) and the development of short versions', Fam Pract, 11(3), pp. 260-6. 
Dang-Vu, T.T., Gagnon, J.F., Vendette, M., Soucy, J.P., Postuma, R.B. and Montplaisir, 
J. (2012) 'Hippocampal perfusion predicts impending neurodegeneration in 
REM sleep behavior disorder', Neurology, 79(24), pp. 2302-6. 
David, R., Koulibaly, M., Benoit, M., Garcia, R., Caci, H., Darcourt, J. and Robert, P. 
(2008) 'Striatal dopamine transporter levels correlate with apathy in 
neurodegenerative diseases A SPECT study with partial volume effect 
correction', Clin Neurol Neurosurg, 110(1), pp. 19-24. 
Del Ser, T., Hachinski, V., Merskey, H. and Munoz, D.G. (2001) 'Clinical and 
pathologic features of two groups of patients with dementia with Lewy bodies: 
effect of coexisting Alzheimer-type lesion load', Alzheimer Dis Assoc Disord, 
15(1), pp. 31-44. 
Del Ser, T., McKeith, I., Anand, R., Cicin-Sain, A., Ferrara, R. and Spiegel, R. (2000) 
'Dementia with lewy bodies: findings from an international multicentre study', 
Int J Geriatr Psychiatry, 15(11), pp. 1034-45. 
Department of Health (2013) Mental Health Clustering Booklet (v3.0). London: 
Department of Health. 
Donaghy, P.C. and McKeith, I.G. (2014) 'The clinical characteristics of dementia with 
Lewy bodies and a consideration of prodromal diagnosis', Alzheimers Res Ther, 
6(4), p. 46. 
Doraiswamy, P.M., Sperling, R.A., Johnson, K., Reiman, E.M., Wong, T.Z., Sabbagh, 
M.N., Sadowsky, C.H., Fleisher, A.S., Carpenter, A., Joshi, A.D., Lu, M., 
Grundman, M., Mintun, M.A., Skovronsky, D.M., Pontecorvo, M.J., Group, 
A.A.S. and Group, A.A.S. (2014) 'Florbetapir F 18 amyloid PET and 36-month 
cognitive decline: a prospective multicenter study', Mol Psychiatry, 19(9), pp. 
1044-51. 
157 
 
Driscoll, I., Troncoso, J.C., Rudow, G., Sojkova, J., Pletnikova, O., Zhou, Y., Kraut, 
M.A., Ferrucci, L., Mathis, C.A., Klunk, W.E., O'Brien, R.J., Davatzikos, C., 
Wong, D.F. and Resnick, S.M. (2012) 'Correspondence between in vivo (11)C-
PiB-PET amyloid imaging and postmortem, region-matched assessment of 
plaques', Acta Neuropathol, 124(6), pp. 823-31. 
Drzezga, A., Grimmer, T., Henriksen, G., Muhlau, M., Perneczky, R., Miederer, I., 
Praus, C., Sorg, C., Wohlschlager, A., Riemenschneider, M., Wester, H.J., 
Foerstl, H., Schwaiger, M. and Kurz, A. (2009) 'Effect of APOE genotype on 
amyloid plaque load and gray matter volume in Alzheimer disease', Neurology, 
72(17), pp. 1487-94. 
Dubois, B., Feldman, H.H., Jacova, C., Cummings, J.L., Dekosky, S.T., Barberger-
Gateau, P., Delacourte, A., Frisoni, G., Fox, N.C., Galasko, D., Gauthier, S., 
Hampel, H., Jicha, G.A., Meguro, K., O'Brien, J., Pasquier, F., Robert, P., 
Rossor, M., Salloway, S., Sarazin, M., de Souza, L.C., Stern, Y., Visser, P.J. and 
Scheltens, P. (2010) 'Revising the definition of Alzheimer's disease: a new 
lexicon', Lancet Neurol, 9(11), pp. 1118-27. 
Dugger, B.N., Boeve, B.F., Murray, M.E., Parisi, J.E., Fujishiro, H., Dickson, D.W. and 
Ferman, T.J. (2012) 'Rapid eye movement sleep behavior disorder and subtypes 
in autopsy-confirmed dementia with Lewy bodies', Mov Disord, 27(1), pp. 72-8. 
Dugger, B.N., Clark, C.M., Serrano, G., Mariner, M., Bedell, B.J., Coleman, R.E., 
Doraiswamy, P.M., Lu, M., Fleisher, A.S., Reiman, E.M., Sabbagh, M.N., 
Sadowsky, C.H., Schneider, J.A., Zehntner, S.P., Carpenter, A.P., Joshi, A.D., 
Mintun, M.A., Pontecorvo, M.J., Skovronsky, D.M., Sue, L.I. and Beach, T.G. 
(2014) 'Neuropathologic heterogeneity does not impair florbetapir-positron 
emission tomography postmortem correlates', J Neuropathol Exp Neurol, 73(1), 
pp. 72-80. 
Duyckaerts, C., Delatour, B. and Potier, M.C. (2009) 'Classification and basic pathology 
of Alzheimer disease', Acta Neuropathol, 118(1), pp. 5-36. 
Edison, P., Ahmed, I., Fan, Z., Hinz, R., Gelosa, G., Ray Chaudhuri, K., Walker, Z., 
Turkheimer, F.E. and Brooks, D.J. (2013) 'Microglia, amyloid, and glucose 
metabolism in Parkinson's disease with and without dementia', 
Neuropsychopharmacology, 38(6), pp. 938-49. 
Edison, P., Rowe, C.C., Rinne, J.O., Ng, S., Ahmed, I., Kemppainen, N., Villemagne, 
V.L., O'Keefe, G., Nagren, K., Chaudhury, K.R., Masters, C.L. and Brooks, D.J. 
(2008) 'Amyloid load in Parkinson's disease dementia and Lewy body dementia 
measured with [11C]PIB positron emission tomography', J Neurol Neurosurg 
Psychiatry, 79(12), pp. 1331-8. 
Eli Lilly (2012) 'Amyvid (Florbetapir F 18 Injection): Highlights of Prescribing 
Information'. Indianapolis: Eli Lilly. 
Emre, M., Aarsland, D., Brown, R., Burn, D.J., Duyckaerts, C., Mizuno, Y., Broe, G.A., 
Cummings, J., Dickson, D.W., Gauthier, S., Goldman, J., Goetz, C., Korczyn, 
A., Lees, A., Levy, R., Litvan, I., McKeith, I., Olanow, W., Poewe, W., Quinn, 
N., Sampaio, C., Tolosa, E. and Dubois, B. (2007) 'Clinical diagnostic criteria 
158 
 
for dementia associated with Parkinson's disease', Mov Disord, 22(12), pp. 1689-
707; quiz 1837. 
Emre, M., Tsolaki, M., Bonuccelli, U., Destee, A., Tolosa, E., Kutzelnigg, A., Ceballos-
Baumann, A., Zdravkovic, S., Bladstrom, A., Jones, R. and Study, I. (2010) 
'Memantine for patients with Parkinson's disease dementia or dementia with 
Lewy bodies: a randomised, double-blind, placebo-controlled trial', Lancet 
Neurol, 9(10), pp. 969-77. 
Fayed, N., Davila, J., Oliveros, A., Castillo, J. and Medrano, J.J. (2008) 'Utility of 
different MR modalities in mild cognitive impairment and its use as a predictor 
of conversion to probable dementia', Academic radiology, 15(9), pp. 1089-98. 
Fereshtehnejad, S.M., Damangir, S., Cermakova, P., Aarsland, D., Eriksdotter, M. and 
Religa, D. (2014) 'Comorbidity profile in dementia with Lewy bodies versus 
Alzheimer's disease: a linkage study between the Swedish Dementia Registry 
and the Swedish National Patient Registry', Alzheimers Res Ther, 6(5-8), p. 65. 
Ferman, T.J., Arvanitakis, Z., Fujishiro, H., Duara, R., Parfitt, F., Purdy, M., Waters, C., 
Barker, W., Graff-Radford, N.R. and Dickson, D.W. (2013a) 'Pathology and 
temporal onset of visual hallucinations, misperceptions and family 
misidentification distinguishes dementia with Lewy bodies from Alzheimer's 
disease', Parkinsonism Relat Disord, 19(2), pp. 227-31. 
Ferman, T.J., Boeve, B.F., Smith, G.E., Lin, S.C., Silber, M.H., Pedraza, O., Wszolek, 
Z., Graff-Radford, N.R., Uitti, R., Van Gerpen, J., Pao, W., Knopman, D., 
Pankratz, V.S., Kantarci, K., Boot, B., Parisi, J.E., Dugger, B.N., Fujishiro, H., 
Petersen, R.C. and Dickson, D.W. (2011) 'Inclusion of RBD improves the 
diagnostic classification of dementia with Lewy bodies', Neurology, 77(9), pp. 
875-82. 
Ferman, T.J., Smith, G.E., Boeve, B.F., Graff-Radford, N.R., Lucas, J.A., Knopman, 
D.S., Petersen, R.C., Ivnik, R.J., Wszolek, Z., Uitti, R. and Dickson, D.W. 
(2006) 'Neuropsychological differentiation of dementia with Lewy bodies from 
normal aging and Alzheimer's disease', Clin Neuropsychol, 20(4), pp. 623-36. 
Ferman, T.J., Smith, G.E., Boeve, B.F., Ivnik, R.J., Petersen, R.C., Knopman, D., Graff-
Radford, N., Parisi, J. and Dickson, D.W. (2004) 'DLB fluctuations: specific 
features that reliably differentiate DLB from AD and normal aging', Neurology, 
62(2), pp. 181-7. 
Ferman, T.J., Smith, G.E., Dickson, D.W., Graff-Radford, N.R., Lin, S.C., Wszolek, Z., 
Van Gerpen, J.A., Uitti, R., Knopman, D.S., Petersen, R.C., Parisi, J.E., Silber, 
M.H. and Boeve, B.F. (2014) 'Abnormal daytime sleepiness in dementia with 
Lewy bodies compared to Alzheimer's disease using the Multiple Sleep Latency 
Test', Alzheimers Res Ther, 6(9), p. 76. 
Ferman, T.J., Smith, G.E., Kantarci, K., Boeve, B.F., Pankratz, V.S., Dickson, D.W., 
Graff-Radford, N.R., Wszolek, Z., Van Gerpen, J., Uitti, R., Pedraza, O., 
Murray, M.E., Aakre, J., Parisi, J., Knopman, D.S. and Petersen, R.C. (2013b) 
'Nonamnestic mild cognitive impairment progresses to dementia with Lewy 
bodies', Neurology, 81(23), pp. 2032-8. 
159 
 
Ferreira, D., Perestelo-Perez, L., Westman, E., Wahlund, L.O., Sarria, A. and Serrano-
Aguilar, P. (2014) 'Meta-Review of CSF Core Biomarkers in Alzheimer's 
Disease: The State-of-the-Art after the New Revised Diagnostic Criteria', Front 
Aging Neurosci, 6, p. 47. 
Firbank, M.J., Barber, R., Burton, E.J. and O'Brien, J.T. (2008) 'Validation of a fully 
automated hippocampal segmentation method on patients with dementia', Hum 
Brain Mapp, 29(12), pp. 1442-9. 
Fischer, P., Jungwirth, S., Zehetmayer, S., Weissgram, S., Hoenigschnabl, S., Gelpi, E., 
Krampla, W. and Tragl, K.H. (2007) 'Conversion from subtypes of mild 
cognitive impairment to Alzheimer dementia', Neurology, 68(4), pp. 288-91. 
Fjell, A.M. and Walhovd, K.B. (2012) 'Neuroimaging results impose new views on 
Alzheimer's disease-the role of amyloid revised', Mol Neurobiol, 45(1), pp. 153-
72. 
Fleisher, A.S., Chen, K., Liu, X., Ayutyanont, N., Roontiva, A., Thiyyagura, P., Protas, 
H., Joshi, A.D., Sabbagh, M., Sadowsky, C.H., Sperling, R.A., Clark, C.M., 
Mintun, M.A., Pontecorvo, M.J., Coleman, R.E., Doraiswamy, P.M., Johnson, 
K.A., Carpenter, A.P., Skovronsky, D.M. and Reiman, E.M. (2013) 
'Apolipoprotein E epsilon4 and age effects on florbetapir positron emission 
tomography in healthy aging and Alzheimer disease', Neurobiol Aging, 34(1), 
pp. 1-12. 
Fodero-Tavoletti, M.T., Brockschnieder, D., Villemagne, V.L., Martin, L., Connor, 
A.R., Thiele, A., Berndt, M., McLean, C.A., Krause, S., Rowe, C.C., Masters, 
C.L., Dinkelborg, L., Dyrks, T. and Cappai, R. (2012) 'In vitro characterization 
of [18F]-florbetaben, an Abeta imaging radiotracer', Nucl Med Biol, 39(7), pp. 
1042-8. 
Foster, E.R., Campbell, M.C., Burack, M.A., Hartlein, J., Flores, H.P., Cairns, N.J., 
Hershey, T. and Perlmutter, J.S. (2010) 'Amyloid imaging of Lewy body-
associated disorders', Mov Disord, 25(15), pp. 2516-23. 
Francis, P.T. and Perry, E.K. (2007) 'Cholinergic and other neurotransmitter 
mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia 
with Lewy bodies', Mov Disord, 22 Suppl 17, pp. S351-7. 
Frigerio, R., Fujishiro, H., Ahn, T.B., Josephs, K.A., Maraganore, D.M., DelleDonne, 
A., Parisi, J.E., Klos, K.J., Boeve, B.F., Dickson, D.W. and Ahlskog, J.E. (2011) 
'Incidental Lewy body disease: do some cases represent a preclinical stage of 
dementia with Lewy bodies?', Neurobiol Aging, 32(5), pp. 857-63. 
Frisoni, G.B., Ganzola, R., Canu, E., Rub, U., Pizzini, F.B., Alessandrini, F., Zoccatelli, 
G., Beltramello, A., Caltagirone, C. and Thompson, P.M. (2008) 'Mapping local 
hippocampal changes in Alzheimer's disease and normal ageing with MRI at 3 
Tesla', Brain, 131(Pt 12), pp. 3266-76. 
Fujishiro, H., Ferman, T.J., Boeve, B.F., Smith, G.E., Graff-Radford, N.R., Uitti, R.J., 
Wszolek, Z.K., Knopman, D.S., Petersen, R.C., Parisi, J.E. and Dickson, D.W. 
(2008) 'Validation of the neuropathologic criteria of the third consortium for 
160 
 
dementia with Lewy bodies for prospectively diagnosed cases', J Neuropathol 
Exp Neurol, 67(7), pp. 649-56. 
Fujishiro, H., Iseki, E., Higashi, S., Kasanuki, K., Murayama, N., Togo, T., Katsuse, O., 
Uchikado, H., Aoki, N., Kosaka, K., Arai, H. and Sato, K. (2010) 'Distribution 
of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy 
body dementia', Neurosci Lett, 486(1), pp. 19-23. 
Fujishiro, H., Iseki, E., Kasanuki, K., Chiba, Y., Ota, K., Murayama, N. and Sato, K. 
(2013a) 'A follow up study of non-demented patients with primary visual 
cortical hypometabolism: Prodromal dementia with Lewy bodies', J Neurol Sci, 
334(1-2), pp. 48-54. 
Fujishiro, H., Iseki, E., Nakamura, S., Kasanuki, K., Chiba, Y., Ota, K., Murayama, N. 
and Sato, K. (2013b) 'Dementia with Lewy bodies: early diagnostic challenges', 
Psychogeriatrics, 13(2), pp. 128-38. 
Fujishiro, H., Nakamura, S., Kitazawa, M., Sato, K. and Iseki, E. (2012) 'Early detection 
of dementia with Lewy bodies in patients with amnestic mild cognitive 
impairment using 123I-MIBG cardiac scintigraphy', J Neurol Sci, 315(1-2), pp. 
115-9. 
G8 (2013) G8 Dementia Summit Declaration. London: Department of Health. 
Gaenslen, A., Swid, I., Liepelt-Scarfone, I., Godau, J. and Berg, D. (2011) 'The patients' 
perception of prodromal symptoms before the initial diagnosis of Parkinson's 
disease', Mov Disord, 26(4), pp. 653-8. 
Garcia-Ptacek, S., Farahmand, B., Kareholt, I., Religa, D., Cuadrado, M.L. and 
Eriksdotter, M. (2014) 'Mortality risk after dementia diagnosis by dementia type 
and underlying factors: a cohort of 15,209 patients based on the Swedish 
Dementia Registry', J Alzheimers Dis, 41(2), pp. 467-77. 
Goetz, C.G., Tilley, B.C., Shaftman, S.R., Stebbins, G.T., Fahn, S., Martinez-Martin, P., 
Poewe, W., Sampaio, C., Stern, M.B., Dodel, R., Dubois, B., Holloway, R., 
Jankovic, J., Kulisevsky, J., Lang, A.E., Lees, A., Leurgans, S., LeWitt, P.A., 
Nyenhuis, D., Olanow, C.W., Rascol, O., Schrag, A., Teresi, J.A., van Hilten, 
J.J., LaPelle, N. and Movement Disorder Society, U.R.T.F. (2008) 'Movement 
Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating 
Scale (MDS-UPDRS): scale presentation and clinimetric testing results', Mov 
Disord, 23(15), pp. 2129-70. 
Gomperts, S.N., Locascio, J.J., Marquie, M., Santarlasci, A.L., Rentz, D.M., Maye, J., 
Johnson, K.A. and Growdon, J.H. (2012) 'Brain amyloid and cognition in Lewy 
body diseases', Movement Disorders, 27(8), pp. 965-73. 
Gomperts, S.N., Locascio, J.J., Rentz, D., Santarlasci, A., Marquie, M., Johnson, K.A. 
and Growdon, J.H. (2013) 'Amyloid is linked to cognitive decline in patients 
with Parkinson disease without dementia', Neurology, 80(1), pp. 85-91. 
Gomperts, S.N., Rentz, D.M., Moran, E., Becker, J.A., Locascio, J.J., Klunk, W.E., 
Mathis, C.A., Elmaleh, D.R., Shoup, T., Fischman, A.J., Hyman, B.T., 
161 
 
Growdon, J.H. and Johnson, K.A. (2008) 'Imaging amyloid deposition in Lewy 
body diseases', Neurology, 71(12), pp. 903-10. 
Graff-Radford, J., Boeve, B.F., Pedraza, O., Ferman, T.J., Przybelski, S., Lesnick, T.G., 
Vemuri, P., Senjem, M.L., Smith, G.E., Knopman, D.S., Lowe, V., Jack, C.R., 
Jr., Petersen, R.C. and Kantarci, K. (2012) 'Imaging and acetylcholinesterase 
inhibitor response in dementia with Lewy bodies', Brain, 135(Pt 8), pp. 2470-
2477. 
Hampel, H., Lista, S., Teipel, S.J., Garaci, F., Nistico, R., Blennow, K., Zetterberg, H., 
Bertram, L., Duyckaerts, C., Bakardjian, H., Drzezga, A., Colliot, O., Epelbaum, 
S., Broich, K., Lehericy, S., Brice, A., Khachaturian, Z.S., Aisen, P.S. and 
Dubois, B. (2014) 'Perspective on future role of biological markers in clinical 
therapy trials of Alzheimer's disease: a long-range point of view beyond 2020', 
Biochem Pharmacol, 88(4), pp. 426-49. 
Harding, A.J., Broe, G.A. and Halliday, G.M. (2002) 'Visual hallucinations in Lewy 
body disease relate to Lewy bodies in the temporal lobe', Brain, 125(Pt 2), pp. 
391-403. 
Harding, A.J. and Halliday, G.M. (2001) 'Cortical Lewy body pathology in the 
diagnosis of dementia', Acta Neuropathol, 102(4), pp. 355-63. 
Heetun, Z.S. and Quigley, E.M. (2012) 'Gastroparesis and Parkinson's disease: a 
systematic review', Parkinsonism Relat Disord, 18(5), pp. 433-40. 
Herholz, K. (2011) 'Perfusion SPECT and FDG-PET', International Psychogeriatrics, 
23, pp. S25-S31. 
Herholz, K. and Ebmeier, K. (2011) 'Clinical amyloid imaging in Alzheimer's disease', 
Lancet Neurol, 10(7), pp. 667-70. 
Hughes, C.P., Berg, L., Danziger, W.L., Coben, L.A. and Martin, R.L. (1982) 'A new 
clinical scale for the staging of dementia', Br J Psychiatry, 140, pp. 566-72. 
Huijbers, W., Mormino, E.C., Schultz, A.P., Wigman, S., Ward, A.M., Larvie, M., 
Amariglio, R.E., Marshall, G.A., Rentz, D.M., Johnson, K.A. and Sperling, R.A. 
(2015) 'Amyloid-beta deposition in mild cognitive impairment is associated with 
increased hippocampal activity, atrophy and clinical progression', Brain, 138(Pt 
4), pp. 1023-35. 
Hyman, B.T., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Carrillo, M.C., 
Dickson, D.W., Duyckaerts, C., Frosch, M.P., Masliah, E., Mirra, S.S., Nelson, 
P.T., Schneider, J.A., Thal, D.R., Thies, B., Trojanowski, J.Q., Vinters, H.V. and 
Montine, T.J. (2012) 'National Institute on Aging-Alzheimer's Association 
guidelines for the neuropathologic assessment of Alzheimer's disease', 
Alzheimers Dement, 8(1), pp. 1-13. 
Ihl, R., Frolich, L., Winblad, B., Schneider, L., Burns, A. and Moller, H.J. (2011) 
'World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for 
the biological treatment of Alzheimer's disease and other dementias', World J 
Biol Psychiatry, 12(1), pp. 2-32. 
162 
 
Ikeda, M., Mori, E., Matsuo, K., Nakagawa, M. and Kosaka, K. (2015) 'Donepezil for 
dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory 
phase III trial', Alzheimers Res Ther, 7(1), p. 4. 
Ikonomovic, M.D., Abrahamson, E.E., Price, J.C., Hamilton, R.L., Mathis, C.A., Paljug, 
W.R., Debnath, M.L., Cohen, A.D., Mizukami, K., DeKosky, S.T., Lopez, O.L. 
and Klunk, W.E. (2012) 'Early AD pathology in a C-11 PiB-negative case: a 
PiB-amyloid imaging, biochemical, and immunohistochemical study', Acta 
Neuropathologica, 123(3), pp. 433-447. 
Ikonomovic, M.D., Klunk, W.E., Abrahamson, E.E., Mathis, C.A., Price, J.C., Tsopelas, 
N.D., Lopresti, B.J., Ziolko, S., Bi, W., Paljug, W.R., Debnath, M.L., Hope, 
C.E., Isanski, B.A., Hamilton, R.L. and DeKosky, S.T. (2008) 'Post-mortem 
correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's 
disease', Brain, 131(Pt 6), pp. 1630-45. 
Iranzo, A., Lomena, F., Stockner, H., Valldeoriola, F., Vilaseca, I., Salamero, M., 
Molinuevo, J.L., Serradell, M., Duch, J., Pavia, J., Gallego, J., Seppi, K., Hogl, 
B., Tolosa, E., Poewe, W. and Santamaria, J. (2010) 'Decreased striatal 
dopamine transporter uptake and substantia nigra hyperechogenicity as risk 
markers of synucleinopathy in patients with idiopathic rapid-eye-movement 
sleep behaviour disorder: a prospective study [corrected]', Lancet Neurol, 9(11), 
pp. 1070-7. 
Iranzo, A., Tolosa, E., Gelpi, E., Molinuevo, J.L., Valldeoriola, F., Serradell, M., 
Sanchez-Valle, R., Vilaseca, I., Lomena, F., Vilas, D., Llado, A., Gaig, C. and 
Santamaria, J. (2013) 'Neurodegenerative disease status and post-mortem 
pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an 
observational cohort study', Lancet Neurol, 12(5), pp. 443-53. 
Irwin, D.J., White, M.T., Toledo, J.B., Xie, S.X., Robinson, J.L., Van Deerlin, V., Lee, 
V.M., Leverenz, J.B., Montine, T.J., Duda, J.E., Hurtig, H.I. and Trojanowski, 
J.Q. (2012) 'Neuropathologic substrates of Parkinson disease dementia', Ann 
Neurol, 72(4), pp. 587-98. 
Ishii, K., Hosokawa, C., Hyodo, T., Sakaguchi, K., Usami, K., Shimamoto, K., Hosono, 
M., Yamazoe, Y. and Murakami, T. (2015) 'Regional glucose metabolic 
reduction in dementia with Lewy bodies is independent of amyloid deposition', 
Ann Nucl Med, 29(1), pp. 78-83. 
Jack, C.R., Jr., Barrio, J.R. and Kepe, V. (2013) 'Cerebral amyloid PET imaging in 
Alzheimer's disease', Acta Neuropathol, 126(5), pp. 643-57. 
Jack, C.R., Jr., Wiste, H.J., Weigand, S.D., Rocca, W.A., Knopman, D.S., Mielke, 
M.M., Lowe, V.J., Senjem, M.L., Gunter, J.L., Preboske, G.M., Pankratz, V.S., 
Vemuri, P. and Petersen, R.C. (2014) 'Age-specific population frequencies of 
cerebral beta-amyloidosis and neurodegeneration among people with normal 
cognitive function aged 50-89 years: a cross-sectional study', Lancet Neurol, 
13(10), pp. 997-1005. 
Jagust, W.J., Landau, S.M., Koeppe, R.A., Reiman, E.M., Chen, K., Mathis, C.A., 
Price, J.C., Foster, N.L. and Wang, A.Y. (2015) 'The Alzheimer's Disease 
163 
 
Neuroimaging Initiative 2 PET Core: 2015', Alzheimers Dement, 11(7), pp. 757-
71. 
Jagust, W.J., Landau, S.M., Shaw, L.M., Trojanowski, J.Q., Koeppe, R.A., Reiman, 
E.M., Foster, N.L., Petersen, R.C., Weiner, M.W., Price, J.C., Mathis, C.A. and 
Alzheimer's Disease Neuroimaging, I. (2009) 'Relationships between biomarkers 
in aging and dementia', Neurology, 73(15), pp. 1193-9. 
Jansen, W.J., Ossenkoppele, R., Knol, D.L., Tijms, B.M., Scheltens, P., Verhey, F.R., 
Visser, P.J., Amyloid Biomarker Study Group, Aalten, P., Aarsland, D., Alcolea, 
D., Alexander, M., Almdahl, I.S., Arnold, S.E., Baldeiras, I., Barthel, H., van 
Berckel, B.N., Bibeau, K., Blennow, K., Brooks, D.J., van Buchem, M.A., 
Camus, V., Cavedo, E., Chen, K., Chetelat, G., Cohen, A.D., Drzezga, A., 
Engelborghs, S., Fagan, A.M., Fladby, T., Fleisher, A.S., van der Flier, W.M., 
Ford, L., Forster, S., Fortea, J., Foskett, N., Frederiksen, K.S., Freund-Levi, Y., 
Frisoni, G.B., Froelich, L., Gabryelewicz, T., Gill, K.D., Gkatzima, O., Gomez-
Tortosa, E., Gordon, M.F., Grimmer, T., Hampel, H., Hausner, L., Hellwig, S., 
Herukka, S.K., Hildebrandt, H., Ishihara, L., Ivanoiu, A., Jagust, W.J., 
Johannsen, P., Kandimalla, R., Kapaki, E., Klimkowicz-Mrowiec, A., Klunk, 
W.E., Kohler, S., Koglin, N., Kornhuber, J., Kramberger, M.G., Van Laere, K., 
Landau, S.M., Lee, D.Y., de Leon, M., Lisetti, V., Lleo, A., Madsen, K., Maier, 
W., Marcusson, J., Mattsson, N., de Mendonca, A., Meulenbroek, O., Meyer, 
P.T., Mintun, M.A., Mok, V., Molinuevo, J.L., Mollergard, H.M., Morris, J.C., 
Mroczko, B., Van der Mussele, S., Na, D.L., Newberg, A., Nordberg, A., 
Nordlund, A., Novak, G.P., Paraskevas, G.P., Parnetti, L., Perera, G., Peters, O., 
Popp, J., Prabhakar, S., Rabinovici, G.D., Ramakers, I.H., Rami, L., Resende de 
Oliveira, C., Rinne, J.O., Rodrigue, K.M., et al. (2015) 'Prevalence of cerebral 
amyloid pathology in persons without dementia: a meta-analysis', JAMA, 
313(19), pp. 1924-38. 
Jefferis, J.M., Clarke, M.P., Mosimann, U.P., O'Brien, J.T. and Taylor, J.P. (2013) 'The 
influence of two common dementia types on visual symptoms', Acta 
Ophthalmol, 91(2), pp. e159-60. 
Jellinger, K.A. and Attems, J. (2008) 'Prevalence and impact of vascular and Alzheimer 
pathologies in Lewy body disease', Acta Neuropathol, 115(4), pp. 427-36. 
Jellinger, K.A., Seppi, K. and Wenning, G.K. (2003) 'Clinical and neuropathological 
correlates of Lewy body disease', Acta Neuropathol, 106(2), pp. 188-9. 
Jellinger, K.A., Seppi, K., Wenning, G.K. and Poewe, W. (2002) 'Impact of coexistent 
Alzheimer pathology on the natural history of Parkinson's disease', J Neural 
Transm, 109(3), pp. 329-39. 
Jicha, G.A., Schmitt, F.A., Abner, E., Nelson, P.T., Cooper, G.E., Smith, C.D. and 
Markesbery, W.R. (2010) 'Prodromal clinical manifestations of 
neuropathologically confirmed Lewy body disease', Neurobiol Aging, 31(10), 
pp. 1805-13. 
Johansson, A., Savitcheva, I., Forsberg, A., Engler, H., Langstrom, B., Nordberg, A. 
and Askmark, H. (2008) '[(11)C]-PIB imaging in patients with Parkinson's 
disease: preliminary results', Parkinsonism Relat Disord, 14(4), pp. 345-7. 
164 
 
Johns, M.W. (1991) 'A new method for measuring daytime sleepiness: the Epworth 
sleepiness scale', Sleep, 14(6), pp. 540-5. 
Jokinen, P., Scheinin, N., Aalto, S., Nagren, K., Savisto, N., Parkkola, R., Rokka, J., 
Haaparanta, M., Roytta, M. and Rinne, J.O. (2010) '[(11)C]PIB-, [(18)F]FDG-
PET and MRI imaging in patients with Parkinson's disease with and without 
dementia', Parkinsonism Relat Disord, 16(10), pp. 666-70. 
Kantarci, K., Ferman, T.J., Boeve, B.F., Weigand, S.D., Przybelski, S., Vemuri, P., 
Murray, M.E., Senjem, M.L., Smith, G.E., Knopman, D.S., Petersen, R.C., Jack, 
C.R., Jr., Parisi, J.E. and Dickson, D.W. (2012a) 'Focal atrophy on MRI and 
neuropathologic classification of dementia with Lewy bodies', Neurology, 79(6), 
pp. 553-60. 
Kantarci, K., Lowe, V.J., Boeve, B.F., Weigand, S.D., Senjem, M.L., Przybelski, S.A., 
Dickson, D.W., Parisi, J.E., Knopman, D.S., Smith, G.E., Ferman, T.J., Petersen, 
R.C. and Jack, C.R., Jr. (2012b) 'Multimodality imaging characteristics of 
dementia with Lewy bodies', Neurobiology of aging, 33(9), pp. 2091-105. 
Kantarci, K., Yang, C., Schneider, J.A., Senjem, M.L., Reyes, D.A., Lowe, V.J., Barnes, 
L.L., Aggarwal, N.T., Bennett, D.A., Smith, G.E., Petersen, R.C., Jack, C.R., Jr. 
and Boeve, B.F. (2012c) 'Ante mortem amyloid imaging and beta-amyloid 
pathology in a case with dementia with Lewy bodies', Neurobiology of Aging, 
33(5), pp. 878-885. 
Karran, E., Mercken, M. and De Strooper, B. (2011) 'The amyloid cascade hypothesis 
for Alzheimer's disease: an appraisal for the development of therapeutics', Nat 
Rev Drug Discov, 10(9), pp. 698-712. 
Kasuga, K., Nishizawa, M. and Ikeuchi, T. (2012) 'alpha-Synuclein as CSF and Blood 
Biomarker of Dementia with Lewy Bodies', Int J Alzheimers Dis, 2012, p. 
437025. 
Kaur, B., Harvey, D.J., Decarli, C.S., Zhang, L., Sabbagh, M.N. and Olichney, J.M. 
(2013) 'Extrapyramidal signs by dementia severity in Alzheimer disease and 
dementia with Lewy bodies', Alzheimer Dis Assoc Disord, 27(3), pp. 226-32. 
Kempster, P.A., Williams, D.R., Selikhova, M., Holton, J., Revesz, T. and Lees, A.J. 
(2007) 'Patterns of levodopa response in Parkinson's disease: a clinico-
pathological study', Brain, 130(Pt 8), pp. 2123-8. 
Klein, G., Chiao, P., Barakos, J., Purcell, D., Sampat, M., Oh, J.H., Sevigny, J. and 
Suhy, J. (2014) 'Concordance of quantitative SUVR methods with visual 
assessment of florbetapir PET screening results.', Alzheimer's & Dementia, 10(4 
(Supplement)), p. 399. 
Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., 
Bergstrom, M., Savitcheva, I., Huang, G.F., Estrada, S., Ausen, B., Debnath, 
M.L., Barletta, J., Price, J.C., Sandell, J., Lopresti, B.J., Wall, A., Koivisto, P., 
Antoni, G., Mathis, C.A. and Langstrom, B. (2004) 'Imaging brain amyloid in 
Alzheimer's disease with Pittsburgh Compound-B', Ann Neurol, 55(3), pp. 306-
19. 
165 
 
Knesaurek, K., Machac, J., Zhang, Z. and Rafique, A. (2013) 'Comparison of partial 
volume corrections in amyloid PET brain imaging', J Nucl Med, 54(Supplement 
2), p. 1802. 
Kobayashi, S., Tateno, M., Park, T.W., Utsumi, K., Sohma, H., Ito, Y.M., Kokai, Y. and 
Saito, T. (2011) 'Apolipoprotein E4 frequencies in a Japanese population with 
Alzheimer's disease and dementia with Lewy bodies', PLoS One, 6(4), p. 
e18569. 
Kovari, E., Horvath, J. and Bouras, C. (2009) 'Neuropathology of Lewy body disorders', 
Brain Res Bull, 80(4-5), pp. 203-10. 
Kraybill, M.L., Larson, E.B., Tsuang, D.W., Teri, L., McCormick, W.C., Bowen, J.D., 
Kukull, W.A., Leverenz, J.B. and Cherrier, M.M. (2005) 'Cognitive differences 
in dementia patients with autopsy-verified AD, Lewy body pathology, or both', 
Neurology, 64(12), pp. 2069-73. 
Lambon Ralph, M.A., Powell, J., Howard, D., Whitworth, A.B., Garrard, P. and 
Hodges, J.R. (2001) 'Semantic memory is impaired in both dementia with Lewy 
bodies and dementia of Alzheimer's type: a comparative neuropsychological 
study and literature review', J Neurol Neurosurg Psychiatry, 70(2), pp. 149-56. 
Landau, S. and Juagust, W. (2014) Florbetapir Processing Methods. Available at: 
adni.bitbucket.org (Accessed: 13/01/2015). 
Landau, S.M., Breault, C., Joshi, A.D., Pontecorvo, M., Mathis, C.A., Jagust, W.J., 
Mintun, M.A. and Alzheimer's Disease Neuroimaging, I. (2013) 'Amyloid-beta 
imaging with Pittsburgh compound B and florbetapir: comparing radiotracers 
and quantification methods', J Nucl Med, 54(1), pp. 70-7. 
Landau, S.M., Fero, A., Baker, S.L., Koeppe, R., Mintun, M., Chen, K., Reiman, E.M. 
and Jagust, W.J. (2015) 'Measurement of longitudinal beta-amyloid change with 
18F-florbetapir PET and standardized uptake value ratios', J Nucl Med, 56(4), 
pp. 567-74. 
Landau, S.M., Thomas, B.A., Thurfjell, L., Schmidt, M., Margolin, R., Mintun, M., 
Pontecorvo, M., Baker, S.L., Jagust, W.J. and Alzheimer's Disease 
Neuroimaging, I. (2014) 'Amyloid PET imaging in Alzheimer's disease: a 
comparison of three radiotracers', Eur J Nucl Med Mol Imaging, 41(7), pp. 
1398-407. 
Lashley, T., Holton, J.L., Gray, E., Kirkham, K., O'Sullivan, S.S., Hilbig, A., Wood, 
N.W., Lees, A.J. and Revesz, T. (2008) 'Cortical alpha-synuclein load is 
associated with amyloid-beta plaque burden in a subset of Parkinson's disease 
patients', Acta Neuropathol, 115(4), pp. 417-25. 
Lawton, M.P. and Brody, E.M. (1969) 'Assessment of older people: self-maintaining 
and instrumental activities of daily living', Gerontologist, 9(3), pp. 179-86. 
Lee, D.R., McKeith, I., Mosimann, U., Ghosh-Nodial, A., Grayson, L., Wilson, B. and 
Thomas, A.J. (2014) 'The dementia cognitive fluctuation scale, a new 
psychometric test for clinicians to identify cognitive fluctuations in people with 
dementia', Am J Geriatr Psychiatry, 22(9), pp. 926-35. 
166 
 
Lewy Body Dementia Association (2014) Comprehensive Lewy Body Dementia 
Symptom Checklist. Available at: 
www.lbda.org/sites/default/files/2013_comprehensive_lbd_symptom_checklist.
pdf (Accessed: 10/01/2015). 
Lippa, C.F., Smith, T.W. and Perry, E. (1999) 'Dementia with Lewy bodies: choline 
acetyltransferase parallels nucleus basalis pathology', J Neural Transm, 106(5-
6), pp. 525-35. 
Lucetti, C., Logi, C., Del Dotto, P., Berti, C., Ceravolo, R., Baldacci, F., Dolciotti, C., 
Gambaccini, G., Rossi, G. and Bonuccelli, U. (2010) 'Levodopa response in 
dementia with lewy bodies: a 1-year follow-up study', Parkinsonism Relat 
Disord, 16(8), pp. 522-6. 
Lucotte, G., Loirat, F. and Hazout, S. (1997) 'Pattern of gradient of apolipoprotein E 
allele *4 frequencies in western Europe', Hum Biol, 69(2), pp. 253-62. 
Maetzler, W., Liepelt, I., Reimold, M., Reischl, G., Solbach, C., Becker, C., Schulte, C., 
Leyhe, T., Keller, S., Melms, A., Gasser, T. and Berg, D. (2009) 'Cortical PIB 
binding in Lewy body disease is associated with Alzheimer-like characteristics', 
Neurobiol Dis, 34(1), pp. 107-12. 
Maetzler, W., Reimold, M., Liepelt, I., Solbach, C., Leyhe, T., Schweitzer, K., 
Eschweiler, G.W., Mittelbronn, M., Gaenslen, A., Uebele, M., Reischl, G., 
Gasser, T., Machulla, H.J., Bares, R. and Berg, D. (2008) '[11C]PIB binding in 
Parkinson's disease dementia', Neuroimage, 39(3), pp. 1027-33. 
Mahlknecht, P., Iranzo, A., Hogl, B., Frauscher, B., Muller, C., Santamaria, J., Tolosa, 
E., Serradell, M., Mitterling, T., Gschliesser, V., Goebel, G., Brugger, F., 
Scherfler, C., Poewe, W., Seppi, K. and Sleep Innsbruck Barcelona, G. (2015) 
'Olfactory dysfunction predicts early transition to a Lewy body disease in 
idiopathic RBD', Neurology, 84(7), pp. 654-8. 
Marquie, M., Locascio, J.J., Rentz, D.M., Becker, J.A., Hedden, T., Johnson, K.A., 
Growdon, J.H. and Gomperts, S.N. (2014) 'Striatal and extrastriatal dopamine 
transporter levels relate to cognition in Lewy body diseases: an (11)C altropane 
positron emission tomography study', Alzheimers Res Ther, 6(5-8), p. 52. 
Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M. and 
Mucke, L. (2001) 'beta-amyloid peptides enhance alpha-synuclein accumulation 
and neuronal deficits in a transgenic mouse model linking Alzheimer's disease 
and Parkinson's disease', Proc Natl Acad Sci U S A, 98(21), pp. 12245-50. 
Matthews, F.E., Arthur, A., Barnes, L.E., Bond, J., Jagger, C., Robinson, L. and Brayne, 
C. (2013) 'A two-decade comparison of prevalence of dementia in individuals 
aged 65 years and older from three geographical areas of England: results of the 
Cognitive Function and Ageing Study I and II', Lancet, 382(9902), pp. 1405-12. 
Mattila, P.M., Rinne, J.O., Helenius, H., Dickson, D.W. and Roytta, M. (2000) 'Alpha-
synuclein-immunoreactive cortical Lewy bodies are associated with cognitive 
impairment in Parkinson's disease', Acta Neuropathol, 100(3), pp. 285-90. 
167 
 
McKeith, I. (2009) 'Commentary: DLB and PDD: the same or different? Is there a 
debate?', Int Psychogeriatr, 21(2), pp. 220-4. 
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., 
Ferrara, R. and Spiegel, R. (2000) 'Efficacy of rivastigmine in dementia with 
Lewy bodies: a randomised, double-blind, placebo-controlled international 
study', Lancet, 356(9247), pp. 2031-6. 
McKeith, I., Fairbairn, A., Perry, R., Thompson, P. and Perry, E. (1992) 'Neuroleptic 
sensitivity in patients with senile dementia of Lewy body type', BMJ, 305(6855), 
pp. 673-8. 
McKeith, I., O'Brien, J., Walker, Z., Tatsch, K., Booij, J., Darcourt, J., Padovani, A., 
Giubbini, R., Bonuccelli, U., Volterrani, D., Holmes, C., Kemp, P., Tabet, N., 
Meyer, I. and Reininger, C. (2007) 'Sensitivity and specificity of dopamine 
transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a 
phase III, multicentre study', Lancet Neurol, 6(4), pp. 305-13. 
McKeith, I.G., Dickson, D.W., Lowe, J., Emre, M., O'Brien, J.T., Feldman, H., 
Cummings, J., Duda, J.E., Lippa, C., Perry, E.K., Aarsland, D., Arai, H., 
Ballard, C.G., Boeve, B., Burn, D.J., Costa, D., Del Ser, T., Dubois, B., Galasko, 
D., Gauthier, S., Goetz, C.G., Gomez-Tortosa, E., Halliday, G., Hansen, L.A., 
Hardy, J., Iwatsubo, T., Kalaria, R.N., Kaufer, D., Kenny, R.A., Korczyn, A., 
Kosaka, K., Lee, V.M., Lees, A., Litvan, I., Londos, E., Lopez, O.L., 
Minoshima, S., Mizuno, Y., Molina, J.A., Mukaetova-Ladinska, E.B., Pasquier, 
F., Perry, R.H., Schulz, J.B., Trojanowski, J.Q. and Yamada, M. (2005) 
'Diagnosis and management of dementia with Lewy bodies: third report of the 
DLB Consortium', Neurology, 65(12), pp. 1863-1872. 
McKeith, I.G., Galasko, D., Kosaka, K., Perry, E.K., Dickson, D.W., Hansen, L.A., 
Salmon, D.P., Lowe, J., Mirra, S.S., Byrne, E.J., Lennox, G., Quinn, N.P., 
Edwardson, J.A., Ince, P.G., Bergeron, C., Burns, A., Miller, B.L., Lovestone, 
S., Collerton, D., Jansen, E.N., Ballard, C., de Vos, R.A., Wilcock, G.K., 
Jellinger, K.A. and Perry, R.H. (1996) 'Consensus guidelines for the clinical and 
pathologic diagnosis of dementia with Lewy bodies (DLB): report of the 
consortium on DLB international workshop', Neurology, 47(5), pp. 1113-24. 
McKenna, P. and Warrington, E.K. (2007) Graded naming test : object picture book. 
2nd rev. edn. Cambridge: Cambridge Cognition Ltd. 
McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Jr., Kawas, 
C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., 
Morris, J.C., Rossor, M.N., Scheltens, P., Carrillo, M.C., Thies, B., Weintraub, 
S. and Phelps, C.H. (2011) 'The diagnosis of dementia due to Alzheimer's 
disease: recommendations from the National Institute on Aging-Alzheimer's 
Association workgroups on diagnostic guidelines for Alzheimer's disease', 
Alzheimers Dement, 7(3), pp. 263-9. 
Meeus, B., Theuns, J. and Van Broeckhoven, C. (2012) 'The genetics of dementia with 
Lewy bodies: what are we missing?', Arch Neurol, 69(9), pp. 1113-8. 
Merdes, A.R., Hansen, L.A., Jeste, D.V., Galasko, D., Hofstetter, C.R., Ho, G.J., Thal, 
L.J. and Corey-Bloom, J. (2003) 'Influence of Alzheimer pathology on clinical 
168 
 
diagnostic accuracy in dementia with Lewy bodies', Neurology, 60(10), pp. 
1586-90. 
Metzler-Baddeley, C. (2007) 'A review of cognitive impairments in dementia with 
Lewy bodies relative to Alzheimer's disease and Parkinson's disease with 
dementia', Cortex, 43(5), pp. 583-600. 
Miller, M.D., Paradis, C.F., Houck, P.R., Mazumdar, S., Stack, J.A., Rifai, A.H., 
Mulsant, B. and Reynolds, C.F. (1992) 'Rating chronic medical illness burden in 
geropsychiatric practice and research: application of the Cumulative Illness 
Rating Scale', Psychiatry Res, 41(3), pp. 237-48. 
Minguez-Castellanos, A., Chamorro, C.E., Escamilla-Sevilla, F., Ortega-Moreno, A., 
Rebollo, A.C., Gomez-Rio, M., Concha, A. and Munoz, D.G. (2007) 'Do alpha-
synuclein aggregates in autonomic plexuses predate Lewy body disorders?: a 
cohort study', Neurology, 68(23), pp. 2012-8. 
Mioshi, E., Dawson, K., Mitchell, J., Arnold, R. and Hodges, J.R. (2006) 'The 
Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test 
battery for dementia screening', Int J Geriatr Psychiatry, 21(11), pp. 1078-85. 
Mirra, S.S., Heyman, A., McKeel, D., Sumi, S.M., Crain, B.J., Brownlee, L.M., Vogel, 
F.S., Hughes, J.P., van Belle, G. and Berg, L. (1991) 'The Consortium to 
Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization 
of the neuropathologic assessment of Alzheimer's disease', Neurology, 41(4), pp. 
479-86. 
Moghbel, M.C., Saboury, B., Basu, S., Metzler, S.D., Torigian, D.A., Langstrom, B. 
and Alavi, A. (2012) 'Amyloid-beta imaging with PET in Alzheimer's disease: is 
it feasible with current radiotracers and technologies?', Eur J Nucl Med Mol 
Imaging, 39(2), pp. 202-8. 
Molano, J., Boeve, B., Ferman, T., Smith, G., Parisi, J., Dickson, D., Knopman, D., 
Graff-Radford, N., Geda, Y., Lucas, J., Kantarci, K., Shiung, M., Jack, C., 
Silber, M., Pankratz, V.S. and Petersen, R. (2010) 'Mild cognitive impairment 
associated with limbic and neocortical Lewy body disease: a clinicopathological 
study', Brain, 133(Pt 2), pp. 540-56. 
Molloy, S., McKeith, I.G., O'Brien, J.T. and Burn, D.J. (2005) 'The role of levodopa in 
the management of dementia with Lewy bodies', J Neurol Neurosurg 
Psychiatry, 76(9), pp. 1200-3. 
Morgan, S., Kemp, P., Booij, J., Costa, D.C., Padayachee, S., Lee, L., Barber, C., 
Carter, J. and Walker, Z. (2012) 'Differentiation of frontotemporal dementia 
from dementia with Lewy bodies using FP-CIT SPECT', J Neurol Neurosurg 
Psychiatry, 83(11), pp. 1063-70. 
Mori, E., Ikeda, M. and Kosaka, K. (2012) 'Donepezil for dementia with Lewy bodies: a 
randomized, placebo-controlled trial', Ann Neurol, 72(1), pp. 41-52. 
Mori, E., Ikeda, M., Nagai, R., Matsuo, K., Nakagawa, M. and Kosaka, K. (2015) 
'Long-term donepezil use for dementia with Lewy bodies: results from an open-
label extension of Phase III trial', Alzheimers Res Ther, 7(1), p. 5. 
169 
 
Morris, J.C. (1993) 'The Clinical Dementia Rating (CDR): current version and scoring 
rules', Neurology, 43(11), pp. 2412-4. 
Mosimann, U.P., Collerton, D., Dudley, R., Meyer, T.D., Graham, G., Dean, J.L., 
Bearn, D., Killen, A., Dickinson, L., Clarke, M.P. and McKeith, I.G. (2008) 'A 
semi-structured interview to assess visual hallucinations in older people', Int J 
Geriatr Psychiatry, 23(7), pp. 712-8. 
Nedelska, Z., Ferman, T.J., Boeve, B.F., Przybelski, S.A., Lesnick, T.G., Murray, M.E., 
Gunter, J.L., Senjem, M.L., Vemuri, P., Smith, G.E., Geda, Y.E., Graff-Radford, 
J., Knopman, D.S., Petersen, R.C., Parisi, J.E., Dickson, D.W., Jack, C.R., Jr. 
and Kantarci, K. (2015a) 'Pattern of brain atrophy rates in autopsy-confirmed 
dementia with Lewy bodies', Neurobiol Aging, 36(1), pp. 452-61. 
Nedelska, Z., Schwarz, C.G., Boeve, B.F., Lowe, V.J., Reid, R.I., Przybelski, S.A., 
Lesnick, T.G., Gunter, J.L., Senjem, M.L., Ferman, T.J., Smith, G.E., Geda, 
Y.E., Knopman, D.S., Petersen, R.C., Jack, C.R., Jr. and Kantarci, K. (2015b) 
'White matter integrity in dementia with Lewy bodies: a voxel-based analysis of 
diffusion tensor imaging', Neurobiol Aging, 36(6), pp. 2010-7. 
Nelson, P., Jicha, G., Kryscio, R., Abner, E., Schmitt, F., Cooper, G., Xu, L., Smith, C. 
and Markesbery, W. (2010) 'Low sensitivity in clinical diagnoses of dementia 
with Lewy bodies', Journal of Neurology, 257(3), pp. 359-366. 
Nelson, P.T., Alafuzoff, I., Bigio, E.H., Bouras, C., Braak, H., Cairns, N.J., Castellani, 
R.J., Crain, B.J., Davies, P., Del Tredici, K., Duyckaerts, C., Frosch, M.P., 
Haroutunian, V., Hof, P.R., Hulette, C.M., Hyman, B.T., Iwatsubo, T., Jellinger, 
K.A., Jicha, G.A., Kovari, E., Kukull, W.A., Leverenz, J.B., Love, S., 
Mackenzie, I.R., Mann, D.M., Masliah, E., McKee, A.C., Montine, T.J., Morris, 
J.C., Schneider, J.A., Sonnen, J.A., Thal, D.R., Trojanowski, J.Q., Troncoso, 
J.C., Wisniewski, T., Woltjer, R.L. and Beach, T.G. (2012) 'Correlation of 
Alzheimer disease neuropathologic changes with cognitive status: a review of 
the literature', J Neuropathol Exp Neurol, 71(5), pp. 362-81. 
Nelson, P.T., Kryscio, R.J., Jicha, G.A., Abner, E.L., Schmitt, F.A., Xu, L.O., Cooper, 
G., Smith, C.D. and Markesbery, W.R. (2009) 'Relative preservation of MMSE 
scores in autopsy-proven dementia with Lewy bodies', Neurology, 73(14), pp. 
1127-33. 
O'Brien, J.T., Firbank, M.J., Davison, C., Barnett, N., Bamford, C., Donaldson, C., 
Olsen, K., Herholz, K., Williams, D. and Lloyd, J. (2014a) '18F-FDG PET and 
Perfusion SPECT in the Diagnosis of Alzheimer and Lewy Body Dementias', J 
Nucl Med, 55(12), pp. 1959-65. 
O'Brien, J.T., McKeith, I.G., Walker, Z., Tatsch, K., Booij, J., Darcourt, J., Marquardt, 
M. and Reininger, C. (2009) 'Diagnostic accuracy of 123I-FP-CIT SPECT in 
possible dementia with Lewy bodies', Br J Psychiatry, 194(1), pp. 34-9. 
O'Brien, J.T., Oertel, W.H., McKeith, I.G., Grosset, D.G., Walker, Z., Tatsch, K., 
Tolosa, E., Sherwin, P.F. and Grachev, I.D. (2014b) 'Is ioflupane I123 injection 
diagnostically effective in patients with movement disorders and dementia? 
Pooled analysis of four clinical trials', BMJ Open, 4(7), p. e005122. 
170 
 
Olazaran, J., Reisberg, B., Clare, L., Cruz, I., Pena-Casanova, J., Del Ser, T., Woods, 
B., Beck, C., Auer, S., Lai, C., Spector, A., Fazio, S., Bond, J., Kivipelto, M., 
Brodaty, H., Rojo, J.M., Collins, H., Teri, L., Mittelman, M., Orrell, M., 
Feldman, H.H. and Muniz, R. (2010) 'Nonpharmacological therapies in 
Alzheimer's disease: a systematic review of efficacy', Dement Geriatr Cogn 
Disord, 30(2), pp. 161-78. 
Olichney, J.M., Galasko, D., Salmon, D.P., Hofstetter, C.R., Hansen, L.A., Katzman, R. 
and Thal, L.J. (1998) 'Cognitive decline is faster in Lewy body variant than in 
Alzheimer's disease', Neurology, 51(2), pp. 351-7. 
Ossenkoppele, R., Jansen, W.J., Rabinovici, G.D., Knol, D.L., van der Flier, W.M., van 
Berckel, B.N., Scheltens, P., Visser, P.J., Amyloid PET Study Group, Verfaillie, 
S.C., Zwan, M.D., Adriaanse, S.M., Lammertsma, A.A., Barkhof, F., Jagust, 
W.J., Miller, B.L., Rosen, H.J., Landau, S.M., Villemagne, V.L., Rowe, C.C., 
Lee, D.Y., Na, D.L., Seo, S.W., Sarazin, M., Roe, C.M., Sabri, O., Barthel, H., 
Koglin, N., Hodges, J., Leyton, C.E., Vandenberghe, R., van Laere, K., Drzezga, 
A., Forster, S., Grimmer, T., Sanchez-Juan, P., Carril, J.M., Mok, V., Camus, V., 
Klunk, W.E., Cohen, A.D., Meyer, P.T., Hellwig, S., Newberg, A., Frederiksen, 
K.S., Fleisher, A.S., Mintun, M.A., Wolk, D.A., Nordberg, A., Rinne, J.O., 
Chetelat, G., Lleo, A., Blesa, R., Fortea, J., Madsen, K., Rodrigue, K.M. and 
Brooks, D.J. (2015) 'Prevalence of amyloid PET positivity in dementia 
syndromes: a meta-analysis', JAMA, 313(19), pp. 1939-49. 
Palma, J.A. and Kaufmann, H. (2014) 'Autonomic disorders predicting Parkinson's 
disease', Parkinsonism Relat Disord, 20 Suppl 1, pp. S94-8. 
Palmqvist, S., Hertze, J., Minthon, L., Wattmo, C., Zetterberg, H., Blennow, K., 
Londos, E. and Hansson, O. (2012) 'Comparison of brief cognitive tests and CSF 
biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-
year follow-up study', PLoS One, 7(6), p. e38639. 
Papathanasiou, N.D., Boutsiadis, A., Dickson, J. and Bomanji, J.B. (2012) 'Diagnostic 
accuracy of (123)I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-
analysis of published studies', Parkinsonism Relat Disord, 18(3), pp. 225-9. 
Pardo, J.V., Lee, J.T., Kuskowski, M.A., Munch, K.R., Carlis, J.V., Sheikh, S.A., 
Surerus, C., Lewis, S.M., McCarten, J.R., Fink, H., McPherson, S., Shah, H.H., 
Rottunda, S. and Dysken, M.W. (2010) 'Fluorodeoxyglucose positron emission 
tomography of mild cognitive impairment with clinical follow-up at 3 years', 
Alzheimers Dement, 6(4), pp. 326-33. 
Parkkinen, L., Kauppinen, T., Pirttila, T., Autere, J.M. and Alafuzoff, I. (2005) 'Alpha-
synuclein pathology does not predict extrapyramidal symptoms or dementia', 
Ann Neurol, 57(1), pp. 82-91. 
Parkkinen, L., Pirttila, T. and Alafuzoff, I. (2008) 'Applicability of current 
staging/categorization of alpha-synuclein pathology and their clinical relevance', 
Acta Neuropathol, 115(4), pp. 399-407. 
Peraza, L.R., Kaiser, M., Firbank, M., Graziadio, S., Bonanni, L., Onofrj, M., Colloby, 
S.J., Blamire, A., O'Brien, J. and Taylor, J.P. (2014) 'fMRI resting state 
171 
 
networks and their association with cognitive fluctuations in dementia with 
Lewy bodies', Neuroimage Clin, 4, pp. 558-65. 
Petersen, R.C. (2004) 'Mild cognitive impairment as a diagnostic entity', J Intern Med, 
256(3), pp. 183-94. 
Petersen, R.C., Doody, R., Kurz, A., Mohs, R.C., Morris, J.C., Rabins, P.V., Ritchie, K., 
Rossor, M., Thal, L. and Winblad, B. (2001) 'Current concepts in mild cognitive 
impairment', Arch Neurol, 58(12), pp. 1985-92. 
Petersen, R.C., Parisi, J.E., Dickson, D.W., Johnson, K.A., Knopman, D.S., Boeve, 
B.F., Jicha, G.A., Ivnik, R.J., Smith, G.E., Tangalos, E.G., Braak, H. and 
Kokmen, E. (2006) 'Neuropathologic features of amnestic mild cognitive 
impairment', Arch Neurol, 63(5), pp. 665-72. 
Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Tangalos, E.G. and Kokmen, E. 
(1999) 'Mild cognitive impairment: clinical characterization and outcome', Arch 
Neurol, 56(3), pp. 303-8. 
Petrou, M., Bohnen, N.I., Muller, M.L., Koeppe, R.A., Albin, R.L. and Frey, K.A. 
(2012) 'Abeta-amyloid deposition in patients with Parkinson disease at risk for 
development of dementia', Neurology, 79(11), pp. 1161-7. 
Petrou, M., Dwamena, B.A., Foerster, B.R., MacEachern, M.P., Bohnen, N.I., Muller, 
M.L., Albin, R.L. and Frey, K.A. (2015) 'Amyloid deposition in Parkinson's 
disease and cognitive impairment: a systematic review', Mov Disord, 30(7), pp. 
928-35. 
Pletnikova, O., West, N., Lee, M.K., Rudow, G.L., Skolasky, R.L., Dawson, T.M., 
Marsh, L. and Troncoso, J.C. (2005) 'Abeta deposition is associated with 
enhanced cortical alpha-synuclein lesions in Lewy body diseases', Neurobiol 
Aging, 26(8), pp. 1183-92. 
Postuma, R.B., Gagnon, J.F., Bertrand, J.A., Genier Marchand, D. and Montplaisir, J.Y. 
(2015a) 'Parkinson risk in idiopathic REM sleep behavior disorder: preparing for 
neuroprotective trials', Neurology, 84(11), pp. 1104-13. 
Postuma, R.B., Gagnon, J.F., Pelletier, A. and Montplaisir, J. (2013) 'Prodromal 
autonomic symptoms and signs in Parkinson's disease and dementia with Lewy 
bodies', Mov Disord, 28(5), pp. 597-604. 
Postuma, R.B., Gagnon, J.F., Vendette, M., Desjardins, C. and Montplaisir, J.Y. (2011) 
'Olfaction and color vision identify impending neurodegeneration in rapid eye 
movement sleep behavior disorder', Ann Neurol, 69(5), pp. 811-8. 
Postuma, R.B., Gagnon, J.F., Vendette, M., Fantini, M.L., Massicotte-Marquez, J. and 
Montplaisir, J. (2009) 'Quantifying the risk of neurodegenerative disease in 
idiopathic REM sleep behavior disorder', Neurology, 72(15), pp. 1296-300. 
Postuma, R.B., Iranzo, A., Hogl, B., Arnulf, I., Ferini-Strambi, L., Manni, R., 
Miyamoto, T., Oertel, W., Dauvilliers, Y., Ju, Y.E., Puligheddu, M., Sonka, K., 
Pelletier, A., Santamaria, J., Frauscher, B., Leu-Semenescu, S., Zucconi, M., 
Terzaghi, M., Miyamoto, M., Unger, M.M., Carlander, B., Fantini, M.L. and 
172 
 
Montplaisir, J.Y. (2015b) 'Risk factors for neurodegeneration in idiopathic rapid 
eye movement sleep behavior disorder: a multicenter study', Ann Neurol, 77(5), 
pp. 830-9. 
Postuma, R.B., Lanfranchi, P.A., Blais, H., Gagnon, J.F. and Montplaisir, J.Y. (2010) 
'Cardiac autonomic dysfunction in idiopathic REM sleep behavior disorder', 
Mov Disord, 25(14), pp. 2304-10. 
Postuma, R.B., Lang, A.E., Gagnon, J.F., Pelletier, A. and Montplaisir, J.Y. (2012) 
'How does parkinsonism start? Prodromal parkinsonism motor changes in 
idiopathic REM sleep behaviour disorder', Brain, 135(Pt 6), pp. 1860-70. 
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W. and Ferri, C.P. (2013) 'The 
global prevalence of dementia: a systematic review and metaanalysis', 
Alzheimers Dement, 9(1), pp. 63-75. 
Quigley, H., Colloby, S.J. and O'Brien, J.T. (2011) 'PET imaging of brain amyloid in 
dementia: a review', International Journal of Geriatric Psychiatry, 26(10), pp. 
991-999. 
Reitz, C., Brayne, C. and Mayeux, R. (2011) 'Epidemiology of Alzheimer disease', Nat 
Rev Neurol, 7(3), pp. 137-52. 
Reitz, C. and Mayeux, R. (2014) 'Alzheimer disease: epidemiology, diagnostic criteria, 
risk factors and biomarkers', Biochem Pharmacol, 88(4), pp. 640-51. 
Revicki, D.A., Rentz, A.M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N.J. and 
Tack, J. (2003) 'Development and validation of a patient-assessed gastroparesis 
symptom severity measure: the Gastroparesis Cardinal Symptom Index', Aliment 
Pharmacol Ther, 18(1), pp. 141-50. 
Rey, A. (1964) L'examen clinique en psychologie. Paris: Presses Universitaires de 
France. 
Ricci, M., Guidoni, S.V., Sepe-Monti, M., Bomboi, G., Antonini, G., Blundo, C. and 
Giubilei, F. (2009) 'Clinical findings, functional abilities and caregiver distress 
in the early stage of dementia with Lewy bodies (DLB) and Alzheimer's disease 
(AD)', Arch Gerontol Geriatr, 49(2), pp. e101-4. 
Roselli, F., Pisciotta, N.M., Perneczky, R., Pennelli, M., Aniello, M.S., De Caro, M.F., 
Ferrannini, E., Tartaglione, B., Defazio, G., Rubini, G. and Livrea, P. (2009) 
'Severity of neuropsychiatric symptoms and dopamine transporter levels in 
dementia with Lewy bodies: a 123I-FP-CIT SPECT study', Mov Disord, 24(14), 
pp. 2097-103. 
Rosen, C., Hansson, O., Blennow, K. and Zetterberg, H. (2013) 'Fluid biomarkers in 
Alzheimer's disease - current concepts', Mol Neurodegener, 8, p. 20. 
Rosenberg, P.B., Wong, D.F., Edell, S.L., Ross, J.S., Joshi, A.D., Brasic, J.R., Zhou, Y., 
Raymont, V., Kumar, A., Ravert, H.T., Dannals, R.F., Pontecorvo, M.J., 
Skovronsky, D.M. and Lyketsos, C.G. (2013) 'Cognition and Amyloid Load in 
Alzheimer Disease Imaged With Florbetapir F 18(AV-45) Positron Emission 
Tomography', Am J Geriatr Psychiatry, 21(3), pp. 272-8. 
173 
 
Rowan, E., McKeith, I.G., Saxby, B.K., O'Brien, J.T., Burn, D., Mosimann, U., Newby, 
J., Daniel, S., Sanders, J. and Wesnes, K. (2007) 'Effects of donepezil on central 
processing speed and attentional measures in Parkinson's disease with dementia 
and dementia with Lewy bodies', Dement Geriatr Cogn Disord, 23(3), pp. 161-
7. 
Rowe, C.C., Bourgeat, P., Ellis, K.A., Brown, B., Lim, Y.Y., Mulligan, R., Jones, G., 
Maruff, P., Woodward, M., Price, R., Robins, P., Tochon-Danguy, H., O'Keefe, 
G., Pike, K.E., Yates, P., Szoeke, C., Salvado, O., Macaulay, S.L., O'Meara, T., 
Head, R., Cobiac, L., Savage, G., Martins, R., Masters, C.L., Ames, D. and 
Villemagne, V.L. (2013) 'Predicting Alzheimer disease with beta-amyloid 
imaging: results from the Australian imaging, biomarkers, and lifestyle study of 
ageing', Ann Neurol, 74(6), pp. 905-13. 
Rowe, C.C., Ng, S., Ackermann, U., Gong, S.J., Pike, K., Savage, G., Cowie, T.F., 
Dickinson, K.L., Maruff, P., Darby, D., Smith, C., Woodward, M., Merory, J., 
Tochon-Danguy, H., O'Keefe, G., Klunk, W.E., Mathis, C.A., Price, J.C., 
Masters, C.L. and Villemagne, V.L. (2007) 'Imaging beta-amyloid burden in 
aging and dementia', Neurology, 68(20), pp. 1718-25. 
Rowe, C.C. and Villemagne, V.L. (2011) 'Brain amyloid imaging', J Nucl Med, 52(11), 
pp. 1733-40. 
Sabbagh, M.N., Adler, C.H., Lahti, T.J., Connor, D.J., Vedders, L., Peterson, L.K., 
Caviness, J.N., Shill, H.A., Sue, L.I., Ziabreva, I., Perry, E., Ballard, C.G., 
Aarsland, D., Walker, D.G. and Beach, T.G. (2009) 'Parkinson disease with 
dementia: comparing patients with and without Alzheimer pathology', Alzheimer 
Dis Assoc Disord, 23(3), pp. 295-7. 
Saito, Y. and Murayama, S. (2007) 'Neuropathology of mild cognitive impairment', 
Neuropathology, 27(6), pp. 578-84. 
Sanchez-Cubillo, I., Perianez, J.A., Adrover-Roig, D., Rodriguez-Sanchez, J.M., Rios-
Lago, M., Tirapu, J. and Barcelo, F. (2009) 'Construct validity of the Trail 
Making Test: role of task-switching, working memory, inhibition/interference 
control, and visuomotor abilities', J Int Neuropsychol Soc, 15(3), pp. 438-50. 
Sarazin, M., Dorothee, G., de Souza, L.C. and Aucouturier, P. (2013) 'Immunotherapy 
in Alzheimer's disease: do we have all the pieces of the puzzle?', Biol 
Psychiatry, 74(5), pp. 329-32. 
Schade, S. and Mollenhauer, B. (2014) 'Biomarkers in biological fluids for dementia 
with Lewy bodies', Alzheimers Res Ther, 6(5-8), p. 72. 
Schenck, C.H., Boeve, B.F. and Mahowald, M.W. (2013) 'Delayed emergence of a 
parkinsonian disorder or dementia in 81% of older males initially diagnosed 
with idiopathic REM sleep behavior disorder (RBD): 16year update on a 
previously reported series', Sleep Med, 14(8), pp. 744-748. 
Schenck, C.H. and Mahowald, M.W. (2002) 'REM sleep behavior disorder: clinical, 
developmental, and neuroscience perspectives 16 years after its formal 
identification in SLEEP', Sleep, 25(2), pp. 120-38. 
174 
 
Schneider, J.A., Arvanitakis, Z., Bang, W. and Bennett, D.A. (2007) 'Mixed brain 
pathologies account for most dementia cases in community-dwelling older 
persons', Neurology, 69(24), pp. 2197-204. 
Schneider, J.A., Arvanitakis, Z., Leurgans, S.E. and Bennett, D.A. (2009) 'The 
neuropathology of probable Alzheimer disease and mild cognitive impairment', 
Ann Neurol, 66(2), pp. 200-8. 
Schneider, J.A., Arvanitakis, Z., Yu, L., Boyle, P.A., Leurgans, S.E. and Bennett, D.A. 
(2012) 'Cognitive impairment, decline and fluctuations in older community-
dwelling subjects with Lewy bodies', Brain, 135(Pt 10), pp. 3005-14. 
Schneider, L.S., Dagerman, K.S. and Insel, P. (2005) 'Risk of death with atypical 
antipsychotic drug treatment for dementia: meta-analysis of randomized 
placebo-controlled trials', JAMA, 294(15), pp. 1934-43. 
Schreiber, S., Landau, S.M., Fero, A., Schreiber, F., Jagust, W.J. and Alzheimer's 
Disease Neuroimaging, I. (2015) 'Comparison of Visual and Quantitative 
Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild 
Cognitive Impairment Outcomes', JAMA Neurol. 
Schulz-Schaeffer, W.J. (2010) 'The synaptic pathology of alpha-synuclein aggregation 
in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease 
dementia', Acta Neuropathol, 120(2), pp. 131-43. 
Selikhova, M., Williams, D.R., Kempster, P.A., Holton, J.L., Revesz, T. and Lees, A.J. 
(2009) 'A clinico-pathological study of subtypes in Parkinson's disease', Brain, 
132(Pt 11), pp. 2947-57. 
Serby, M., Brickman, A.M., Haroutunian, V., Purohit, D.P., Marin, D., Lantz, M., 
Mohs, R.C. and Davis, K.L. (2003) 'Cognitive burden and excess Lewy-body 
pathology in the Lewy-body variant of Alzheimer disease', Am J Geriatr 
Psychiatry, 11(3), pp. 371-4. 
Shimada, H., Shinotoh, H., Hirano, S., Miyoshi, M., Sato, K., Tanaka, N., Ota, T., 
Fukushi, K., Irie, T., Ito, H., Higuchi, M., Kuwabara, S. and Suhara, T. (2013) 
'beta-Amyloid in Lewy body disease is related to Alzheimer's disease-like 
atrophy', Mov Disord, 28(2), pp. 169-75. 
Siderowf, A., Pontecorvo, M.J., Shill, H.A., Mintun, M.A., Arora, A., Joshi, A.D., Lu, 
M., Adler, C.H., Galasko, D., Liebsack, C., Skovronsky, D.M. and Sabbagh, 
M.N. (2014) 'PET imaging of amyloid with Florbetapir F 18 and PET imaging 
of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with 
Alzheimer's disease and Lewy body disorders', BMC Neurol, 14, p. 79. 
Siepel, F.J., Rongve, A., Buter, T.C., Beyer, M.K., Ballard, C.G., Booij, J. and 
Aarsland, D. (2013) '(123I)FP-CIT SPECT in suspected dementia with Lewy 
bodies: a longitudinal case study', BMJ open, 3(4), p. e002642. 
Sinha, N., Firbank, M. and O'Brien, J.T. (2012) 'Biomarkers in dementia with Lewy 
bodies: a review', Int J Geriatr Psychiatry, 27(5), pp. 443-53. 
175 
 
Slaets, S., Van Acker, F., Versijpt, J., Hauth, L., Goeman, J., Martin, J.J., De Deyn, P.P. 
and Engelborghs, S. (2015) 'Diagnostic value of MIBG cardiac scintigraphy for 
differential dementia diagnosis', Int J Geriatr Psychiatry, 30(8), pp. 864-9. 
Sojkova, J., Driscoll, I., Iacono, D., Zhou, Y., Codispoti, K.E., Kraut, M.A., Ferrucci, 
L., Pletnikova, O., Mathis, C.A., Klunk, W.E., O'Brien, R.J., Wong, D.F., 
Troncoso, J.C. and Resnick, S.M. (2011) 'In vivo fibrillar beta-amyloid detected 
using [11C]PiB positron emission tomography and neuropathologic assessment 
in older adults', Arch Neurol, 68(2), pp. 232-40. 
Stevens, T., Livingston, G., Kitchen, G., Manela, M., Walker, Z. and Katona, C. (2002) 
'Islington study of dementia subtypes in the community', British Journal of 
Psychiatry, 180, pp. 270-6. 
Stubendorff, K., Aarsland, D., Minthon, L. and Londos, E. (2012) 'The impact of 
autonomic dysfunction on survival in patients with dementia with Lewy bodies 
and Parkinson's disease with dementia', PLoS One, 7(10), p. e45451. 
Svedberg, M.M., Hall, H., Hellstrom-Lindahl, E., Estrada, S., Guan, Z., Nordberg, A. 
and Langstrom, B. (2009) '[(11)C]PIB-amyloid binding and levels of Abeta40 
and Abeta42 in postmortem brain tissue from Alzheimer patients', Neurochem 
Int, 54(5-6), pp. 347-57. 
Tan, C.C., Yu, J.T., Wang, H.F., Tan, M.S., Meng, X.F., Wang, C., Jiang, T., Zhu, X.C. 
and Tan, L. (2014) 'Efficacy and safety of donepezil, galantamine, rivastigmine, 
and memantine for the treatment of Alzheimer's disease: a systematic review and 
meta-analysis', J Alzheimers Dis, 41(2), pp. 615-31. 
Taylor, J.P., Colloby, S.J., McKeith, I.G., Burn, D.J., Williams, D., Patterson, J. and 
O'Brien, J.T. (2007) 'Cholinesterase inhibitor use does not significantly 
influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer's disease 
from dementia with Lewy bodies', J Neurol Neurosurg Psychiatry, 78(10), pp. 
1069-71. 
Thal, D.R., Rub, U., Orantes, M. and Braak, H. (2002) 'Phases of A beta-deposition in 
the human brain and its relevance for the development of AD', Neurology, 
58(12), pp. 1791-800. 
Tiraboschi, P., Attems, J., Thomas, A., Brown, A., Jaros, E., Lett, D.J., Ossola, M., 
Perry, R.H., Ramsay, L., Walker, L. and McKeith, I.G. (2015) 'Clinicians' ability 
to diagnose dementia with Lewy bodies is not affected by beta-amyloid load', 
Neurology, 84(5), pp. 496-9. 
Tiraboschi, P., Hansen, L.A., Alford, M., Merdes, A., Masliah, E., Thal, L.J. and Corey-
Bloom, J. (2002) 'Early and widespread cholinergic losses differentiate dementia 
with Lewy bodies from Alzheimer disease', Archives of general psychiatry, 
59(10), pp. 946-51. 
Tombaugh, T.N., Kozak, J. and Rees, L. (1999) 'Normative data stratified by age and 
education for two measures of verbal fluency: FAS and animal naming', Arch 
Clin Neuropsychol, 14(2), pp. 167-77. 
176 
 
Treglia, G. and Cason, E. (2012) 'Diagnostic performance of myocardial innervation 
imaging using MIBG scintigraphy in differential diagnosis between dementia 
with lewy bodies and other dementias: a systematic review and a meta-analysis', 
J Neuroimaging, 22(2), pp. 111-7. 
Troster, A.I. (2008) 'Neuropsychological characteristics of dementia with Lewy bodies 
and Parkinson's disease with dementia: differentiation, early detection, and 
implications for "mild cognitive impairment" and biomarkers', Neuropsychology 
review, 18(1), pp. 103-19. 
Tsuang, D., Leverenz, J.B., Lopez, O.L., Hamilton, R.L., Bennett, D.A., Schneider, 
J.A., Buchman, A.S., Larson, E.B., Crane, P.K., Kaye, J.A., Kramer, P., Woltjer, 
R., Trojanowski, J.Q., Weintraub, D., Chen-Plotkin, A.S., Irwin, D.J., Rick, J., 
Schellenberg, G.D., Watson, G.S., Kukull, W., Nelson, P.T., Jicha, G.A., 
Neltner, J.H., Galasko, D., Masliah, E., Quinn, J.F., Chung, K.A., Yearout, D., 
Mata, I.F., Wan, J.Y., Edwards, K.L., Montine, T.J. and Zabetian, C.P. (2013) 
'APOE epsilon4 increases risk for dementia in pure synucleinopathies', JAMA 
Neurol, 70(2), pp. 223-8. 
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., 
Delcroix, N., Mazoyer, B. and Joliot, M. (2002) 'Automated anatomical labeling 
of activations in SPM using a macroscopic anatomical parcellation of the MNI 
MRI single-subject brain', Neuroimage, 15(1), pp. 273-89. 
Vanderstichele, H., Bibl, M., Engelborghs, S., Le Bastard, N., Lewczuk, P., Molinuevo, 
J.L., Parnetti, L., Perret-Liaudet, A., Shaw, L.M., Teunissen, C., Wouters, D. 
and Blennow, K. (2012) 'Standardization of preanalytical aspects of 
cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a 
consensus paper from the Alzheimer's Biomarkers Standardization Initiative', 
Alzheimers Dement, 8(1), pp. 65-73. 
Vann Jones, S.A. and O'Brien, J.T. (2014) 'The prevalence and incidence of dementia 
with Lewy bodies: a systematic review of population and clinical studies', 
Psychol Med, 44(4), pp. 673-83. 
Varrone, A., Dickson, J.C., Tossici-Bolt, L., Sera, T., Asenbaum, S., Booij, J., Kapucu, 
O.L., Kluge, A., Knudsen, G.M., Koulibaly, P.M., Nobili, F., Pagani, M., Sabri, 
O., Vander Borght, T., Van Laere, K. and Tatsch, K. (2013) 'European 
multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): 
age-related effects, gender differences and evaluation of different methods of 
analysis', Eur J Nucl Med Mol Imaging, 40(2), pp. 213-27. 
Vemuri, P., Lesnick, T.G., Przybelski, S.A., Knopman, D.S., Preboske, G.M., Kantarci, 
K., Raman, M.R., Machulda, M.M., Mielke, M.M., Lowe, V.J., Senjem, M.L., 
Gunter, J.L., Rocca, W.A., Roberts, R.O., Petersen, R.C. and Jack, C.R., Jr. 
(2015) 'Vascular and amyloid pathologies are independent predictors of 
cognitive decline in normal elderly', Brain, 138(Pt 3), pp. 761-71. 
Verghese, P.B., Castellano, J.M. and Holtzman, D.M. (2011) 'Apolipoprotein E in 
Alzheimer's disease and other neurological disorders', Lancet Neurol, 10(3), pp. 
241-52. 
177 
 
Vijayaraghavan, S., Maetzler, W., Reimold, M., Lithner, C.U., Liepelt-Scarfone, I., 
Berg, D. and Darreh-Shori, T. (2014) 'High apolipoprotein E in cerebrospinal 
fluid of patients with Lewy body disorders is associated with dementia', 
Alzheimers Dement, 10(5), pp. 530-540. 
Villemagne, V.L., Fodero-Tavoletti, M.T., Masters, C.L. and Rowe, C.C. (2015) 'Tau 
imaging: early progress and future directions', Lancet Neurol, 14(1), pp. 114-24. 
Villemagne, V.L., Klunk, W.E., Mathis, C.A., Rowe, C.C., Brooks, D.J., Hyman, B.T., 
Ikonomovic, M.D., Ishii, K., Jack, C.R., Jagust, W.J., Johnson, K.A., Koeppe, 
R.A., Lowe, V.J., Masters, C.L., Montine, T.J., Morris, J.C., Nordberg, A., 
Petersen, R.C., Reiman, E.M., Selkoe, D.J., Sperling, R.A., Van Laere, K., 
Weiner, M.W. and Drzezga, A. (2012) 'A beta Imaging: feasible, pertinent, and 
vital to progress in Alzheimer's disease', European Journal of Nuclear Medicine 
and Molecular Imaging, 39(2), pp. 209-219. 
Villemagne, V.L., Ong, K., Mulligan, R.S., Holl, G., Pejoska, S., Jones, G., O'Keefe, 
G., Ackerman, U., Tochon-Danguy, H., Chan, J.G., Reininger, C.B., Fels, L., 
Putz, B., Rohde, B., Masters, C.L. and Rowe, C.C. (2011) 'Amyloid Imaging 
with F-18-Florbetaben in Alzheimer Disease and Other Dementias', Journal of 
Nuclear Medicine, 52(8), pp. 1210-1217. 
Walker, L., McAleese, K.E., Thomas, A.J., Johnson, M., Martin-Ruiz, C., Parker, C., 
Colloby, S.J., Jellinger, K. and Attems, J. (2015a) 'Neuropathologically mixed 
Alzheimer's and Lewy body disease: burden of pathological protein aggregates 
differs between clinical phenotypes', Acta Neuropathol, 129(5), pp. 729-48. 
Walker, M.P., Ayre, G.A., Cummings, J.L., Wesnes, K., McKeith, I.G., O'Brien, J.T. 
and Ballard, C.G. (2000a) 'The Clinician Assessment of Fluctuation and the One 
Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion 
in dementia', Br J Psychiatry, 177, pp. 252-6. 
Walker, M.P., Ayre, G.A., Cummings, J.L., Wesnes, K., McKeith, I.G., O'Brien, J.T. 
and Ballard, C.G. (2000b) 'Quantifying fluctuation in dementia with Lewy 
bodies, Alzheimer's disease, and vascular dementia', Neurology, 54(8), pp. 1616-
25. 
Walker, Z., Costa, D.C., Walker, R.W., Lee, L., Livingston, G., Jaros, E., Perry, R., 
McKeith, I. and Katona, C.L. (2004) 'Striatal dopamine transporter in dementia 
with Lewy bodies and Parkinson disease: a comparison', Neurology, 62(9), pp. 
1568-72. 
Walker, Z., Jaros, E., Walker, R.W., Lee, L., Costa, D.C., Livingston, G., Ince, P.G., 
Perry, R., McKeith, I. and Katona, C.L. (2007) 'Dementia with Lewy bodies: a 
comparison of clinical diagnosis, FP-CIT single photon emission computed 
tomography imaging and autopsy', J Neurol Neurosurg Psychiatry, 78(11), pp. 
1176-81. 
Walker, Z., McKeith, I., Rodda, J., Qassem, T., Tatsch, K., Booij, J., Darcourt, J. and 
O'Brien, J. (2012) 'Comparison of cognitive decline between dementia with 
Lewy bodies and Alzheimer's disease: a cohort study', BMJ open, 2, p. e000380. 
178 
 
Walker, Z., Moreno, E., Thomas, A., Inglis, F., Tabet, N., Rainer, M., Pizzolato, G., 
Padovani, A. and DaTscan DLB Phase 4 Study Group (2015b) 'Clinical 
usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in 
patients with possible dementia with Lewy bodies: randomised study', Br J 
Psychiatry, 206(2), pp. 145-52. 
Wang, N., Gibbons, C.H., Lafo, J. and Freeman, R. (2013) 'alpha-Synuclein in 
cutaneous autonomic nerves', Neurology, 81(18), pp. 1604-10. 
Watson, R., Blamire, A.M. and O'Brien, J.T. (2009) 'Magnetic resonance imaging in 
lewy body dementias', Dement Geriatr Cogn Disord, 28(6), pp. 493-506. 
Weisman, D., Cho, M., Taylor, C., Adame, A., Thal, L.J. and Hansen, L.A. (2007) 'In 
dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body 
distribution', Neurology, 69(4), pp. 356-9. 
Wesnes, K.A., Aarsland, D., Ballard, C. and Londos, E. (2014) 'Memantine improves 
attention and episodic memory in Parkinson's disease dementia and dementia 
with Lewy bodies', Int J Geriatr Psychiatry. 
Whitwell, J.L., Josephs, K.A., Murray, M.E., Kantarci, K., Przybelski, S.A., Weigand, 
S.D., Vemuri, P., Senjem, M.L., Parisi, J.E., Knopman, D.S., Boeve, B.F., 
Petersen, R.C., Dickson, D.W. and Jack, C.R., Jr. (2008) 'MRI correlates of 
neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study', 
Neurology, 71(10), pp. 743-9. 
Williams, M.M., Xiong, C., Morris, J.C. and Galvin, J.E. (2006) 'Survival and mortality 
differences between dementia with Lewy bodies vs Alzheimer disease', 
Neurology, 67(11), pp. 1935-41. 
Wimo, A., Jonsson, L., Bond, J., Prince, M. and Winblad, B. (2013) 'The worldwide 
economic impact of dementia 2010', Alzheimers Dement, 9(1), pp. 1-11. 
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L.O., 
Nordberg, A., Backman, L., Albert, M., Almkvist, O., Arai, H., Basun, H., 
Blennow, K., de Leon, M., DeCarli, C., Erkinjuntti, T., Giacobini, E., Graff, C., 
Hardy, J., Jack, C., Jorm, A., Ritchie, K., van Duijn, C., Visser, P. and Petersen, 
R.C. (2004) 'Mild cognitive impairment--beyond controversies, towards a 
consensus: report of the International Working Group on Mild Cognitive 
Impairment', J Intern Med, 256(3), pp. 240-6. 
Wood, J.S., Firbank, M.J., Mosimann, U.P., Watson, R., Barber, R., Blamire, A.M. and 
O'Brien, J.T. (2013) 'Testing visual perception in dementia with Lewy bodies 
and Alzheimer disease', Am J Geriatr Psychiatry, 21(6), pp. 501-8. 
Yoon, J.H., Kim, M., Moon, S.Y., Yong, S.W. and Hong, J.M. (2015) 'Olfactory 
function and neuropsychological profile to differentiate dementia with Lewy 
bodies from Alzheimer's disease in patients with mild cognitive impairment: A 
5-year follow-up study', J Neurol Sci, 355(1-2), pp. 174-9. 
Yoshita, M., Arai, H., Arai, H., Arai, T., Asada, T., Fujishiro, H., Hanyu, H., Iizuka, O., 
Iseki, E., Kashihara, K., Kosaka, K., Maruno, H., Mizukami, K., Mizuno, Y., 
Mori, E., Nakajima, K., Nakamura, H., Nakano, S., Nakashima, K., Nishio, Y., 
179 
 
Orimo, S., Samuraki, M., Takahashi, A., Taki, J., Tokuda, T., Urakami, K., 
Utsumi, K., Wada, K., Washimi, Y., Yamasaki, J., Yamashina, S. and Yamada, 
M. (2015) 'Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial 
scintigraphy in dementia with Lewy bodies: a multicenter study', PLoS One, 
10(3), p. e0120540. 
Yoshizawa, H., Vonsattel, J.P. and Honig, L.S. (2013) 'Early neuropsychological 
discriminants for Lewy body disease: an autopsy series', J Neurol Neurosurg 
Psychiatry, 84(12), pp. 1326-30. 
Zaccai, J., Brayne, C., McKeith, I., Matthews, F. and Ince, P.G. (2008) 'Patterns and 
stages of alpha-synucleinopathy: Relevance in a population-based cohort', 
Neurology, 70(13), pp. 1042-8. 
Zakzanis, K.K., Graham, S.J. and Campbell, Z. (2003) 'A meta-analysis of structural 
and functional brain imaging in dementia of the Alzheimer's type: a 
neuroimaging profile', Neuropsychol Rev, 13(1), pp. 1-18. 
Zhang, B., Ferman, T.J., Boeve, B.F., Smith, G.E., Maroney-Smith, M., Spychalla, A.J., 
Knopman, D.S., Jack, C.R., Jr., Petersen, R.C. and Kantarci, K. (2015) 'MRS in 
mild cognitive impairment: early differentiation of dementia with Lewy bodies 
and Alzheimer's disease', J Neuroimaging, 25(2), pp. 269-74. 
Zhang, X., Jin, H., Padakanti, P.K., Li, J., Yang, H., Fan, J., Mach, R.H., Kotzbauer, P. 
and Tu, Z. (2014) 'Radiosynthesis and Evaluation of Two PET Radioligands for 
Imaging alpha-Synuclein', Appl Sci, 4(1), pp. 66-78. 
Ziebell, M., Andersen, B.B., Pinborg, L.H., Knudsen, G.M., Stokholm, J., Thomsen, G., 
Karlsborg, M., Hogh, P., Mork, M.L. and Hasselbalch, S.G. (2013) 'Striatal 
dopamine transporter binding does not correlate with clinical severity in 
dementia with Lewy bodies', J Nucl Med, 54(7), pp. 1072-6. 
 
 
